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Abstract 
There are an estimated 14.1 million cancer cases around the world every year, with this 
number expected to increase to 24 million by 2035. Breast cancer is the most common 
cancer in the UK, with 50,000 new cases per year. Due to the limitations and side effects of 
most available anticancer therapy, there is an urgent need to develop new anticancer 
agents. There has been significant progress in utilizing nanotechnology in several areas of 
cancer care, including in vitro diagnostics, imaging, and therapy. The first generation of 
novel nanomaterials (NMS) as anticancer agents has successfully entered a widespread use. 
Recent studies demonstrate that zinc oxide (ZnO) NMS hold a considerable promise as 
potential anticancer agents. In addition to the novel size and shape properties, ZnO NMS 
exhibit a pH-sensitive dissolution. These properties of ZnO NMS could potentially allow 
increased cancer selectivity, changes in pharmacokinetics and amplification of cytotoxic 
effects. The selectivity of ZnO NMS can be further induced by attaching of cancer target 
reactive-ligands.  
 The aim of this study is to test the hypothesis that zinc oxide nanoparticles (ZnO 
NPs), grafted with RGD peptide, would target tumours that up- regulate integrin alpha v 
beta 3 (αvβ3) receptors, and that targeting using this peptide would further enhance the 
antitumor efficacy of ZnO. Therefore, the toxicity and uptake of bare zinc oxide 
nanostructures and their RGD-targeted counterparts to a panel of malignant breast cancer 
cell lines was investigated. Two breast cancer cell lines of differing metastatic and invasive 
capacities were used: MDA-MB-231 cell line that is oestrogen receptor-negative and highly 
invasive; and, MCF-7 cell line that is oestrogen receptor-positive and non-metastatic. 
Healthy epithelial MCF-10-2A cell line was used as a control. To test the toxicity of the ZnO 
NPs (bare and RGD targeted), a combination of cell viability assays including; Alamar Blue, 
LDH, and ATP assays was used. Flow Cytometry was used to detect necrosis and apoptosis. 
The intracellular uptake of the ZnO NPs (bare and RGD targeted) was investigated and 
compared using different correlative microscopy techniques; Transmission electron 
microscopy (TEM), scanning electron microscopy (SEM), and confocal microscopy. 
Furthermore, the protein corona formed around the particles was analysed using mass 
spectroscopy (MS). The bare and RGD targeted ZnO NPs exhibited dose and time dependent 
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toxicity to the MCF-7 and the MDA-MB-231 cell lines in a concentration range of 10-100 
µg/ml. Significant differences in the responses of the MCF-7 and MDA-MB-231 cells after 
exposure to the bare ZnO NPs were observed in the LDH assay and the Alamar Blue assays. 
Cell death had features of necrosis and apoptosis with mitochondrial structural changes. 
RGD-targeting of the ZnO NPs was efficient and successfully increased the toxicity of the 
ZnO NPs to breast cancer cells at lower doses, while preserving the viability of the healthy 
cells at the same dose and exposure time indicating that a potential therapeutic dose 
window exists. In the Alamar Blue viability assay, for example, the IC50 values of the bare 
and targeted ZnO NPs after 24 h exposure to the MDA-MB-231 cells were 30 and 22 μg/ml, 
respectively. In cell free experiments, the bare ZnO NPs dissolved very rapidly in simulated 
body fluid of lysosomal pH 5.2, whereas they were more stable at pH 7.4. Confocal and 
transmission electron microscopy confirmed uptake of both classes of ZnO NPs and a rise in 
intracellular Zn2+ concentration prior to cell death after exposure to ZnO NPs. RGD-grafted 
ZnO NPs were more associated to MDA-MB-231 cells possibly by binding to integrin αvβ3 
compared to the bare ZnO. The kinetics of intracellular dissolution of the RGD-targeted and 
bare ZnO NPs showed differences. The bare ZnO NPs, showed a clear time dependent 
increase in intracellular dissolution while the RGD-targeted ZnO NPs showed very low 
intracellular dissolution with time and then a sudden burst of ionic zinc. Preliminary studies 
were also performed on one dimensional ZnO nanowires and data are in broad agreement 
with the NP study, showing dose and time dependent toxicity in the MDA-MB-231 cells. This 
research establishes a successful NP-based platform for cancer targeting and therapy. 
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1 Introduction  
Chemotherapy is one of the main systemic treatments for early breast cancer, and its use 
has led to an improvement in the survival of women diagnosed with breast cancer. 
However, the non-specific systemic delivery causes damage to normal unaffected tissue 
resulting in both short- and long- term adverse effects including, myelosupression, heart 
failure and infertility. Given its non-specific nature and the resultant problems, there is a 
clear and urgent need to devise new therapies which specifically target and eliminate cancer 
cells. The homing of the drug, specifically to the cancer cells, reduces the toxicity and 
increases the antitumor efficacy [1].  
 Zinc is an essential trace element involved in a number of biological processes [2, 
3]; however an increase in the local zinc concentration has been shown to cause cell death 
[4]. It has been reported that Zn2+ has many effects on cancer cells, which includes 
alteration in gene expression, reduction in cellular metabolism and induction of apoptosis 
[5]. It has also been reported that Zn2+ exhibits anti-apoptotic effects in breast cells. The 
induction of apoptosis by zinc in cancers appears to be cell type specific [5]. The apoptotic 
effects of zinc suggests that ZnO nanostructures can be applied as an anticancer agent and 
provide a potential target for the development of anti-tumor agents [5]. Even more striking 
are in vitro observations indicating that ZnO nanoparticles (NPs) can preferentially kill 
cancer cells with significantly less toxicity against normal cells [6]. Despite the significant 
promise of this technology, the clear therapeutic and imaging potential of ZnO NPs in 
vivo has been undermined by their susceptibility to protein fouling and their lack of colloidal 
stability [7, 8]. These concerns need to be addressed before this technology can be 
translated to clinic.  In particular, it is crucial to characterize the nanomaterials at the point 
of exposure to cells as changes in the aggregation state or surface chemistry of the nano 
ZnO could drastically alter their reactivity with cells.   
  The anti-cancer properties of nanomaterials can be improved by attaching cancer 
targeting reactive-ligands or antibodies, potentially allowing amplification of cytotoxic 
effects [9]. ZnO NMS are known to be very sensitive to dissolution in acidic conditions: the 
phase-solubility diagram of ZnO indicates that it will dissolve below pH 6.7 at physiological 
temperature and will dissolve rapidly in the acidic pH of the lysosomes (pH~5.7) [10] or in 
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the acidic (pH~5-6) cancer environment , whereas they will not dissolve in the environment 
of healthy cells (pH 7.2) [11]. However no prior studies have tested the potential of using 
fluorescent RGD-ZnO nanomaterials to treat breast cancer. It is hypothesized that, with the 
right targeting of the ZnO nanostructures to the αvβ3 integrin on the breast cancer cells, the 
functionalised ZnO NPs can be targeted to cancer cells, specifically kill these cells and a 
lower therapeutic dose of ZnO NMS could probably be achieved. This approach could 
probably increase the therapeutic window of ZnO for cancer therapeutics and bioimaging. 
 Bare ZnO NPs have recently been used to destroy breast cancer cells. Release of 
Zn2+ ions, following incubation of ZnO NPs with MCF-7 breast cancer epithelial cells, leads to 
generation of reactive oxygen species, resulting in damage to the plasma membrane and 
mitochondria leading to apoptosis [11]. Another study exploited the intrinsic fluorescent 
property of ZnO nanowires (NWs) to track the tumour targeting ability of the ZnO NWs in 
vivo [12]. The ZnO NWs were functionalized with an RGD group which selectively binds to 
the integrin αvβ3 on human glioblastoma cells in vivo [12]. However, neither of these 
studies demonstrated selective toxicity of cell targeting ZnO nanostructures to breast cancer 
cells, or provided direct evidence that the ZnO NMS are targeted, internalised by the 
cancerous cells and cause cell death. Furthermore little evidence was provided about the 
mode by which the ZnO nanostructures cause cell death or the heterogeneity in the 
resistance between cancer cell types (oestrogen receptor positive and triple negative) to 
ZnO exposure. 
 This PhD project aims to further investigate the in vitro cancer cell specific targeting 
and cytotoxicity of bare and cancer cell targeted ZnO nanostructures, and to address the 
role of physicochemical properties of ZnO NWs such as solubility on their interaction with 
live cells. The development of our proposed ZnO NP delivery system would reduce the side 
effects associated with chemotherapy, leading to an improvement in the quality of life of 
women receiving this treatment, as well as limiting the associated morbidity and mortality.   
 Thorough characterisation of the physicochemical properties of the ZnO NPs has 
been performed alone, and in different physiological environments (varying pH, proteins, 
cell culture medium), to provide an accurate characterisation of the particles at the point of 
exposure to the cells (Chapter 3). Such characterisation is frequently neglected in the 
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literature and could provide important information which explains the bioreactivity of the 
particles in vitro. A combination of biochemical assays (Chapter 4), electron and confocal 
microscopy techniques (Chapter 5) have enabled direct correlation between the uptake and 
dissolution of the ZnO nanostructures with their effect on the cell health. Protocols were 
developed to track the dissolution from bare and targeted ZnO NPs inside live breast cancer 
cells in the confocal optical microscope. This enabled us to correlate ZnO dissolution at the 
nanoscale, with any changes in cell metabolism inside the live cells in confocal microscope 
at the cellular level.  
 The composition of protein corona formed from human plasma protein onto the 
surface of the bare ZnO NPs at different conditions of temperature, centrifugation force and 
composition, as well as concentration of human plasma protein were characterised (Chapter 
6) to assess how the properties of the particles could become altered in vivo. 
 High aspect ratio ZnO NWs were fabricated by electrochemical deposition into high 
quality polycarbonate membrane filters and on glass substrates (Chapter 7). The obtained 
wires were successfully liberated from their polycarbonate templates and glass substrates. 
The ZnO NWs were characterised using scanning electron microscopy (SEM) and 
transmission electron microscopy (TEM). Detailed and in-depth analysis of the experimental 
results shows that the wires have a uniform diameter of 37 nm and are 330 nm long. The 
ZnO NWs were suspended in ethanol for cell exposure experiments. The ZnO NWs resulted 
in a dose and time dependent toxicity in the MDA-MB-231 cells. 
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2  Literature review 
The goal of this chapter is to provide a background to the subject. In depth critique of the 
literature is provided in greater detail in the introduction to each chapter. 
2.1 Nanotechnology 
The prefix “nano” is derived from the Greek “nanos” meaning “dwarf” [13]. The term ‘nano’ 
is a unit prefix denoting 10-9  for the metric unit of length ‘nanometre’, which denotes one 
billionth of a meter or 10-9 m. Nanotechnology is the manipulation of matter with at least 
one dimension of 100 nanometres or less. Nanomaterials (NMS) are engineered structures 
with reduced particle size and increased surface area with high proportion of atoms 
exposed to the surface. Consequently, NMS have different physical and chemical properties 
than their bulk forms. Nanotechnology is expected to revolutionize many aspects of human 
life offering extraordinary opportunities in various technological fields such as electronics, 
energy management, and information technology, as well as in the pharmaceutical and 
medical fields. It is projected to become a $1 trillion market by 2015 [14]. However, this 
increased manufacture and use of NMS has raised serious concerns about their safety for 
human health and the environment. It has been suggested that certain classes of NMS could 
become “The asbestos of the 21st Century” [15]. Because of these concerns, a part of 
nanoscience ‘Nanotoxicology’ has emerged to understand what specific properties of 
nanomaterials could lead to harmful effects. 
2.1.1 Nanotoxicology 
At the nano-scale, materials can display unique physical and chemical properties that are 
neither those of bulk materials, nor those of molecular compounds, therefore they will 
presumably have unique interactions with biological systems and the environment and 
could be potentially toxic. Consequently, detailed studies need to be carried out to precisely 
characterize the physicochemical properties of NMS, their internalization, intracellular 
distribution, biostability, and to evaluate the possible mechanisms underlying their toxicity. 
It is very important to ensure safe manufacture and marketing of engineered nanoproducts 
in particular if they come in contact with the human body. To fully understand the toxic 
potential of NMS, a multidisciplinary collaboration involving material scientists, physicians 
18 
 
and toxicologists is essential. Indeed, a proper understanding of nanotoxicity could also 
have a positive impact for achieving their efficient utilization and design in medicine. For 
example, the unique ability of some NMS to preferentially dissolve locally inside cancerous 
cells only, as will be shown in this work, and to initiate programmed cell death, could be 
used as new cancer therapy [14].  
 The evaluation of the potential hazard of NMS started in 1992 [11]. The toxicity of 
NMS has been reported using chemical (cell-free) and biological (in vivo and in vitro) assays, 
however, the results of the reports were inconclusive. There is an urgent need to develop 
and validate simple high-throughput in vitro assays to determine NMS toxicity because using 
laboratory animal (in vivo) tests could be impossible for both ethical and economic reasons 
[16-18]. In vitro studies using different mammalian cells showed that NMS can produce 
cytotoxic, genotoxic, inflammatory and oxidative stress responses. Despite collecting 
voluminous data from in vitro and in vivo studies, knowledge about the interaction of NMS 
with biological systems is still in its infancy [19]. Current comparison between in vitro and in 
vivo studies found little correlation and the relevancy of the in vitro results is questionable 
[20]. In vitro toxicity of NMS has been observed at concentrations much higher than the 
trace tissue concentrations in animals. The toxicological effects from in vitro and in vivo 
studies of some widely used NMS from about 101 publications were summarised by Dhwan 
and Sharma [19]. The toxic effects ranged from induction of inflammatory responses and 
oxidative stress to DNA damage and genotoxicity. In response to the recent findings that 
suggest the use of multiple in vitro assays to assess the toxicity of NMS, Kroll et al. [20] 
screened the toxicity of 23 engineered NMS using ten cell lines and three different 
standardised assays. They concluded that the toxic outcomes from exposure to NMS is not 
only cell-type-specific, but also depends on the particle type used, as well as on the toxicity 
endpoint measured. The toxicity of metal oxide NPs, proposed for use in industrial 
production, has been extensively studied [21-23].  
2.1.2 Factors affecting toxicity of nanomaterials 
The hazard potential of NMS and their biological activity depends on a combination of 
material physico-chemical properties rather than a single property as suggested by many in 
vitro toxicity assays [20, 24, 25]. The known indicators of the biological impact of NMS 
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include the size (surface area and size distribution) [26], chemical composition (purity, 
crystallinity, etc.), surface structure (surface reactivity, surface groups, inorganic or organic 
coatings, etc.), solubility (in lipid, aqueous, in vitro media), shape, and reactive oxygen 
species generation [14, 22, 27, 28]. The cellular uptake, protein binding, translocation from 
portal of entry to the target site, and the possibility of causing tissue injury are all 
determined by these NMS parameters [14]. Therefore, a thorough understanding of NMS 
specific properties is required for interpretation of toxicological results. The mentioned 
physicochemical properties of NMS can change with the method of production, preparation 
process, and storage media and also when the NMS are introduced into the culture media 
or organism. Consequently, physicochemical characterisation methods should be carefully 
adapted, and the guidelines for sample preparation, dosimetry, degradation and fate should 
be newly developed or revised. Recently, many studies emphasized on the importance for 
conscious characterisation methods beyond the naive application of characterisation 
methods that claim to cover the relevant parameters of nanotoxicology [22, 29-31].  
 From toxicological perspective, the particle size and surface area are one of the 
proposed key material characteristics. The size is a critical key factor that determines 
translocation across the cell membrane of cells [26, 32, 33]. As the size of a particle 
decreases, its surface area increases which allows a greater proportion of its atoms or 
molecules to be displayed on the surface, rather than the interior of the material [14]. 
Shrinkage in size may create discontinuous crystal planes that increase the number of 
structural defects, as well as disrupt the well–structured electronic configuration of the 
material, resulting in altered electronic properties. This could create reactive sites on the 
surface of the material by exposing specific surface groups. These surface groups can make 
the NMS hydrophobic or hydrophilic, or catalytically active or passive [14]. Therefore full 
characterisation of the NMS must be complimented with the actual state of dispersion of 
the NMS, as well as any changes in their physicochemical properties, in biological media.  
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2.2 Nanomedicine and nanotechnology in cancer applications 
Nanomedicine refers to the application of nanotechnology to medical fields, which aims to 
set new tools, devices and therapies for the treatment of human diseases. Oncology has 
benefited and been influenced by this field for several years [34]. The applications of NPs for 
improved therapeutics are at the forefront of cancer nanotechnology. The advantages of 
nanoparticle therapeutics are based on enhanced efficacy and reduced side effects, due to 
more targeted localization in tumours and active cellular uptake.  
Various types of nano-sized drug carriers, such as liposomes, polymeric micelles, 
dendrimers, superparamagnetic iron oxide crystals, and colloidal gold, have been 
investigated in cancer therapy [35]. Liposomes, which are microscopic phospholipid bubbles 
with a bilayered membrane structure [36], were the premier drug-delivery NPs in clinical 
use [37]. Doxorubicin (DNR), a powerful and toxic chemotherapeutic was encapsulated in 
liposomes and approved for the treatment of metastatic breast cancer and recurrent 
ovarian cancer since 1995 [38]. AbraxaneTM, an albumin-bound form of paclitaxel, is another 
chemotherapeutic agent approved in January 2005 [39]. Both formulations increased 
efficacy and reduced toxicity of the anticancer agents. Based on these success stories, the 
FDA has approved several investigational new drug (IND) applications for the treatment of 
several types of cancers. Over 20 nanoparticle therapeutics have been approved by the FDA 
for clinical use [40]. Examples of FDA approved nano-therapeutics for clinical use in breast 
cancer treatment, as well as nanoscale systems for systemic cancer therapy are listed in 
Table 1 and Table 2, respectively.  
Liposomes and other drug delivery systems (DDS) have often been criticized on the 
basis of their pharmaceutical and commercial qualities such as complexity, cost, storage 
stability, and control over the rate and extent of drug bioavailability [41]. Furthermore, 
there has been growing interest in semiconductor NMS, such as titanium dioxide TiO2 [42] 
and ZnO [43], as anticancer drug carriers very recently. For example, the incorporation of 
daunorubicin (DNR) in cancer cells through the use of ZnO nanorods (20x50 nm) could 
increase the intracellular concentration of DNR and enhance its potential anti-tumor 
efficiency in human hepatocarcinoma (SMMC-7721) cells by reactive oxygen species (ROS) 
[43]. It has also been shown that a pH-triggered controlled doxorubicin release from 
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mesoporous silica NPs was achieved via intracellular dissolution of ZnO nanolids [44]. These 
findings revealed that such modality combinations represent a promising approach in 
cancer therapy because ZnO nanostructures behave as a dual-purpose entity that not only 
inhibit premature drug release but also has a synergistic antitumor effect on cancer cells 
due to the release of toxic Zn2+ ions. 
Table 1: FDA approved nano-therapeutics for clinical use. 
Product 
trade name 
composition Use Date of approval Company reference 
Doxil® Doxorubicin encapsulated 
into liposomes 
Metastatic breast 
cancer and 
recurrent ovarian 
cancer 
17/11/1995 
FDA19627 
Zeneca 
Pharmaceuticals 
[38] 
Abraxane® Albumin nanoparticle 
comprising paclitaxel 
Various cancers 7/01/2005 
FDA21660 
American 
Pharmaceutical 
Partners 
[45] 
Megace ES® Nanocrystal/megestrol 
acetate 
Breast cancer  7/5/2005 Elan/Par 
Pharmaceutical 
Companies 
[45] 
  
Table 2: Nanoscale systems for systemic cancer therapy , adapted from [40]. 
Platform Latest stages of development examples 
Liposomes Approved DaunoXome, Doxil 
 
Albumin-based particles 
 
Approved Abraxane 
PEGylated proteins Approved Oncospar, PEG-Intron, PEGASYS, Neulasta 
Biodegradable polymer–drug 
composites 
Clinical trials Doxorubicin Transdrug 
 Polymeric micelles Clinical trials Genexol-PM*, SP1049C, NK911, NK012, NK105, 
NC-6004 
Polymer–drug conjugate-based 
particles 
Clinical trials XYOTAX (CT-2103), CT-2106, IT-101, AP5280, 
AP5346, FCE28068 (PK1), FCE28069 (PK2), 
PNU166148, PNU166945, MAG-CPT, DE-310, 
Pegamotecan, NKTR-102, EZN-2208 Dendrimers Preclinical Polyamidoamine (PAMAM) 
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2.3 Uptake of nanomaterials 
The mechanisms of cellular uptake of NMS are extensively studied recently [46-49]. NPs 
enter the cell through a process called endocytosis, which is generally classified into two 
broad categories- phagocytosis and pinocytosis. Phagocytosis is involved in the uptake of 
large particles (as large as 20 μm) and is characteristic of specialised professional 
phagocytosis, such as, macrophages, monocytes, and dendritic cells [50]. Pinocytosis, on the 
other hand, is present in all types of cells, and has multiple forms depending on the cell 
origin and function. The most recent classification of pinocytosis is based on the proteins 
involved in different endocytic pathways (Figure 1). According to this approach, pinocytosis 
is classified as clathrin-dependent endocytosis (also known as clathrin-mediated endocytosis 
(CME)) and clathrin-independent endocytosis [51]. The clathrin-independent pathways are 
further classified as macropinocytosis, caveolae-mediated endocytosis, and clathrin- and 
caveolae-independent endocytosis [52] (Figure 1). Another classification of endocytosis, 
based on NMS interaction with the cellular membrane (receptor-mediated, adsorptive, fluid 
phase), has also been used to describe cellular uptake of NMS [48]. However, nanomedicine 
community has been recently advised to utilize the classification based on endocytosis 
proteins, as the latter classification is less precise and often mistakenly used 
interchangeably with the previously described classification (e.g., receptor-mediated 
endocytosis is sometimes confused with CME) [48].  
 It has been reported that most NMS exploit more than one pathway to gain cellular 
entry [48]. The most current tools utilised in trafficking cellular uptake of NMS involve either 
colocalisation of NMS with specific endocytosis markers and structures or exclusion of 
specific endocytosis mechanisms by inhibitors of endocytosis or cell mutants [48]. A 
summary of most methods utilised in trafficking the uptake of NMS summarised by Sahay et 
al. in 2010 [48]. 
 
 
23 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Classification of endocytosis based on endocytosis proteins that are involved in the initial entry of particles and 
solutes. 
2.4 Zinc oxide nanomaterials 
ZnO nanostructures have recently attracted a big interest because of their useful electronic 
and optoelectronic properties. ZnO is an important II-VI direct band gap (3.40 eV at room 
temperature) semiconducting oxide for smart devices and optoelectronics. ZnO is 
characterised by photocatalytic and photo-oxidising ability against chemical and biological 
species [53]. This makes it an ideal material for nano-scale optoelectronics and 
biotechnology applications. Among the various morphologies of ZnO, nanowires (NWs) have 
recently attracted particular attention due to their unique one dimensional structure with 
highly controlled length and diameters.  
Endocytosis 
Phagocytosis Pinocytosis 
Caveolae and 
clathrin 
independent 
 
Caveolae- 
mediated 
 
Macropinocytosis 
Clathrin-
dependent  
Clathrin-
independent 
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2.4.1 Toxicity of zinc oxide nanostructures 
 The toxicity of ZnO nanostructures against a wide range of mammalian cells has 
been extensively studied in recent years [54-56]. The number of publications in ISI Web of 
Science (WoS) on May 5th and 6th, 2013 concerning uptake, oxidative stress and other 
mechanistic nanotoxicological information (damage to membranes, mitochondria, DNA and 
lipid peroxidation) on ZnO against mammalian cells was 286 [55]. Some of these studies are 
summarised in Table 3. ZnO NMS has been reported to be more toxic than other metal 
oxides [55, 56]. A review on the toxicity of ZnO NPs to mammalian cells has been reported 
by Vandebriel et al. in 2012 [57]. Vandebriel et al. [57], concluded that the induction of 
oxidative stress is the most important and the most likely mechanism underlying ZnO NP 
toxicity. However, only few reports on the cellular uptake of ZnO NMs are available [10, 49, 
58-60], and that was mainly attributed to either rapid intracellular dissolution of ZnO NPs or 
the effect of protein corona on the uptake [8]. All these studies will be critically discussed in 
Chapter 5. 
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Table 3: Summary of toxicity studies of ZnO nanostructures on mammalian cells. Blank cells represent information that 
is not given in the specific publication. 
Year  
ZnO 
nanostructures/size/shape 
 
Tested cells 
 
Results 
Assays and 
techniques used 
to assess the 
toxicity 
Suggested 
mechanism 
of toxicity 
2006 
[54]  
NPs
a
,  MPs
b
 Normal human 
Osteoblast cells 
-NPs were less toxic 
than MPs
b
 
  
 
 
2007 
[61]  
 
 
NPs (rod shaped) 
20-70 X 100-200 nm  
 
 
Human aortic 
endothelial cells 
(HAECs) 
 
 
IC50
 c
= 50 µg/mL 
(0.6 mM) after 4 h. 
-TEM 
- PCR (Real-time 
polymerase chain 
reaction) 
- ELISA
d
 
- ICP-MS
e
 
 
 
2007 
[62] 
 
 
 
NPs≈ 13 nm 
 
Human-T 
lymphocytes 
Not toxic at conc. < 
400 µg/mL 
(5mM) 
IC50≈ 800 µg/mL 
(10 mM) 
after 24 h 
-Flow cytometry            
-viability assays 
2008 
[49] 
 
 
NPs ≈ 13 nm  
Human bronchial 
epithelial cells 
(HBES-2B) 
12.5 µg/ml 
Toxic 
 
PI
f
 
MTS viability assay 
ROS
g
 
Mouse leukaemic 
macrophage cell 
line 
(RAW 264.7 cells) 
25 µg/ml 
toxic 
2008 
 [63] 
NPs ≈ 20 nm Primary mouse 
embryo fibroblast 
(PMEF) cells 
IC50
c
= 15 μg/ml 
(0.25 mM) after 24 
h exposure 
MTT viability assay 
WST viability assay 
Oxidative stress  
2008 
[64] 
NWs
h
 
100 nm x 1.5 µm 
Hela epithelial 
cells 
Nontoxic at conc. 
up to 100 µg/ml  
MTT viability assay  
 Subcutaneous 
connective 
tissues (L-929) 
IC50= 100 µg/ml. 
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Year  
ZnO 
nanostructures/size/shape 
 
Tested cells 
 
Results 
Assays and 
techniques used 
to assess the 
toxicity 
Suggested 
mechanism 
of toxicity 
 
 
2009  
[65] 
 
 
NPs 
10, 30, 60 and 200 nm  
 
 
Mouse neural 
stem cells 
(MNCs) 
IC50
c
 (10 nm)=9.3-
11.3 µg/ml 
IC50 (200 nm) 
=10.2-13.5 µg/ml 
after 24 h. 
Dose dependent, 
size independent 
toxicity. 
 
Confocal 
microscopy 
TEM 
FACS 
(Fluorescence-
activated cell 
sorting) 
 
2010 
[10] 
NWs
h
 
327 nmX10.5 μm 
 
Human monocyte 
macrophages 
(HMMs) 
IC50
c
= 14.5 μg/ml Confocal 
microscopy 
Neutral red 
Zn
2+  
ions 
dissolution of 
ZnO NWs inside 
the cells 
 
2010  
[66] 
 
NPs 
20 nm  
 
Human bronchial 
epithelial cells 
(HBES-2B) 
Dose and time 
dependent toxicity 
IC50
c
= 8 µg/ml after 
24 h exposure 
 
 
LDH viability assay 
 
 
ROS
g
 and 
oxidative stress 
 
 
2010 
[67] 
 
NPs 
20, 30 and 40 nm 
 
 
 
Human 
embryonic lung 
fibroblasts (HELF) 
cells 
- Toxic at 
concentrations 
tested (2.5-150 
µg/ml) 
-Toxicity was 
independent on the 
particle size 
 
MTT viability assay 
SEM  (Scanning 
electron 
microscopy) 
 
Zn
2+  
ions and  
(penetration of 
NP inside the 
cells) 
 
2010 
[68] 
 
NPs 
- 10-30 nm, spherical 
- 30 nm, 100 nm, and fine 
rod shaped 
 
Mouse 
macrophage Ana-
1 cells 
IC50
c
≈  40 µg/ml 
- Dose dependent 
but size 
independent 
toxicity 
- Spherical NPs 
were slightly more 
toxic than 
Nanorods 
 
LDH viability assay 
CCK-8 viability 
assay 
ROS
d
 
2010 
[69] 
NPs ≈ 10 nm Human bronchial 
epithelial cells 
(HBES-2B) 
IC50 
c
≈ 20 µg/ml 
(0.25 mM) after 24 
h exposure 
WST-8 viability 
assay 
ROS
g
 and 
oxidative stress 
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Year  
ZnO 
nanostructures/size/shape 
 
Tested cells 
 
Results 
Assays and 
techniques used 
to assess the 
toxicity 
Suggested 
mechanism 
of toxicity 
 
 
2011 
 [70] 
 
 
NPs ≈75.6 ± 19 nm 
Glomerular 
mesangial cell 
(IP15) 
Dose-dependent 
toxicity 
IC50
c
≈3.04  μg/ml 
After 24 h 
Neutral Red 
MTT viability assay 
WST-1 viability 
assay 
ROS
g 
and 
Oxidative stress 
Proximal 
epithelial tubular 
cell line HK-2 
IC50
c
≈ 2.42 μg/ml 
After 24 h 
a
Nanoparticles (NPs), 
b
Microparticles (MPs), 
c
Median lethal concentration (IC50): is a measure of the effectiveness of a 
substance in inhibiting a specific biological or biochemical function, 
d
Enzyme-linked immunosorbent assay (ELISA), 
e 
Inductively coupled plasma-mass spectroscopy (ICP-MS), 
f 
Propedium Iodide (PI), 
g
reactive oxygen species (ROS), 
h
Nanowires (NWs) 
 
2.4.2 The role of zinc ions in the toxicity of ZnO nanostructures and factors affecting 
dissolution of ZnO NPs 
When the thermodynamic properties of ZnO nanostructures (including surface free energy) 
favour dissolution in a suspending media or biological environment, toxic Zn2+ ions may be 
generated [71]. Zinc oxide NPs can dissolve in an aqueous media to form hydrated Zn2+; this 
dissolution is enhanced in acidic pH as well as the presence of biological components such 
as amino acids and peptides [49]. Several studies attributed the toxicity of nano-ZnO to the 
free zinc ions and labile zinc complexes released upon dissolution of ZnO [67].  
 The involvement of zinc ions in the toxicity ZnO NMS necessitates a proper 
understanding of the role of zinc in the body. Zinc is an essential trace element involved in a 
number of biological processes. The daily recommended dose of Zn2+ for adult men and 
women is 9.5 and 7.0 mg, respectively. It acts prominently as a structural part of proteins 
and the heart of the catalytic site of enzymes [72]. There is also a fraction of zinc that is not 
in strong association with organic molecules, called “vesicular” or “chelatable” [73]. Zinc can 
protect from oxidative stress, and it plays a regulatory role in apoptosis, ageing and the 
immune system [2, 74]. Within mitochondria of yeast cells, zinc is equally abundant to iron 
and appears to be a component of many proteins involved in mitochondrial protein 
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transport and folding of newly imported mitochondrial proteins within the matrix. Studies 
suggest that pools of bioavailable iron, copper and zinc exist in the mitochondrial matrix and 
that the regulation of this pool size is important for correct metallation reactions [75]. 
However, excessive zinc concentrations have been shown to be toxic to a number of 
organisms and to alter cellular morphology. For instance, exposure of different species of 
ciliates to excess zinc leads to various ultrastructural alterations, such as cytoplasmic 
vacuolation; nuclear changes such as chromatin condensation and nucleolus fusion; 
mitochondrial degeneration; autophagosome formation and formation of immature cyst 
walls [76]. Evidence is also mounting that zinc is toxic to neurons by inhibition of cellular 
ATP production and has been classified as an endogenous neurotoxin [4]. Zinc is very 
abundant in the brain with levels of ~ 200 ng/mg protein. This zinc pool exists either tightly 
bound to intracellular proteins, sequestered into vesicles together with glutamate or as a 
labile, free pool in the cytoplasm. One study suggests an LC50 for free Zn
2+ of 300 nM in 
cultured neurons [77]. Zinc has to enter the cell to exert its toxicity, as treatments that 
decrease Zn2+ influx, increase Zn2+ efflux or increase intracellular Zn2+ buffering, all 
ameliorate its toxicity. Therefore any treatment that traffics local dose of Zn2+ into the cells 
is more likely to be effective therapeutically. 
2.4.3 Where do ZnO NPs and released Zn2+ ions end up in the body 
The liver could act as the main organ for disposal of ZnO NPs [78, 79] . Wang et al. [80] 
observed increase in zinc concentration in the liver and kidney in ZnO NPs-treated rats after 
12 h exposure.  
2.4.4 The use of ZnO nanomaterials in cancer therapy 
 Tumour tissues are characterised by increased capillary permeability or what is called 
‘enhanced permeability and retention’ effect (EPR) proposed by Matsumura and Maeda 
[81]. According to their report, solid tumors have abnormal blood vessels with loose 
junction and insufficient lymphatic drainage, so that the NPs easily escape from the blood 
vessel and accumulate in tumor tissues but they hardly return to the blood stream again. 
EPR effect-based drug delivery is considered as the “gold standard” in anticancer drug 
design and anticancer strategies using macromolecular drugs. The EPR effect allows an 
increased rate of tumoural uptake of NPs [82]. In contrast, the EPR effect-driven drug 
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delivery does not occur in normal tissues. ZnO NMS have been reported recently to show a 
high degree of cancer cell selectivity with potential use in cancer imaging and therapy [14, 
83, 84].  
 ZnO nanostructures are known to be very sensitive to dissolution in acidic 
conditions: the phase-solubility diagram of ZnO indicates that it will dissolve below pH 6.7 at 
physiological temperature and will dissolve rapidly in the acidic pH of the lysosomes (pH 5.7) 
[10] or in the acidic (pH 5-6) cancer environment [11] whereas they will not dissolve in the 
environment of healthy cells (pH 7.2). 
  It has been recently reported the use of ZnO NWs in cell-localized photodynamic 
therapy for breast cancer [85]. The ZnO NWs were conjugated to a photosensitizer which 
was then successfully delivered by ZnO NWs to breast cancer cells. The green emission from 
ZnO NWs after UV exposure activates the photosensitizer and initiates necrosis within few 
minutes [85]. Zhang et al. [86] reported the use of ZnO nanorods as drug carriers for the 
chemotherapeutic drug DNR. The antitumor activity of DNR against hepatocarcinoma cells 
was improved significantly by its combination with ZnO NWs. The increase in the 
intracellular concentration of DNR and in its anti-tumour activity by the wires indicates the 
potential application of ZnO NWs in drug delivery into target cancer cells. A recent study 
reported the potential use of ZnO NPs as a pH-sensitive drug delivery system that minimizes 
drugs toxicity [87]. ZnO NPs has also reported to preferentially kill cancer cells and activated 
human T-cells [6]. Punnoose et al. [88] has recently registered a patent for the use of ZnO 
against cancerous T-cells. They showed that ZnO NPs exhibit a strong preferential ability to 
kill cancerous T-cells (~ 28-35 x) compared to normal T-cells.  
 Targeting tumor cells has gained credence as an alternative approach for treating 
cancer and offers both an increased therapeutic index and decreased drug resistance. The 
use of ZnO NMS as a targeted fluoroprobe due to its intrinsic fluorescent properties has 
been investigated. ZnO quantum dots (QDs) was targeted to the breast cancer MDA-MB-231 
cells by transferrin ligand. The NPs were biocompatible with selective binding to the cell 
surface receptor and they were internalised through receptor mediated endocytosis [89]. 
RGD- targeted ZnO NWs to αvβ3 integrin receptors expressed on the glioblastoma cells 
were found biocompatible for imaging purposes [12]. Both studies indicated the potential 
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use of ZnO NMS for cancer targeted imaging and drug delivery. Porous ZnO nanorods 
conjugated with folic acid were used to target and deliver the anticancer drug doxorubicin 
to MDA-MB-231 cells [90]. The αvβ3 integrin receptors are better targets than transferrin 
and folic acid [91]; transferrin is expressed at elevated levels on cancer cells but also on 
brain capillaries, endocrine pancreas, or Kupffer cells of the liver [92]. In addition, folate, 
which is supplied by food, show naturally high concentrations in the human body and thus 
might compete with the NP-conjugated ligand for binding to the receptor, and consequently 
reducing the intracellular concentration of delivered drug [93]. 
2.5 Protein corona formation around nanoparticles  
2.5.1 Effect of protein corona on the pharmacokinetics and toxicity of nanomaterials 
Blood plasma  is the liquid component of whole blood, and makes up approximately 55% of 
the total blood volume. It is composed primarily of water with small amounts of minerals, 
salts, ions, nutrients, and proteins in solution. Plasma contains a large variety of proteins 
including human serum albumin (HAS), immunoglobulins (IgG), and clotting proteins such 
as fibrinogen.  Albumin constitutes about 60% of the total protein in plasma and is present 
at concentrations between 35 and 55 mg/mL [94]. When NPs come in contact with 
biological fluids, they interact with proteins and other biomolecules. This interaction of NPs 
with protein molecules results in the formation of a dynamic layer of proteins on the surface 
of the NPs (Figure 2). This conjugated system is known as “NP-protein corona” [95]. 
Professor Dawson's group of collaborators introduced the concept of a “hard protein 
corona” seven years ago [96]. At equilibrium, the corona would have a unique composition 
of proteins. The adsorption of proteins onto metal oxides have been found to reach 
equilibrium within the first few minutes of incubation [8]. The NP-protein corona is 
composed of a dynamic layer of proteins, low affinity proteins being gradually replaced by 
lower abundance, higher affinity proteins [33]. The low affinity proteins form the “soft 
corona”, while the higher affinity proteins form the “hard corona” [97]. The hard corona 
proteins interact directly with the nanomaterial surface, while the soft corona proteins 
interact with the hard corona via weak protein–protein interactions [98]. A schematic of soft 
and hard protein corona formed on the surface of NPs is presented in Figure 3. 
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Figure 2: Simplified schematic of nanoparticle-protein corona formation process. Single type (i) protein attached to the 
nanoparticle surface at a rate Ki
on
, leaving the nanoparticle at rate Ki
off
. On average, a total number of ni proteins can 
fully cover the nanoparticle surface [99]. Analytical Results from Population Balance Equations by Sahneh, F.D., C. 
Scoglio, and J. Riviere is licenced under creative Commons Attribution (CC BY) 4.0 international. 
 
 
Figure 3: Schematic of soft and hard protein corona formed on the surface of NPs. In plasma, NPs are surrounded by a 
corona of proteins. Left, a weakly bound dynamic protein outer layer on the surface on a NP in exchange with proteins 
in the plasma (soft corona). Right, with time a more strongly bound “hard” corona on the surface of NPs are formed  
[100] “Courtesy of F. Bombelli”.   
 The extent of adsorption of protein on the surface of NPs as well as the effect on 
the protein structure and stability are dependent on the chemical nature, shape [8], surface 
charge [101-105], size [106-108], colloidal stability of NPs [109], types of proteins [110], and 
ambient temperature [111]. For example, despite comparable surface charges, ZnO NPs 
showed different plasma protein binding profiles compared to TiO2 and SiO2 [8]. Electrostatic 
interactions may also determine the nature and extent of protein binding. NPs with an 
acidic surface will preferentially bind to proteins with isoelectric point (pI) greater than 5.5, 
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while NPs with basic surfaces predominantly bind to proteins with pI less than 5.5. It has 
been shown that the composition of the protein corona of silicon NPs was different for the 
nanospheres, nanorods, and nanotubes [8]. 
 This adsorption of proteins at the NPs surface may lead to a substantial change of 
the physicochemical properties of the NPs and could result in NPs of different identity. The 
protein-NPs interaction could also result in the change of proteins’ structure and activity. 
Since protein corona could change NPs properties such as polarity, charge, shape and size, 
they could in turn critically affect the interaction of these NPs with the lipid bilayer of cell 
membrane and eventually their biodistribution [60]. The protein corona could also affect 
uptake mechanisms, and intracellular localisation of the NPs in vivo. Therefore, evaluation 
of the protein corona is crucial for understanding the biological responses to the NPs. The 
contradictory reports of nanomaterial toxicity could also be resolved by understanding the 
effect of serum proteins within toxicology assays.  
 Chemical fabrication of the surface of the NPs to avoid adsorption of proteins can 
be carried out using polyethylene glycol (PEG) [112], also referred to as “PEGylation” and 
through siliconate treatment of the surface of the NPs [8] . 
2.5.2 Effect of protein corona on opsonisation  
 Protein corona formed on the surface of NPs could act as ‘opsonins’. Opsonins can be 
recognised by scavenger receptors on the macrophage cell surface and internalised. This 
internalisation by macrophages leads to significant loss of NPs from the circulation. The 
macrophages responsible for the loss of injected dose of NPs are also known as the 
reticuloendothelial system (RES). Consequently, understanding how and why plasma 
proteins are adsorbed to these NPs may be important for understanding their biological 
responses and will be the key point for developing a long circulation time NP formulation.  
 Size, charge and surface chemistry of NPs greatly influence their opsonisation and 
consequently their PK and fate in vivo [32, 65]. Prolonged blood circulation and an increased 
level of tumour delivery are achieved by NPs that have a mean diameter of approximately 
100 nm, ζ potential within 10 mV, and PEGylation [32]. The most commonly used strategy to 
minimise opsonisation is conjugation of PEG polymer onto the surface of the NPs. PEG is a 
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relatively inert hydrophilic polymer that provides good steric hindrance for preventing 
protein binding. Several studies reported that PEGylation reduces the rate of RES uptake 
and increases circulation half-life for various types of NPs [32]. However, PEGylation also 
weakens the interaction of NPs and the target cells causing an inefficient intracellular 
delivery. 
2.5.3 Effect of protein corona on active targeting yield of nanoparticles 
It has been found that protein corona reduces the targeting capability of NPs by screening 
the active sites of the targeting ligands [113]. A schematic of the process is shown in Figure 
4. 
 
Figure 4: Simplified schematic of reduction of targeted NP delivery by protein corona. Left, NP with surface targeting 
ligand. Right, protein corona bound to the surface of NP screened NP targeting ligands, preventing the ligands from 
binding to their targets on a cell surface, “Mirshafiee, V., et al., Protein corona significantly reduces active targeting 
yield. Chemical communications (Cambridge, England), 2013. 49(25): p. 2557-2559- Reproduced by permission of The 
Royal Society of Chemistry”  [113].   
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2.6 Aims of the study  
The aim of this work is to investigate the in vitro cancer cell specific targeting and 
cytotoxicity of ZnO NPs and nanowires to different breast cancer cell lines. 
Specific aims: 
1. To demonstrate selective targeting and toxicity of RGD surface-modified ZnO NMS by 
 comparing targeting, uptake and cytotoxicity in a panel of malignant breast cancer cells 
 compared with healthy breast epithelial cells. 
2. To correlate targeting, intracellular destination and local dissolution of the surface-
 modified ZnO NPs with their toxicity mechanism.  
3. To investigate the mechanism of cell death induced by the ZnO NPs in the malignant 
 breast cancer cells. 
4. To assess ZnO NWs toxicity to malignant breast cancer cells. 
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3   Characterization and functionalisation of bare zinc oxide 
nanoparticles 
In this chapter, the physicochemical properties of ZnO NPs have been investigated. These 
include, shape, size, zeta potential and hydrodynamic size distribution. The dissolution of 
these NPs in the different cell culture media used in this study is also discussed. 
Characterisation of the ZnO NPs was conducted using transmission electron microscopy 
(TEM), Zetasizer and inductively coupled plasma optical emission spectroscopy (ICP-OES).  
3.1 Materials and methods 
3.1.1 Bare ZnO NPs 
Bare ZnO NPs were purchased from SkySpring Nanomaterials, Inc., (product number 
8410DL, Westhollow Drive, Houston, USA) at 99.8% purity and nominal size of 10-30 nm. 
The powder was white to light yellow in colour, and was stored at room temperature (RT) 
and vacuum sealed.  
3.1.2 Cell culture media and chemicals 
Dulbecco’s Modified Eagle’s Medium (DMEM), Minimum Essential Media (MEM), a 1:1 
mixture of Dulbecco's Modified Eagle's Medium (DMEM) and Ham's F-12 media (DMEM:F-
12) and horse serum were obtained from Gibco (Life Technologies Ltd, UK), fetal bovine 
serum (FBS) was purchased from Cellgro, Mediatech, Inc. Leibovitz's L-15 (L-15) medium was 
obtained from American Type Culture Collection  (ATCC, Manassas,  USA). Epidermal growth 
factor was purchased from Invitrogen. Penicillin-Streptomycin, Cholera toxin, insulin, 
hydrocortisone and CaCl2 (≥99%) were purchased from Sigma Aldrich, Ltd, UK. HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid, ≥99%), NaCl (≥99.5 %), MgCl2, KCl, and 
MgSO4 (≥99%), were purchased from Fisher Scientific Ltd, UK. 2-Deoxy-D-glucose (99%) and 
MES (2-(N-morpholino) ethane-sulfonic acid) were purchased from Acros Organics, US.  
3.1.3 Preparation of cell culture media and buffers 
MEM, DMEM, and L-15 media were supplemented with 10% FBS, and Penicillin-
Streptomycin solution (100 units/ml penicillin, 100 μg/ml streptomycin). DMEM:F-12 
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medium was supplemented with 20 ng/ml epidermal growth factor, 100 ng/ml cholera 
toxin, 0.01 mg/ml insulin, 100 ng/ml hydrocortisone, Penicillin-Streptomycin solution (100 
units/ml penicillin, 100 μg/ml streptomycin), and 5% horse serum. Herein, these will be 
referred to as complete media (CMEM, CDMEM, CL-15, and CDMEM: F-12, respectively). 
HEPES confocal imaging buffer was prepared as 10 mM HEPES at pH 7.4, containing 145 mM 
NaCl, 5 mM KCl, 1 mM MgSO4, 1.5 mM CaCl2, and 0.16% glucose. Lysosomal simulated body 
fluid (Lyso-SBF) was also prepared as 25 mM MES-NaOH at pH 5.2, containing 0.5 mM CaCl2, 
1 mM MgCl2, and 200 mM KCl. 
3.1.4 Functionalisation of ZnO nanoparticles 
The targeting peptide conjugated to the ZnO NPs was prepared by our collaborators in the 
department of chemistry, Montana State University, and was labelled with a green 
fluorescent protein (GFP). The method used to prepare the targeting peptide by our 
collaborators is novel. Cell targeting of the ZnO NPs was achieved using an immobilization of 
dual domain peptides which is composed of cell targeting domain and ZnO binding domain. 
Cell targeting domain comprises peptides with established cell-specific tumor targeting 
sequences (CDCRGDCFC). ZnO binding motif (HCV) is a tripeptide composed of histidine 
(His), cysteine (Cys), and valine (Val) which binds to αvβ3 integrin upregulated in breast 
tumor. The targeting motif (RGD) is a tripeptide composed of L-arginine, glycine, and L-
aspartic acid. These peptide sequences have been discovered using in vivo phage display 
selection and combinatorial library methods and have been shown to maintain targeting 
capability when presented on other nanoscale platforms. These two peptide domains were 
connected via a glycine linker to ensure flexibility. These short peptides were produced 
heterologously in an E.coli. The dual domain peptides were genetically conjugated with 
green fluorescence protein (GFP) so that fluorescence microscopy is available to evaluate 
cellular uptake and targeting of modified ZnO NMS. 
 The exact binding mechanism of the HCV peptide motif to ZnO NPs is not fully 
investigated. I their study, Okochi, M., et al. [114] showed that 99.6% of the 6-mer peptide 
HCVAHR were adsorbed onto ZnO NPs and the kinetic binding constant (Ka) of the peptide 
against ZnO NPs was 9.8x106 M-1, and its maximum amount of adsorption was 2 mmol 
peptides/g ZnO (105 peptides/ZnO particle). In [114], they suggested that the His is the key 
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amino acid for binding to ZnO and by ZnO-binding assay, they confirmed that the His 
residues, which possess the imidazolium cation, were involved in the ZnO interaction. Also, 
the Cys-substitution found to increase the binding especially with next to His. These results 
seem to be related to the amino acids associated with Zn2+ in zinc fingers and 
metalloproteins [3]. The thiol–Zn interaction might modulate the His-binding to ZnO 
nanoparticles [114]. Therefore, His–Cys motif would increase the binding capacity and 
specificity. Based on the strong binding of the HCV motif to the surface of ZnO, it is expected 
that the targeting peptide is expected to stay attached to the NP during culture and 
internalisation. However, the stability of the targeting ligand as the NP dissolves during 
culture and internalisation are to be investigated. 
 After preparing the targeting peptide, it was suspended in HEPES buffer (HEPES 
50mM, NaCl 100mM) at pH 7.5. The peptide was then diluted with the same buffer to an 
absorbance of 1.6 at 490 nm. The bare ZnO NPs were suspended in HEPES buffer (50 mM 
HEPES, 100 mM NaCl) at pH 7.5 and a concentration of 10 mg/ml. The particles were then 
incubated with the diluted protein solution to a concentration of 1 mg/ml over night at RT in 
the dark with gentle shaking. Finally, the NPs dispersions were centrifuged at 13,000 rpm for 
five min on a table-top centrifuge. To test the efficiency of binding of the targeting peptide 
to ZnO NPs, the absorbance of the protein solution, before and after incubation with the 
particles, was measured at 490 nm. A schematic of the functionalisation peptide is 
presented in Figure 5. A negative control peptide (HCV-GGG-GFP) which has the ZnO binding 
motif (HCV) and a GGG peptide instead of receptor binding motif (RGD) was also prepared. 
The ZnO-HCV-GGG-GFP NPs were also prepared using the same procedure described above. 
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Figure 5: Simplified schematic of ZnO functionalization peptide. The peptide is composed of a ZnO binding peptide (HCV, 
purple), and a targeting peptide (RGD, red). To track binding of the targeting peptide to the surface of the bare ZnO NPS, 
the NPs were tagged with a GFP protein (green). RE: restriction enzyme. This schematic was prepared by Masaki Uchida 
with modification. 
3.1.5 Size and morphology of the bare zinc oxide nanoparticles 
The particle size distribution and morphology of the bare ZnO NPs were evaluated on FEI 
Tecnai T-12 transmission electron microscope (TEM) operated at 120 V. The particles were 
suspended in ethanol and sonicated for 20 min, then 2 μL of the suspension was dropped on 
a carbon grid and allowed to air-dry before examination in the TEM. To measure the particle 
size distribution from the TEM images, 200 particles were randomly selected and the long 
and short diameters were measured (since not all of the particles were spherical) with the 
help of ImageJ (http://rsbweb.nih.gov/ij). The size of each NP was calculated as an average 
of the two lengths, and a frequency plot was prepared using a class interval of 10 nm.   
3.1.6 Hydrodynamic radii and zeta potential of bare and functionalised ZnO 
nanoparticles 
The hydrodynamic radii of bare ZnO NPs in different vehicles (deionised distilled water, 
CMEM, CDMEM, CDMEM: F-12, 10 mM HEPES+50 mM NaCl at pH 7.4 (used for protein 
binding experiment in Chapter 6) and HEPES confocal imaging buffer at pH=7.4), as well as 
their zeta potential in deionised-distilled water at pH 6.3 were analysed using a Zetasizer 
Nano ZS (Malvern Instruments INC, UK). Bare ZnO NPs, dispersed in ethanol were sonicated 
for 20 min, and then diluted at 100 μg/ml before hydrodynamic size measurement. This 
concentration was chosen as a previous study [115] which showed that the hydrodynamic 
size was the same for concentrations between 10-100 μg/ml. To check the effect of 
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adsorbed proteins from the FBS on the size distribution of the bare ZnO NPs in the cell 
culture media, the same experiment was repeated with DMEM and MEM using 1% instead 
of 10% FBS, and with DMEM:F-12 using 1% instead of 5% horse serum. To assess the effect 
of the targeting protein (HCV-RGD-GFP) on the agglomeration status of the ZnO NPs, the 
hydrodynamic radii of the ZnO-HCV-RGD-GFP NPs were measured in the HEPES imaging 
buffer. The targeted ZnO NPs stock dispersion in 10 mM HEPES+50 mM NaCl was sonicated 
for 30 s and 100 μg/ml dispersion in HEPES confocal imaging buffer was prepared for 
hydrodynamic size measurements. The targeted ZnO NPs were sonicated for 30 s only to 
prevent any possible break down of the targeting peptide that might consequently reduce 
the targeting efficiency of ZnO NPs to the cancer cells. 
 The zeta potential of the bare ZnO NPs was measured in deionised distilled water 
at pH 6.3 and 10 mM HEPES buffer at pH 7.4. The bare ZnO NPs ethanolic dispersions were 
sonicated for 20 min, and then diluted at 100 μg/ml before zeta potential measurements. 
The effect of the adsorbed FBS proteins on the surface charge of ZnO NPs was also analysed. 
The bare ZnO NPs were incubated in CDMEM at 100 μg/ml for 1 h at 37°C while shaking. At 
the end of incubation time, the NP-protein complex was centrifuged at 12,000 xg and the 
supernatant was removed. The pellet was then washed three times with 10 mM HEPES 
buffer at pH=7.4. Finally, the NP-protein complexes were resuspended in 10 mM HEPES 
buffer at 100 µg/ml and the zeta potential was measured, as described previously. 
 For the measurement of zeta potential and hydrodynamic radii, DTS 1061-folded 
capillary cells (Malvern), and D51588 (SARSTEDT AG and Co.) disposable sizing cuvettes 
were utilized, respectively. All the measurements were repeated at least 3 times and the 
average result was calculated. 
3.1.7 Dissolution of zinc oxide NPs in cell culture media and simulated body fluids (ICP 
OES) 
 The dissolution of bare ZnO NPs in CMEM, CDMEM, CL-15, and CDMEM: F-12, HEPES 
confocal imaging buffer at pH 7.4 and Lys- SBF at pH 5.2 were analysed using a Varian 720-
ES Axial ICP-OES. The ZnO NPs dispersed in ethanol were sonicated for 20 min, and 100 
μg/ml dispersions in CDMEM, CMEM, and confocal imaging buffer at pH 7.4 were prepared. 
The dispersions were then incubated immediately at 37°C for 0, 1, 2, 4, 8, 24 and 48 h. For 
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the lys-SBF at pH 5.2, 600 μg/ml of bare ZnO NPs dispersion was prepared and additional 
time points at 5, 15 and 30 min were prepared as described previously. Undissolved ZnO 
NPs were removed at each time point by centrifugation for 30 min at 12,000 xg at RT in a 
table-top centrifuge using Vivacon 500 filter inserts (2 KDal molecular weight cut off; 
Sartorius Stedium Biotech, Germany). An aliquot of the filtrate was then diluted using 2% 
aqueous HNO3 for measurement of total Zn
2+ concentration. Each experiment was repeated 
three times.  
 To study the effect of FBS on the dissolution of bare ZnO NPs in culture media, 100 
μg/ml dispersion of bare ZnO NPs in MEM supplemented with 1% FBS was prepared, and 
the dispersions were processed, as above. 
 For the ZnO-HCV-RGD-GFP, the dissolution was studied in the HEPES confocal 
imaging buffer. The targeted ZnO NPs were sonicated for 30 s and 100 μg/ml dispersions in 
the HEPES confocal imaging buffer at pH 7.4 were prepared. The dispersions were then 
incubated immediately after preparation at 37°C for 0, 1, 2, 4, 8, 24 and 48 h. Samples for 
ICP-OES  analysis were prepared, as described above with the bare ZnO NPs. 
 Quantification of the amount of ionic zinc was undertaken via external calibration 
with a series of matrix-matched zinc standard solutions in the approximate range of 0.1-
1000 μg/ml Zn2+.  
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3.2 Results and Discussion 
3.2.1 Size and morphology of the bare zinc oxide nanoparticles 
The morphology and the relative frequency size distribution of the bare ZnO NPs are shown 
in Figure 6. While most of the NPs were spherical, a small proportion were irregular in 
shape, and aggregates of different sizes of the NPs, which could be due to room 
temperature drying artefacts, could be observed (Figure 6 (a-c)).  (Figure 6, a-c). 
Characteristic peaks of zinc (K and L at 8.63 and 1.012 keV, respectively) could be observed 
in the EDX profile (Figure 6, d). The size of the bare ZnO NPs provided by the manufacturer 
was 10-30 nm; however the average size measured by TEM was 56.7 ± 21.7 nm. The bare 
ZnO NPs had a wide size distribution, ranging from 20 to 150 nm (Figure 6, e). 
3.2.2 Functionalisation and binding of targeting peptide to ZnO NPs 
 To test the efficiency of binding of the targeting peptide (HCV-RGD-GFP) to ZnO NPs, the 
absorbance of the targeting protein solution before and after incubation with the particles 
was measured at 490 nm.  
  Both the targeting peptide (HCV-RGD-GFP) and the negative control (HCV-GGG-
GFP) proteins were found to bind to ZnO NPs after incubation, as shown by a reduction in 
the UV-Visible absorbance measured at 490 nm (Figure 7, a and b). This binding was 
effective after only 1h of incubation of the particles with the proteins. The GFP protein 
without the HCV binding motif did not show any binding to the ZnO NPs (data not shown).  
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Figure 6: Bright field TEM images (a-c), EDX spectrum (d), and the relative diameter frequency distribution (e) of the bare 
ZnO NPs.  
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Figure 7: Binding of GFP proteins to ZnO NPs. (A) HCV-RGD-GFP protein and (B) HCV-GGG-GFP protein. Bare ZnO NPs 
were prepared in 50 mM HEPES buffer containing 100 mM NaCl at pH 7.5 and then incubated with the proteins in the 
same buffer at a concentration of 1 mg/ml for 12 h at RT in the dark and absorbance was measured at 490 nm. 
3.2.3 Hydrodynamic radii and zeta potentials measurement of the ZnO nanoparticles 
To assess the effect of culture media on the dispersion state of the particles and their 
subsequent cellular uptake and bioreactivity, dispersions of the bare ZnO NPs in the 
different vehicles (deionised water, CMEM, CDMEM, CDMEM:F-12, and HEPES confocal 
imaging buffer) used throughout the study were analysed using a Malvern Nanosizer. The 
hydrodynamic size of the ZnO-HCV-RGD-GFP NPs was measured in HEPES confocal imaging 
buffer. The frequency size distribution curves of the bare ZnO NPs in the different vehicles 
are presented in Figure 8-Figure 12. The frequency size distribution curve of the ZnO-HCV-
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RGD-GFP NPs in the HEPES confocal imaging buffer is presented in Figure 13. The mean 
hydrodynamic diameter of the bare and targeted ZnO NPs in the different vehicles, as 
determined by DLS, is summarized in Table 4.  
 The results suggested that both the bare and the targeted ZnO NPs aggregated. The 
PdI of the bare ZnO NPs was < 0.25 in all tested vehicles, while the PdI of the targeted ZnO-
HCV-RGD-GFP NPs was high (0.76), which means a very heterogeneous size distribution of 
the targeted ZnO NPs in the HEPES confocal buffer. However, the Malvern Zetasizer 
analyses the laser light scattered from the particles and does not directly measure the 
aggregate size; moreover, the average size of the aggregates measured can be skewed by 
the presence of extremely large or small aggregates [116, 117]. This agglomeration of ZnO 
nanostructures in cell culture media has been reported previously; Moos et al., [118] 
showed that 8-10 nm ZnO NPs formed micrometre-sized ZnO NPs in DMEM supplemented 
with 2% FBS. The aggregation of the NPs in different media used is most probably due to 
high ionic strength of the media. It has been reported that the stability of metal oxide NPs in 
aqueous solutions depends to a large extent on the ionic strength [119-122].  Suspensions of 
4 nm ZnO NPs were found to be more stable at low ionic strength while they were prone to 
aggregation as the ionic strength was increased [122]. It has also been shown that the zeta 
potential of ZnO NPs decreases with increasing ionic strength, and thus ZnO NP-NP 
interaction is quite repulsive at low ionic strength (below 0.04 M NaCl) [122]. In this study, 
the bare and targeted ZnO NPs were prepared in HEPES confocal imaging buffer. The HEPES 
confocal imaging buffer was prepared as 10 mM HEPES at pH 7.4, containing 145 mM NaCl, 
5 mM KCl, 1 mM MgSO4 1.5 mM CaCl2, and 0.16% Glucose to simulate body fluids. This high 
ionic strength buffer could cause aggregation of the ZnO NPs. This aggregation could affect 
the uptake of the ZnO NPs and consequently their toxicity. It would have been too 
ambitious in this study to develop methods to increase the colloidal stability of ZnO NPs and 
also target them to cancer cells.  This should be the subject of future investigations.  Instead 
my work is a platform for future studies to understand how and by which mechanism ZnO 
NPs interacts with cancer cells and whether is safe to use.  These fundamental studies need 
to be performed to understand whether ZnO NPs have the potential to be used in cancer 
therapy before designing much more sophisticated nanoparticles for testing.   
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 The effect of FBS in MEM, DMEM and DMEM: F-12 media on the hydrodynamic size 
distribution of ZnO NP-protein complexes was also investigated. The ZnO NP-protein 
complex size distribution in MEM and DMEM supplemented with 1 and 10% FBS, (or 1 and 
5% horse serum in DMEM: F-12) is presented in Figure 9- Figure 11. The results suggest a 
smaller ZnO NP aggregate size was formed in the media supplemented with a higher 
percentage of serum (10% FBS in MEM and DMEM, and 5% horse serum in DMEM: F-12). 
This finding could indicate that the size distribution of ZnO NP dispersions is more stable in 
the presence of FBS. This effect of proteins on the size stabilisation of ZnO NPs has been 
reported previously [60], and could be due to the reduction of surface free energy of the 
ZnO NPs, preventing significant aggregation. 
  
 
Figure 8: Hydrodynamic size distribution of the bare ZnO NPs after dispersion in (A) deionised distilled water (pH 6.3) 
and (B) Confocal imaging buffer (pH 7.4). The average diameter ZnO NPs was 703.8 and 1231 nm, respectively.  
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Figure 9: Hydrodynamic size distribution of the bare ZnO NPs after dispersion in DMEM supplemented with (A) 1% FBS 
and (B) 10% FBS. The average diameter ZnO NPs was 1375 and 797 nm, respectively.  
 
Figure 10: Hydrodynamic size distribution of the bare ZnO NPs after dispersion in MEM culture media supplemented 
with (A) 1% FBS and (B) 10% FBS. The average diameter ZnO NPs was 1335 and 480.6 nm, respectively. 
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Figure 11: Hydrodynamic size distribution of the bare ZnO NPs after dispersion in DMEM: F-12 culture media 
supplemented with (A) 1% horse serum and (B) 5% horse serum. The average diameter ZnO NPs was 784.3 and 746.9 
nm, respectively. 
 
Figure 12: Hydrodynamic size distribution of the bare ZnO NPs after dispersion in HEPES buffer at pH 7.4 (10 mM 
HEPES+50 mM KCl) used for protein binding experiments. The average diameter ZnO NPs was 1121 nm, and the PdI was 
0.102.  
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Figure 13: Hydrodynamic size distribution of ZnO-HCV-RGD-GFP NPs after dispersion in 10 mM HEPES confocal imaging 
buffer. The average diameter ZnO NPs was 1370 nm, PdI=0.760.  
 The zeta potential measurements of the bare ZnO NPs in deionised water at pH 6.3 
showed that the particles had a positive zeta potential of +39.6 mV (Figure 14). The zeta 
potential of the bare ZnO NPs was not possible to measure in the different culture media 
used in this study, even in the absence of FBS. This is because the proteins in the FBS and 
amino acids in the cell culture media interfered with the measuring electrodes of the cell 
used for the zeta potential measurements. Therefore, to study the effect of adsorbed 
proteins on the surface charge of the bare ZnO NPs, the NPs were washed three times after 
incubation in CDMEM before resuspended in 10 mM HEPES buffer (pH=7.4). The zeta 
potential of the bare ZnO NPs was +28.6 mV (Figure 15) compared to -28.6 mV with the 
protein corona in 10 mM HEPES buffer (pH 7.4) (Figure 16) showing that the adsorbed 
proteins on the surface of ZnO NPs dramatically change the zeta potential of the ZnO NPs. 
The observed charge reversal of the bare ZnO NPs provided evidence for the adsorption of 
negatively charged serum proteins onto the ZnO NPs. This change in the surface charge of 
the bare ZnO NPs, upon adsorption of serum proteins, may affect the mobility and 
interaction of these particles with cellular membranes [123].  
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Figure 14: Zeta potential of 0.1 mg/ml bare ZnO NPs in deionised distilled water at pH 6.3 (+39.6 mV). 
 
Figure 15: Zeta potential of 0.1 mg/ml bare ZnO NP-protein complex in 10 mM HEPES buffer at pH 7.4 (+28.6 mV). 
 
Figure 16: Zeta potential of 0.1 mg/ml bare ZnO NP-protein complex in 10 mM HEPES buffer at pH 7.4 (-28.6 mV). 
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Table 4: Average size distribution and PdI of ZnO NPs in different media. 
 
NPs 
 
Media 
 
Average diameter (nm) 
 
PdI 
 
Zeta potential (mV) 
Bare ZnO  DMEM+1% FBS 1375 0.203  
 DMEM+10% FBS 797 0.219  
 MEM+1%FBS 1335 0.274  
 MEM+10%FBS 480.6 0.318  
 DMEM:F-12+1% horse 
serum 
784.3 0.299  
 DMEM:F-12+5% horse 
serum 
746.9 0.255  
 Deionised distilled 
water (pH=6.3) water 
703.8 0.233 +39.6 
 Confocal imaging buffer 1231 0.141  
 10 mM HEPES buffer 
(pH 7.4) 
  +28.6 
 10 mM HEPES+ 50 mM 
NaCl (pH 7.4) 
1121 0.102  
Bare ZnO with protein 
corona from FBS 
10 mM HEPES buffer 
(pH 7.4)  
  -28.6 
ZnO-HCV-RGD-GFP  Confocal imaging buffer 1370 0.760  
 
3.2.4 Dissolution of zinc oxide nanoparticles in cell culture media and simulated body 
fluids 
When the thermodynamic properties of ZnO nanostructures (including surface free energy) 
favour dissolution in a suspending media or biological environment, toxic Zn2+ ions may be 
generated [71]. Zinc oxide NPs can dissolve in an aqueous media to form hydrated Zn2+. This 
dissolution is enhanced in acidic pH, as well as in the presence of biological components 
such as amino acids and peptides [49]. As illustrated in section 2.4.2, several studies had 
shown that the toxicity of ZnO NPs is attributed to the release of ionic zinc [124]. Since 
different cell culture media have a different composition, it is necessary to measure the 
dissolution of ZnO NPs in each medium before its use in any viability studies. However, few 
studies quantified the amount of released Zn2+ from ZnO NMS into the media used for their 
studies. Some of the reported dissolution studies on ZnO NPs in different culture media are 
illustrated in Table 5. However, saturated concentrations of ionic zinc as well as zinc ion 
complexes were not apparent in these studies. In Reed et al. study [125], for instance, 
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saturated conditions with respect to ionic zinc were not apparent in studied matrices, even 
after more than 1,000 h of dissolution. These studies reported a higher solubility of ZnO NPs 
in culture media compared to ultrapure water [125]. The high solubility of ZnO NPs in the 
culture media was attributed to the formation of aqueous complexes of Zn2+ with organic or 
inorganic constituents of the complex media. After dissolution, zinc ions generate a range of 
poorly soluble Zn-containing NPs (e.g. zinc phosphate, -carbonate, and/or -sulphides) when 
added to commonly used mammalian cell culture media [125-129]. Therefore the Zn2+ 
released by dissolving ZnO NPs in a given matrix may simply precipitate in another form and 
not be present as either ZnO NPs or dissolved Zn2+.  
 In this study, the dissolution of the bare ZnO NPs in different complete culture 
media used throughout this study, as well as in the HEPES confocal imaging buffer (pH=7.4) 
and lyso-SBF (pH=5.2), was measured (Figure 17, a and b). The bare ZnO NPs showed ≤ 10% 
dissolution in all cell culture media (pH 7.3) and in the confocal imaging buffer at pH 7.4 
(Figure 17, a). The maximum dissolved zinc ions concentration was achieved rapidly within 
the first hour of incubation of the bare ZnO NPs in the different media, and therefore the 
dissolution profile before equilibrium conditions was not obvious (Figure 17, a). The 
dissolved zinc ions interact with the inorganic salts present in the different culture media 
(e.g. phosphate, carbonate and/or sulphate), which results in reprecipitation of ionic zinc as 
zinc phosphates and phosphate (Figure 17, a). However, the dissolved zinc ions reached 
equilibrium within the first 8 h of incubation in all cell culture media buffered at pH=7.3 
(Figure 17, a). The dissolution of ZnO NPs in DMEM in Xia et al. [49] and Reed et al. [125], 
was 14.63 μg/ml and  >34 μg/ml, respectively (Table 5), which is much higher than the 
values obtained in this study (Figure 17, a). As expected from the phase-solubility diagram of 
zinc oxide [130], the bare ZnO NPs completely dissolved in lyso-SBF (pH=5.2) (Figure 17, b). 
The presence of proteins from 10% FBS in MEM media slightly increased the amount of 
dissolved Zn2+ from the bare ZnO NPs compared to 1% FBS in the same medium. The effect 
of the media on the dissolution of the ZnO NPs was clear in L-15 medium. Almost 52% of the 
total amount of the bare ZnO NPs dissolved in CL-15 after 3 h of incubation at 37°C (Figure 
18). Therefore, if L-15 or other media with similar Zn solubility profile was used in ZnO 
toxicity studies, it could be incorrectly concluded that the ZnO NPs are responsible for any 
observed toxic effect, even though no actual exposure of the cells to ZnO NPs would have 
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occurred, as they would have completely dissolved. The composition of all culture media 
used in this study is illustrated in the eppendix at the end of this thesis. 
 To assess any effects of the RGD-targeting peptide on the dissolution of the NPs, 
the dissolution of the ZnO-HCV-RGD-GFP NPs was studied in HEPES confocal imaging buffer 
at pH 7.4 (Figure 19). The targeted ZnO-HCV-RGD-GFP NPs experienced a low amount of 
dissolution (< 1%) in the HEPES confocal imaging buffer (Figure 19). 
Table 5: Reported dissolution of zinc oxide particles in DMEM, BEGM, RPMI cell culture media and water.  
Study Primary 
particle size of 
ZnO 
(nm) 
Total 
amount of 
ZnO used 
Conditions 
 
Maximum dissolved zinc concentration 
Time Temperature 
(°C) 
DMEM
a
 
 
BEGM
b
 
 
RPMI
c
 water 
Xia et al., [49] 13 
 
Excess 
amount 
4 
days 
22 225 µM 
(14.63 
μg/ml) 
190 µM 
(12.35 
μg/ml) 
  
Song et al., [68] 10-30 nm, 30 
nm, 100 nm, 
fine particles 
 
40 μg/ml 24 h 37   153.79 
µM 
(10.0 
μg/ml) 
nanopure 
water  
7.18–
7.40 
μg/ml 
Reed et al., 
[125] 
159±4 100 mg/ml 24 h 20 >34 
μg/ml 
 5 μg/ml  
a
DMEM: Complete Dulbecco’s modified eagle media which contains 10% fetal bovine serum (FBS) 
b
BEGM: Bronchial epithelial growth medium, which includes growth factors, cytokines, and supplements (no serum) 
c
PRMI-1640: Roswell Park Memorial Institute medium with 10% fetal bovine serum (FBS) 
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Figure 17: Dissolution of bare ZnO NPs in (a) MEM with 1% and 10% FBS, CDMEM: F-12, CDMEM, and HEPES confocal 
imaging buffer (pH=7.4), (b) lyso-SBF at pH 5.2. A 100 and 600 μg/ml ZnO NPs μg/ml were prepared at zero time for 
curve (a) and (b) respectively. Experiments were repeated in triplicate in three independent experiments. 
Concentrations are presented as mean ± SD (n=3). 
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Figure 18: Dissolution of bare ZnO NPs in L-15+10 % FBS. 100 μg/ml ZnO-HCV-RGD-GFP NPs dispersions were prepared at 
zero time. Experiments were repeated in triplicate in three independent experiments. Concentrations are presented as 
mean ± SD (n=3). 
 
Figure 19: Dissolution of ZnO-HCV-RGD-GFP in 10 mM confocal imaging buffer pH 7.4. 100 μg/ml ZnO-HCV-RGD-GFP NPs 
dispersions were prepared at zero time. Experiments were done in triplicate in three independent experiments. Bars are 
presented as mean ± SD (n=3). 
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3.3 Summary and conclusions 
ZnO NPs were prone to rapid agglomeration and they tend to have a wide size distribution 
once they are dispersed in different media. The use of surfactants is reported to stabilize 
NPs dispersions [131], but this will change the surface chemistry of the NPs and 
subsequently their bioreactivity. The adsorbed protein corona formed onto the surface of 
the NPs was found to stabilize the dispersions of the ZnO NPs. Aggregation of the NPs could 
decrease the available surface area of the NPs, which would decrease the dissolution rate. 
 ZnO dissolution was affected by the pH and the type of vehicle. The bare ZnO NPs 
showed a low solubility in MEM, DMEM and DMEM: F-12 cell culture media, and HEPES 
confocal imaging buffer. Therefore, these media could be used for the viability and uptake 
studies with the ZnO NPs. The L-15 medium, which is recommended by the ATCC for culture 
of MDA-MB-231 cells, on the other hand dissolved more than 52% of the particles within 1 
h. Consequently L-15 could not be used in this study and DMEM was used instead. The bare 
ZnO NPs were completely dissolved in the lys-SBF at pH 5.2. 
 One of the major features of solid tumour tissues is the acidic pH of their 
extracellular matrix. The acidic extracellular pH of tumour tissues is due to the anaerobic 
metabolism which releases lactic acid and due to poor perfusion of the tumour tissues [132, 
133]. This extracellular acidity of solid tumours is suggested to have varying effects on the 
response of cells to conventional anticancer drugs and it might allow the development of 
new and relatively specific types of therapy [134]. The pH-specific dissolution of ZnO NPs 
can be utilised to target these NPs to tumor tissue. At acidic pH, the ZnO NPs will dissolve 
and exert their toxic effects, with minimal effects on healthy cells. In in vitro assays, 
however, the cells are grown in media with buffers that maintain the pH at 7.4, so the cells 
are not likely to have such extracellular acidic pH. Therefore, upon exposure of the breast 
cancer cells to ZnO NPs in in vitro assays, the NPs will dissolve intracellularly inside the 
lysosomes after their uptake. Herein, the ZnO NPs dissolved quickly in the lyso-SBF at pH 
5.2; consequently, they are expected to dissolve in the tumor tissue acidic extracellular pH, 
as well as within the acidic pH of the lysosomes upon their cellular uptake. 
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 The protein corona on the surface of the bare ZnO NPs changed the surface charge 
of the bare ZnO NPs from +28.6 to -28.6. This change in the surface charge of the NPs can 
change their bioreactivity [135, 136].   
 In conclusion, before in vitro testing, the toxicity of NPs on cells, a thorough 
characterisation of the NPs which include their hydrodynamic size, their solubility, and 
interaction with proteins or with other component of cell culture media, is crucial. Upon 
interaction of the NPs with proteins and cell culture media, their physicochemical properties 
(e.g. surface charge) may be altered and this could affect their bioreactivity and 
consequently their toxicity.    
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4 Toxicity of bare and RGD-targeted zinc oxide NPs to breast cancer 
cells 
The aim of this chapter was to study the toxicity of ZnO NPs to breast cancer cells. Breast 
cancer is a complex and heterogeneous disease that can be classified according to the 
presence of predictive markers like oestrogen receptor (ER), progesterone receptor (PR) and 
human epidermal growth factor receptor 2 (HER-2) [137, 138]. Approximately 60–70% of 
breast cancers express estrogen receptors (ER) and/or progesterone receptors (PR) and 
approximately 20–30% of breast cancers have amplified HER-2 and express high levels of 
the HER-2 protein [138]. Molecular targeted therapies that inhibit the oestrogen pathway or 
that target amplified HER-2 are effective in the treatment of breast cancer cells in patients 
whose tumours express these targets [138]. In approximately 15–20% of patients with 
breast cancer, the tumours do not express ER or PR and do not have amplification of HER-2 
and these are called triple-negative breast cancer and they do not respond to hormonal 
therapy [138, 139]. In the laboratory, breast cancer is often modelled using established cell 
lines. In this study, two breast cancer cell lines have been used; MCF-7 and MDA-MB-231 
cells. We have chosen these cell lines for the following reasons; first, these breast cancer 
cells have been widely used in vitro as a model to study toxicity against breast cancer cells 
[140]. Second, MCF-7 and MDA-MB-231 cells were used as ER+, PR+/–, HER2– and ER–, PR–, 
HER-2– cell models, respectively. MCF-7 cells, which are the most commonly used breast 
cancer cell line in the world, express estrogen receptors but not HER2 and they respond to 
hormonal therapy [137]. MDA-MB-231 cells, on the other hand, are triple negative breast 
cancers, so they do not respond to hormonal therapy. Third, treatment options of triple 
negative breast cancers are limited because of lack of targeted treatments [138, 139]. Thus, 
identification of novel, targeted therapies for triple-negative breast cancer would be of 
great benefit.  
 One of the serious drawbacks of the current cancer chemotherapy is the non-
specific systemic delivery to cancer cells. This results in damage to normal unaffected tissue 
as well as to cancer cells and can result in both short-term and long-term negative damaging 
effects. Therefore, in this study the effect of ZnO NPs on healthy MCF-10-2A breast 
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epithelial cell line was also investigated. MCF-10-2A cells have been used as a model of 
healthy breast cells in several breast cancer studies [141-143].  
 The effect of RGD-targeting of the ZnO NPs to integrin αvβ3 receptors on the 
toxicity of breast cancer cell lines was also investigated. We have chosen to attach an RGD 
peptide (discussed in section 3.1.4) to the bare ZnO NPs that specifically binds the integrin 
αvβ3 receptors expressed on breast cancer cells, but not on the healthy epithelial cells. We 
will refer to the targeted NPs as ZnO-HCV-RGD-GFP NPs. Integrin αvβ3 is present on the 
surface of several cancer cells [91, 144, 145]. Analysis of metastatic breast tumours showed 
10-15- fold higher expression levels of integrin αvβ3 receptors vs. healthy epithelial cells 
[146, 147]. Consequently,  is considered an ideal cancer biomarker [148] and a potential 
delivery systems for cancer therapeutics [149]. The tripeptide sequence, Arg-Gly-Asp has 
been found to be highly selective for the integrin αvβ3 [91, 150, 151]. Recently, one study 
has successfully used the RGD as a ligand for ZnO NPs targeting to the integrin αvβ3 of 
human glioblastoma cells to detect these cells optically [12].  
 A number of different assays have been used to evaluate the toxicity of ZnO NMS in 
different cells in the literature. Different viability assays measure different cytotoxic end 
points such as oxidative stress, metabolic activity, and cell death [20]. Consequently, 
comparisons between the outcomes of these assays can be difficult. For example, the 
Alamar Blue assay measures cell metabolic activity, while the lactate dehydrogenase (LDH) 
assay measures cell membrane integrity. After certain time exposure to the NPs, the cell 
could be metabolically inactive, but its cell membrane may not be compromised, and 
therefore it will be recorded as dead (or not viable) in the Alamar Blue assay but not dead in 
the LDH assay. Furthermore, some viability assays (e.g. MTT, Alamar Blue, etc.), which are 
based on the detection of the metabolic activity of the cells after exposure to the NPs, 
require a long incubation time with the cells and this could lead to a false-positive results. 
These false positive results could be due to the fact that the NPs are not fully removed 
before adding the assay solution or inefficient washing of the NPs before adding the assay 
solution. Consequently, a number of viability assays should be used in combination to assess 
the toxicity of the NPs. Therefore, in this study, three viability assays have been used; the 
Alamar Blue, lactate dehydrogenase (LDH), and adenosine triphosphate (ATP) assays. The 
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toxicity of the bare and targeted ZnO NPs at different concentrations and exposure times 
has been studied in order to find a concentration window at which the ZnO NPs will exert 
toxic effects to the breast cancer cell lines, but not to the healthy epithelial breast cells. 
 Finally, to detect whether the cell death induced by the bare ZnO NPs occurred 
through apoptotic or necrotic pathways, an Annexin V/7-Aminoactinomycin D (7AAD) assay 
was conducted. Cell death is typically discussed as either apoptosis or necrosis. Apoptosis is 
described as an active, programmed process that results in cellular fragmentation into 
apoptotic bodies which are engulfed by macrophages or adjacent cells without eliciting 
inflammation [152]. Necrosis, on the other hand, has been characterized as passive, 
accidental cell death process that elicit uncontrolled inflammatory cellular responses [153]. 
As apoptosis is considered to be a regulated and controlled process, its occurrence during 
cancer treatment has received great attention [154, 155].    
 Through in depth understanding of the cellular responses resulting from ZnO NPs 
interactions with breast cancer cells, the inherent toxicity and selectivity of ZnO NPs against 
cancer may be further improved to make them attractive new anti-cancer agents.  
4.1 Materials and methods 
PE-Annexin V Apoptosis Detection Kit was from BD Pharmingen, UK. Hank's Balanced Salt 
Solution (HBSS) was purchased from Invitrogen Ltd, UK. ZnCl2 (98%), Trypsin (0.25%) and 
Triton X-100 were purchased from Sigma Aldrich Ltd, UK. Mouse anti-human integrin αvβ3 
antibody (cat.no CBL544, clone 23C6) was purchased from Millipore (Temecula, CA, USA). 
4.1.1 Cell culture 
The MDA-MB-231, MCF-7 and MCF-10-2A cell lines were purchased from ATCC (Manassas, 
VA, USA). The MDA-MB-231 and MCF-7 were maintained in DMEM, MEM, respectively. 
MEM and DMEM media were supplemented with 10% fetal bovine serum (FBS), and 
Penicillin/Streptomycin solution (100 units/ml penicillin, 100 μg/ml streptomycin). Cells 
were maintained in a humidified incubator at 37°C and 5% CO2. MCF-10-2A cells were grown 
in DMEM:F-12 media supplemented with 20 ng/ml epidermal growth factor (Invitrogen, Life 
Technologies Ltd, UK), 100 ng/ml cholera toxin (Sigma-Aldrich Ltd, UK), 0.01 mg/ml insulin, 
100 ng/ml hydrocortisone, Penicillin/Streptomycin solution (100 units/ml penicillin, 100 
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μg/ml streptomycin) and 5% horse serum was used. MCF-10-2A cells were maintained in a 
humidified incubator at 37°C and 5% CO2.  
4.1.2 Cell viability assays  
For the cytotoxicity testing, three assays; Alamar Blue, LDH and ATP assays were employed. 
In all assays, cells were used from passages 5-25 and plated in flat-bottomed 96-well plates 
(Fisher Scientific Ltd, UK). The MCF-7 and MCF-10-2A were plated at a density of 3 × 105 
cells mL−1 (9 x 104 cells/cm2), while MDA-MB-231 was plated at a density of 2×105 cells mL-1 
(6×104 cells/cm2). These cell densities were chosen to ensure almost 80-90% confluency for 
each cell line. The plates were incubated at 37°C and 5% CO2 in a humidified incubator for 
24 hours. Then, supernatants from the culture plates were removed and fresh aliquots of 
growth medium containing different concentrations of ZnO NPs (bare and targeted) were 
added to the cells and then incubated with the cells for another 3, 24 h and/or 48 h for 
toxicity and IC50 analysis. The cytotoxicity was determined in at least three independent 
experiments performed in triplicate.   
 Stock suspensions of the bare ZnO NPs were prepared in ethanol, to ensure the 
NPs sterility for the assays. In each viability study, the particles were freshly prepared in 
media by sonication of the stock dispersions for 20 min on a bench sonicator and the 
particles were diluted to the desired concentration in the media and directly applied to 
breast cancer cell lines. The targeted ZnO NPs stock suspensions were prepared in 50 mM 
HEPES+100 mM NaCl buffer at pH 7.5. In each viability study, the targeted ZnO-HCV-RGD-
GFP NPs were freshly prepared in media by sonication of the stock dispersions for 30 s on a 
bench sonicator and the particles were diluted to the desired concentration in the media 
and directly applied to breast cancer cell lines.  
 As the NPs have been shown to interact with dyes in the colorimetric assays [117], 
control experiments using the Alamar Blue, LDH and ATP assays were performed using the 
same protocol as the experiments in this study, but without the cells-in order to confirm 
that the ZnO NPs did not interfere with the viability assays. No effects were observed for all 
assays (data not shown). 
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 Alamar Blue assay 4.1.2.1
To assess the metabolic activity of the cells after exposure to ZnO NPs, the Alamar Blue 
assay was carried out using the water soluble reagent, Alamar Blue (Invitrogen). Alamar Blue 
detects the reducing environment of living cells. Reduction of Alamar Blue can indicate the 
impairment of cellular metabolism and not only mitochondrial dysfunction [156]. In this 
assay, the cells were registered as viable, as long as they maintained their ability to reduce 
Alamar Blue. 
 The Alamar blue assay was used according to the manufacturer’s protocol. Briefly, 
at the end of the incubation time (3 and 24 h) with the bare (10, 20, 25, 30, 35, 40, 50, and 
60 μg/ml) and targeted (10, 20, 25, 30, 35, 40, 50, 60 and 100 μg/ml) ZnO NPs, the medium 
was removed and the cells were washed twice with fresh media. Alamar Blue was diluted 
with the medium to 10% (v/v) in the dark, and the plates were then treated with 100 μL of 
Alamar Blue 10% solution and incubated in a humidified atmosphere at 37°C and 5% CO2. 
After an appropriate incubation time, i.e. 4, 9, and 11 h for MCF-10-2A, MCF-7, and MDA-
MB-231, respectively, the spectrophotometric absorbance was measured at two 
wavelengths 570 nm (reduced form of Alamar Blue) and 600 nm (oxidised form of Alamar 
Blue) using a Bio-Rad plate-reader. The mean absorbance reading from the wells without 
the particles was used as the control (100% viability) and those treated with 1% Triton X-100 
was used as a positive control (0% viability). The toxicity of the targeting peptide (GFP-HCV-
RGD) to the cells was tested at the highest concentration used in the assays (50 μg/ml). IC50 
values were determined by interpolation of the resulting curves.  
Expression of integrin αvβ3 by breast cancer and normal epithelial cells 
Expression of integrin αvβ3 receptors on cells has been shown to be cell line specific [157]. 
Therefore and since the ZnO-HCV-RGD-GFP NPs were used in our study to target the 
integrin αvβ3 receptors on the breast cancer cells, it was important to assess the expression 
of these receptors on all cell lines used in this study before exposure to the RGD-targeted 
ZnO NPs.   
 The expression of integrin αvβ3 was determined in the two breast cancer cell lines 
MDA-MB-231, MCF-7 and in the healthy breast MCF-10-2A cells. The cells were harvested 
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from T-175 flasks using 3 ml Accutase, counted, and washed with HBSS. A total of 500,000 
cells were incubated with, or without, 10 μg/ml of purified mouse anti-human integrin αvβ3 
antibody (cat.no CBL544, clone 23C6, Millipore, Temecula, CA, USA) in 50 μL HBSS for 30 
min at 4°C. The cells were then washed three times with ice-cold HBSS, suspended in 200 μL 
of HBSS, and then incubated with 10 μg/ml secondary antibody (Alexa Fluor 488 Goat Anti-
Mouse IgG (H+L), Invitrogen, UK) for 15 min on ice. The cells were washed twice and 
resuspended in 500 μL HBSS and subjected to flow cytometric analysis on a FACSCanto II 
flow cytometer (BD bioscience, Franklin lakes, NJ). Mouse IgG1 (Biolegend, UK) was used as 
an isotype control. 
 Lactate dehydrogenase (LDH) assay 4.1.2.2
LDH is a cytoplasmic enzyme that is released into the supernatant upon cell lysis. The LDH 
assay, therefore, is a measure of membrane integrity. The kit includes a catalyst 
(diaphorase/ NAD+) and a dye solution (iodotetrazolium chloride (INT) and sodium lactate). 
The LDH enzyme oxidizes lactate to pyruvate which reacts with the tetrazolium salt to form 
formazan. The water-soluble formazan dye is then detected spectrophotometrically [158]. 
In this assay, a dying cell could register as viable as long the cell membrane was intact for 
LDH release. 
  The LDH released upon exposure to ZnO NPs from damaged cells into the culture 
media was determined by Takara LDH Kit (Takara, CA, USA) and using the manufacturer’s 
protocol. Briefly, after 24 and 48 h incubation with the bare particles (10, 20, 25, 30, 35, 40, 
50, 60, and 100 μg/ml), 50 μL of the culture media above the cells was collected both cell 
and nanoparticle- free and incubated for 30 min with the reaction mixture (mentioned 
above) from the kit, and the reaction was stopped using 1 M HCL to a final concentration of 
0.2 M. The rate of reduction of tetrazolium is directly proportional to LDH activity in the cell 
medium. Absorbance was measured using a Bio-Rad plate reader at 490 nm. The LDH assay 
requires low-serum medium because FBS contains LDH and thus can increases background 
absorbance [159], and therefore all culture media used were supplemented with 1% FBS for 
the MCF-7 and the MDA-MB-231 cells, and 1% horse serum for the MCF-10-2A cells. The 
mean absorbance reading from the wells without the particles was used as the negative 
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control (100% viability), and those treated with 1% Triton X-100 was used as a positive 
control (0% viability) [11]. 
 ATP assay 4.1.2.3
The ATP assay determines the number of viable cells in culture based on quantification of 
the ATP present, which signals the presence of metabolically active cells, which produce ATP 
as energy for respiration and other vital processes. ATP content was determined using 
CellTiter-Glo Luminescent Cell Viability kit (Promega, Madison, USA). The kit includes the 
enzyme luciferase and the substrate luciferin. In the presence of ATP, luciferin is reduced to 
oxyluciferin with the production of light. The Light signal is proportional to the amount of 
ATP present which correlates with the number of viable cells present. Because ATP assay 
was used to assess the viability results obtained from the Alamar Blue assay, only MDA-MB-
231 cells were tested using this assay.  
 After 24 and 48 h incubation of MDA-MB-231 cells with the bare (10, 20, 30, 40, 50, 
and 100 μg/ml) and targeted (20, 30, and 50 μg/ml) ZnO NPs particles, the plate and its 
contents were equilibrated at RT for approximately 30 min. Then 100 μL of the CellTiter-
Glo® Reagent was added to each well and the contents were mixed for 2 min on an orbital 
shaker to induce cell lysis. The plates were then incubated at RT for 10 min to stabilize 
luminescent signal. Finally, chemical luminescence was measured with a GloMax 
Luminometer (Promega, UK). The toxicity of ZnO-HCV-GGG NPs used as a negative control 
for RGD targeting was also tested at the same concentrations. The experiment was repeated 
twice (n=2) for each NP type and the percentage cell cytotoxicity and cellular level of ATP 
were expressed as a percentage of the nontreated control (100% viability). Triton X-100 was 
used as a positive control (0% viability). 
4.1.3 Mode of Cell death by Annexin V- 7AAD (necrosis and apoptosis) 
The mode of cell death induced by the bare ZnO NPs was evaluated using a PE Annexin V-
7AAD Apoptosis Detection Kit (BD Bioscience, CA, USA). Briefly, the cells were plated in flat-
bottomed 96- well plates as described in section 4.1.2, and they were then exposed to bare 
ZnO NPs (20, 30, 50 μg/ml) for 3, 8, and 12 h, and to the whole range of concentrations of 
the bare ZnO NPs (10, 20, 25, 30, 35, 40, 50, 60, and 100 μg/ml) for 24 h. Following each 
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incubation time, the untreated and treated cells were harvested from triplicate wells, and 
washed with ice-cold HBSS. Subsequently, the cells were mixed with 100 μL of pre-diluted 
Annexin V-binding buffer (1×). Annexin V-PE (5 μL) and 7AAD (5 μL) were added sequentially 
to the cell suspension and further incubated at RT in the dark. After 15 min of incubation, 
400 μL of binding buffer (1×) was added into each tube. The percentage of cells undergoing 
apoptosis and necrosis was quantified on a FACSCanto II flow cytometer (BD bioscience, 
Franklin lakes, NJ) equipped with FlowJo 7.6 software within 1 h. Cells without treatment 
with ZnO NPs were used as negative control. Cells staining with Annexin V-/7AAD+ were 
recognized as necrotic, those staining with Annexin V+/7AAD+ were taken as late apoptotic 
or secondary necrotic, whilst Annexin V+/7AAD- cells were recognized as apoptotic cells 
[79]. 
 The apoptotic and/or necrotic effects of ionic Zn2+ on breast cancer cell lines was 
also measured and compared to those of the bare ZnO NPs to assess the role of ionic zinc in 
the mechanism of cellular death. After 24 h plating the cells in flat-bottomed 96 well plates, 
the MDA-MB-231 and the MCF-7 cells were exposed to ZnCl2 solutions with concentrations 
of 16, 24, and 40 μg/ml of ionic zinc (Zn2+). These concentrations of ionic zinc (Zn2+) are 
equivalent to the ionic zinc contents of 20, 30 and 50 μg/ml bare ZnO NPs, respectively. The 
cells were then incubated with the ZnCl2 solutions for 3, 8, 12 and 24 h of exposure as 
mentioned with the bare ZnO NPs, and the apoptotic and/or necrotic cells were analysed 
after each exposure time. 
4.1.4 Statistical Analysis 
Statistical analysis was carried out using a paired Student's t-test in all the viability assays. 
One way analysis of variance (ANOVA) was used to determine the statistical significance in 
the Annexin V/7AAD assay. The level of significance was accepted at p≤0.05. The levels of 
significance was indicated by the Asterisks: *p < = 0.05, **p < = 0.01, ***p < = 0.001, and 
****p < = 0.0001 [160].  
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4.2 Results and Discussion 
4.2.1 Cell viability assays 
 Alamar Blue  4.2.1.1
 Alamar blue assay of bare ZnO NPs 4.2.1.1.1
The effect of the bare ZnO NPs on the metabolic activity of the ER+, PR+/–, HER2– MCF-7 
and the triple negative MDA-MB-231 breast cells, as well as the healthy breast MCF-10-2A 
cells was tested using the Alamar Blue assay. The bare ZnO NPs were used in a 
concentration range of 10-60 μg/ml. This range of concentration was chosen after several 
preliminary experiments with different range of concentrations of the bare ZnO NPs, and 
showed a trend in reduction in the viability of both breast cancer cell lines.  
 The effect of the bare ZnO NPs on the viability of the cells was evaluated after 24 h 
exposure. Figure 20 shows that the bare ZnO NPs did not reduce the viability of the MDA-
MB-231 and the MCF-7 cells at 10 μg/ml. The MDA-MB-231 and the MCF-7 cells showed a 
dose dependent reduction in viability at concentrations 20-60 and 30-60 μg/ml of the bare 
ZnO NPs, respectively (Figure 20). Compared to nontreated controls (100% viability), the 
reduction in the viability of the cells was significant at concentrations 30-60 and 35-60 μg/ml 
in the MDA-MB-231 and the MCF-7 cells, respectively (p<0.05) (Figure 20). The estimated 
median lethal concentration (IC50) of the bare ZnO NPs on the MDA-MB-231 and the MCF-7 
after 24 h exposure was 30 (Figure 21) and 36 μg/ml (Figure 22), respectively. Although the 
MDA-MB-231 cells were more sensitive to the toxic effects of the bare ZnO NPs than the 
MCF-7 cells, this was only significant (p<0.01) at 40 μg/ml (Figure 20). The MDA-MB-231 
cells showed a linear response (r2=0.9983) to the bare ZnO NPs concentrations 20-40 μg/ml 
(Figure 21). The exposed MCF-7 cells, on the other hand, did not show this linear response 
to the bare ZnO NPs and they exhibited, instead, a sudden reduction of 30% in their viability 
between 25-30 μg/ml and between 40-50 μg/ml of the bare ZnO NPs (Figure 22). A similar 
sudden drop in the cell viability after exposure to bare ZnO NPs has been previously 
reported in human monocyte derived macrophages (HMM) and lung epithelial cells [10, 49, 
117, 161, 162]. This metabolic collapse in the MCF-7 is considered as one of the hallmarks of 
necrosis [163]. It has been reported that zinc induces apoptosis in cancer cells, and this 
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effects of zinc, in the regulation of apoptosis, appear to be cell type specific [5]. The effect of 
the bare ZnO NPs on the metabolic activity of the healthy MCF-10-2A cells after 24 h 
exposure was conducted only twice, and no reproducibility in the results was obtained (data 
not shown), however, this will be completed in the future work.  
 
Figure 20: Alamar Blue viability assay of MCF-7 and MDA-MB-231 cells exposed to bare ZnO NPs for 24 h. Cells treated 
under similar conditions but without ZnO NPs were used as controls. The values represent the mean ± STD of three 
experiments each performed in triplicate. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001, ****p ≤ 0.0001. 
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Figure 21: Dose response sigmoidal fit of viability of MDA-MB-231 cells exposed to bare ZnO NPs for 24 h. IC50= 30 
μg/ml. The values represent the mean ± STD of three experiments each performed in triplicate. 
 
Figure 22: Dose response sigmoidal fit of viability of MCF-7 cells exposed to bare ZnO NPs for 24 h. IC50= 36 μg/ml. The 
values represent the mean ± STD of three experiments each performed in triplicate. 
 To assess if the reduction in the viability in the breast cancer cells by the bare ZnO 
NPs starts at earlier exposure time, the Alamar Blue assay was conducted after 3 h of 
exposure to the bare ZnO NPs. The effect of the bare ZnO NPs on the viability of the healthy 
epithelia MCF-10-2A cells was also studied after 3 h exposure to the bare ZnO NPs. Figure 23 
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shows the viability results of the MDA-MB-231, MCF-7 and MCF-10-2A cells after 3 h 
exposure to the bare ZnO NPs at concentrations 10-60 μg/ml. The three cell lines 
experienced differential responses to the bare ZnO NPs after 3 h exposure (Figure 23). The 
viability of the three cell lines was not reduced at 10 μg/ml of the bare ZnO NPs (Figure 23). 
At 20 μg/ml, the bare ZnO NPs did not reduce the viability of both the triple negative MDA-
MB-231 breast cancer cells and the healthy epithelial MCF-10-2A cells, while the MCF-7 
showed a metabolic collapse, indicative of cell necrosis, at that concentration (Figure 23). 
The same figure shows that all cells experienced a concentration dependent trend in the 
reduction of their viability after 3 h exposure to the bare ZnO NPs. In the MDA-MB-231 cells, 
the reduction in the viability was significant (p <0.05) at 25, 35-60 μg/ml, while it was 
significant (p<0.05) in the MCF-7 cells at concentrations 25-50 μg/ml. In the healthy 
epithelial MCF-10-2A cells, which experienced a higher viability at all concentrations tested, 
the reduction in viability was only significant (p<0.05) at concentrations 40-60 μg/ml. The 
MCF-7 cells were significantly (p<0.05) more sensitive to the bare ZnO NPs compared to the 
MCF-10-2A cells at concentrations between 35-50 μg/ml. This difference in the viability of 
the breast cancer cells and the healthy MCF-10-2A cells could be probably due to the 
differences in the effect of the bare ZnO NPs on the metabolic activity of the cells and the 
mechanism by which they induce the toxicity in each cell line. 
 Figure 24 to Figure 26 show the IC50 values of the bare ZnO NPs in the three cell 
lines after 3 h exposure. The IC50 values of the bare ZnO NPs calculated after 3 h exposure 
was 21, 34, and 45 μg/ml for MCF-7, MDA-MB-231, and MCF-10-2A cells, respectively. 
Therefore, for clinical applications, 35 μg/ml of the bare ZnO NPs could be used as a toxic 
dose to the breast cancer MCF-7 and MDA-MB-231 cells with minimal toxic effects on the 
healthy breast MCF-10-2A cells, which showed >65% viability at this concentration.  
 This finding of the ability of the bare ZnO NPs to selectively kill the breast cancer 
cells but not the healthy epithelial cells, as well as, its ability to effectively kill the triple 
negative MDA-MB-231 breast cancer cells, which account for a high proportion of breast 
cancer mortality due to the lack of effective therapies [64], will open new options for this 
material in cancer therapy. 
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Figure 23: Alamar Blue viability assay of MCF-10-2A, MDa-MB-231 and MCF-7 cells exposed to bare ZnO NPs for 3 h. The 
NPs were significantly more toxic to MCF-7 compared to MCF-10-2A at 35 and 50 μg/ml. Cells treated under similar 
conditions but without ZnO NPs were used as controls. The values represent the mean ± STD of three experiments each 
performed in triplicate. *p ≤ 0.05; **p ≤ 0.01.  
 
Figure 24: Dose response sigmoidal fit of viability of MCF-7 cells exposed to bare ZnO NPs for 3 h. IC50= 21 μg/ml. The 
values represent the mean ± STD of three experiments each performed in triplicate. 
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Figure 25: Dose response sigmoidal fit of viability of MDA-MB-231 cells exposed to bare ZnO NPs for 3 h. IC50= 34 μg/ml. 
The values represent the mean ± STD of three experiments each performed in triplicate. 
 
Figure 26: Dose response sigmoidal fit of viability of MCF-10-2A cells exposed to bare ZnO NPs for 3 h. IC50= 45 μg/ml. 
The values represent the mean ± STD of three experiments each performed in triplicate. 
 The bare ZnO NPs showed a dose dependent reduction in the viability of breast 
cancer cells after 3 and 24 h of exposure at concentrations 10-60 μg/ml. In order to assess 
the effect of exposure time on the viability after exposure to the bare ZnO NPs, the viability 
of each breast cancer cell line after 3 and 24 h of exposure was compared using the Alamar 
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Blue assay (Figure 27 and Figure 28). Figure 27 shows that the bare ZnO NPs resulted in a 
time dependent reduction in the viability of the MDA-MB-231 cells at all tested 
concentrations; however, this time dependent toxicity of the bare ZnO NPs in the MDA-MB-
231 cells was not significant (p> 0.05) at any tested concentration (Figure 27). On the other 
hand, the less aggressive ER+ MCF-7 cells did not show reduction in their viability with time 
after exposure to the bare ZnO NPs (Figure 28). The MCF-7 cells showed a higher viability 
after 24 h exposure compared to 3 h exposure, at all tested concentrations (10-60 μg/ml) 
(Figure 28). The difference in the viability of the MCF-7 after 3 and 24 h exposure to the 
bare ZnO NPs was highly significant (p<0.05) at 25 and 40 μg/ml (Figure 28). There is no such 
response of the MCF-7 cells to toxins reported in the literature. However, this higher 
viability of the cells after 24 h exposure compared to 3 h exposure could indicate recovery 
of the cells upon long exposure times with the NPs, and could be due to the complex effects 
of zinc on the metabolic activity of cancer cells [5]. This requires further investigation to fully 
understand the underlying factors.  
 
 
Figure 27: Alamar Blue viability assay of MDA-MB-231 cells exposed to bare ZnO NPs for 3 and 24 h. Cells treated under 
similar conditions but without ZnO NPs were used as controls. The values represent the mean ± STD of three 
experiments each performed in triplicate. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. 
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Figure 28: Alamar Blue viability assay of MCF-7 cells exposed to bare ZnO NPs for 3 and 24 h. The values represent the 
mean ± STD of three experiments each performed in triplicate. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001, ****p ≤ 0.0001. 
 Alamar blue assay of targeted ZnO-HCV-RGD-GFP NPs 4.2.1.1.2
Expression of integrin αvβ3 by breast cancer and normal epithelial cells 
To increase the selectivity of the ZnO NPs to cancer cells, we have chosen to target the ZnO 
NPs to the integrin αvβ3 receptors of the breast cancer cells which are shown to express a 
higher percentage of these receptors compared to the healthy breast cells [146, 147]. 
Before testing the effect of RGD-targeting on toxic effects of the ZnO NPs to the breast cells, 
the expression of integrin αvβ3 receptors by the breast cancer cells as well as the healthy 
epithelial cells was measured by flow cytometric analysis. 
  Figure 29 shows that both breast cancer cell lines expressed the integrin αvβ3 
receptor, while the healthy epithelial MCF-10-2A breast cells did not show expression of 
these receptors. The MDA-MB-231 cells showed almost two times increased expression of 
the integrin αvβ3 receptors compared to the MCF-7 cells (Figure 29). Therefore, the RGD-
targeted ZnO NPs were hypothesised to selectively target and destroy MCF-7 (ER+) and 
more significantly the triple negative MDA-MB-231 (ER-, PR-, HER2-) breast cancer cells, 
with minimal toxicity towards the healthy breast MCF-10-2A cells.  
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Figure 29: Flow cytometric analysis of integrin αvβ3 in MCF-7, MDA-MB-231, and MCF-10-2A cells. Cells were harvested 
and incubated with the mouse antihuman αvβ3 antibody, followed by incubation with a fluorescent-labelled secondary 
antibody and then analysed by flow cytometry (black lines). IgG1 antibody was used as an isotype control (grey lines). 
 Figure 30 shows the effect of RGD-targeting of the ZnO NPs on the viability of the 
MDA-MB-231 and MCF-7 cells. The breast cancer cells were exposed to concentrations of 
10-100 μg/ml ZnO-HCV-RGD-GFP NPs for 24 h.  At 10 μg/ml, the ZnO-HCV-RGD-GFP did not 
reduce the viability of both MCF-7 and MDA-MB-231 cells (Figure 30). At 20 μg/ml, and 
compared to nontreated control, a rapid and significant (p<0.05) drop in the viability of both 
cell lines was observed. This reduction in the cell viability at 20 μg/ml was different between 
the two breast cancer lines, and this difference was statistically significant (p>0.05); while 
the MCF-7 cells experienced a metabolic collapse and lost >90% of their viability, the more 
aggressive MDA-MB-231 cells maintained > 60% of their viability. The MDA-MB-231 and the 
MCF-7 cells lost their viability at concentrations of 25 and 30 μg/ml, respectively (Figure 30). 
The IC50 of the ZnO-HCV-RGD-GFP NPs to the MCF-7 and MDA-MB-231 cells after 3 h 
exposure was 16 and 22 µg/ml, respectively (Figure 31 and Figure 32). This higher sensitivity 
of the MCF-7 cells to the targeted ZnO NPs could be again due to their higher sensitivity to 
zinc ions released from the RGD-targeted ZnO NPs upon their intracellular dissolution. It has 
been reported that zinc induce apoptosis in cancers and this appear to be cell type specific 
[5]. 
 Compared to the bare ZnO NPs, the RGD- targeted ZnO NPs resulted in a massive 
reduction in the viability of both breast cancer cell lines. The measured IC50 of the ZnO NPs 
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after 24 h exposure to the MCF-7 and the MDA-MB-231 cells was reduced by 56 and 27 %, 
respectively, by RGD-targeting of the ZnO NPs (Figure 31 and Figure 32, Table 6). This 
implies that the targeted ZnO-HCV-RGD-GFP NPs were more toxic to breast cancer cells than 
the bare NPs, and therefore, a lower dose of the ZnO-HCV-RGD-GFP NPs is required to kill 
the breast cancer cells. This higher toxicity of the RGD-targeted ZnO NPs compared to the 
bare ZnO NPs could be related to several factors. First, both cell lines expressed the integrin 
αvβ3 receptors, as previously shown in Figure 29, and therefore the RGD-targeting of the 
ZnO NPs may increase the concentration of the targeted ZnO NPs at the surface of the cells, 
as suggested by Pastorino et al., in 2013 [164]. Second, after binding to the cell membrane, 
the RGD-targeted ZnO NPs could be taken up by the integrin αvβ3 receptor (clathrin-
mediated endocytosis) as well as by clathrin-independent endocytosis, which leads to higher 
intracellular concentrations of ZnO and consequently a higher toxicity. On the other hand, 
the uptake of the bare ZnO NPs could be restricted to clathrin-independent endocytosis. 
Cellular fate and processing of the ZnO NPs after these two different uptake mechanisms 
could be different. It has been shown very recently that the transport of the NPs across the 
cell membrane dictates the NPs fate and toxicity [165]. Third, the surface chemistries of 
both the targeted and the bare ZnO NPs could be different, which again could cause 
different interactions with the cells. It has been shown that the surface chemistry of NPs 
largely affect their toxic outcomes [166, 167]. The higher sensitivity and the rapid drop in 
the viability of the cells after exposure to the targeted ZnO-HCV-RGD-GFP NPs, compared to 
the bare ZnO NPs, could also be due to the heterogeneity within the same breast cancer cell 
line. While the targeted ZnO-HCV-RGD-GFP could be equally toxic to both the sensitive and 
the highly resistant breast cells within the same breast cancer cell line, the bare ZnO NPs 
could be highly toxic to the sensitive cells, and higher doses are needed to eradicate the 
more aggressive cancer cells. Further investigations are required address these points.  
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Figure 30: Alamar Blue viability assay of MCF-7 and MDA-MB-231 cells exposed to ZnO-HCV-RGD-GFP NPs for 24 h.  The 
values represent the mean ± STD of three experiments each performed in triplicate. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001, 
****p ≤ 0.0001. 
 
Figure 31: Dose response curve of MCF-7 cells exposed to ZnO-HCV-RGD-GFP NPs for 24 h, IC50= 16 μg/ml. The values 
represent the mean ± STD of three experiments each performed in triplicate. 
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Figure 32: Dose response curve of MDA-MB-231 cells exposed to ZnO-HCV-RGD-GFP NPs for 24 h, IC50= 22  μg/ml. The 
values represent the mean ± STD of three experiments each performed in triplicate. 
 Since the targeted ZnO NPs manifested high toxic outcomes to both breast cancer 
cell lines at concentrations 10-100 μg/ml, and a rapid drop in the viability was observed 
between 10-20 μg/ml of the targeted ZnO NPs after 24 h exposure (Figure 30), a reduced 
exposure time to the targeted ZnO NPs was tested. Both the MCF-7 and the MDA-MB-231 
cells were exposed to the targeted ZnO NPs for 3 h at concentrations 10-100 μg/ml. The 
measured viability of the MCF-7 and MDA-MB-231 cells after 3 h exposure is presented in 
Figure 33 and Figure 34, respectively, and compared to that after 24 h exposure. The 
targeted ZnO-HCV-RGD-GFP NPs showed a dose dependent reduction in the viability of the 
MCF-7 and MDA-MB-231 cells at concentrations 20-40 µg/ml, and 20-100 µg/ml after 3 h 
exposure, respectively. Both cell lines showed a time dependent reduction in the viability 
after 3 and 24 h exposure at each concentration of the targeted ZnO-HCV-RGD-GFP NPs 
tested. The MCF-7 did not show a significant time dependent reduction in the viability 
(p>0.05) at all tested concentrations <30 µg/ml of the targeted ZnO NPs (Figure 33), 
therefore the IC50 of the ZnO-HCV-RGD-GFP to the MCF-7 after 3 h exposure was still 16 
μg/ml (Figure 35) which is the same as that obtained after 24 h of exposure (Figure 31). In 
the MDA-MB-231 cells, however, the toxicity was time dependent and was significant (p< 
0.05) at all concentrations between 20-100 µg/ml of the targeted ZnO-HCV-RGD-GFP NPs. 
The ZnO-HCV-RGD-GFP NPs showed an IC50 of 33 μg/ml after 3 h exposure to the MDA-MB-
77 
 
231 cells (Figure 36), which is higher than that measured after 24 h, which was 22 μg/ml 
(Figure 32).  
 A summary of all values of IC50 of both bare and targeted ZnO NPs against MCF-7 
and MDA-MB-231 breast cancer cell lines, as well as the healthy epithelial breast cells MCF-
10-2A measured by Alamar Blue assay after 3 and 24 h, is summarized in Table 6 in the 
section of summary and conclusions of this chapter. 
 
Figure 33: Alamar Blue viability assay of MCF-7 cells exposed to ZnO-HCV-RGD-GFP NPs for 3and 24 h. The values 
represent the mean ± STD of three experiments each performed in triplicate. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001, ****p ≤ 
0.0001. 
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Figure 34: Alamar Blue viability assay of MDA-MB-231 cells exposed to ZnO-HCV-RGD-GFP NPs for 3 and 24 h. The values 
represent the mean ± STD of three experiments each performed in triplicate. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001, ****p ≤ 
0.0001. 
 
 
Figure 35: Dose response curve of MCF-7 cells exposed to ZnO-HCV-RGD-GFP NPs for 3 h, IC50= 16 μg/ml. The values 
represent the mean ± STD of three experiments each performed in triplicate. 
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Figure 36: Dose response curve of MDA-MB-231 cells exposed to ZnO-HCV-RGD-GFP NPs for 3 h, IC50= 33 μg/ml. The 
values represent the mean ± STD of three experiments each performed in triplicate. 
 LDH assay of bare ZnO nanoparticles 4.2.1.2
Theoretically, necrosis always results in disruption of the cytoplasmic membrane and 
necrotic cells release cytoplasmic LDH into the medium [168]. The effect of the bare ZnO 
NPs on plasma membrane permeability of the MCF-7 and the MDA-MB-231 cells was 
evaluated using the LDH assay. The cells were treated with the bare ZnO NPs at a 
concentration range from 10-100 μg/ml for 24 h. Figure 37 shows that, compared to the 
positive control (1% Triton X-100), the bare ZnO NPs exhibited a significant (p<0.05) dose 
dependent toxicity in the MCF-7 cells at all tested concentrations after 24 h exposure. The 
bare ZnO NPs were toxic to 57% of the MCF-7 cells at 100 μg/ml concentration. In the MDA-
MB-231 cells, the bare ZnO NPs did not show a clear dose dependent toxicity at 
concentrations 10-100 μg/ml after 24 h exposure. In the MDA-MB-231 cells, the toxicity was 
only significant at 60 μg/ml of the bare ZnO NPs, and the bare ZnO NPs were toxic to <25% 
of the cells at 100 μg/ml (Figure 37). 
 Figure 37 also shows that there was a significant difference (p<0.05) in the LDH 
release between the MCF-7 and the MDA-MB-231 cells after 24 h exposure to the bare ZnO 
NPs at concentrations between 20-60 μg/ml. The bare ZnO NPs were more toxic to the MCF-
7 cells than to MDA-MB-231 cells. The IC50 of the bare ZnO NPs in the MCF-7 cells after 24 h 
80 
 
exposure was 48 μg/ml (Figure 38). In the MDA-MB-231 cells, the IC50 could not be 
determined since the bare ZnO NPs were only toxic to < 25% of the MDA-MB-231 cells after 
24 h exposure even at the highest concentration tested (100 µg/ml) (Figure 37). The 
increased LDH release in the MCF-7 cells, but not in the MDA-MB-231 cells, after 24 h 
exposure to the bare ZnO NPs could indicate that the bare ZnO NPs cause necrosis in the 
MCF-7 cells. It has been reported that MCF-7 cells are less prone to apoptosis due to the 
lack of caspase-3 activation [169, 170].  
 
 
Figure 37: LDH viability assay of MCF-7 and MDA-MB-231 breast cancer cells exposed to bare ZnO NPs for 24 h at 
increasing concentrations (10-100 μg/ml). The values represent the mean ± SD of three experiments each performed in 
triplicate. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001. 
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Figure 38: LDH dose response curve of MCF-7 cells exposed to the bare ZnO NPs for 24 h, IC50= 48 μg/ml. The values 
represent the mean ± STD of three experiments each performed in triplicate. 
 Since the maximum release of LDH was <25% in the MDA-MB-231 cells after 24 h 
exposure to the bare ZnO NPs even at the highest concentration tested (100 µg/ml), a 
longer incubation time (48 h) was tested for both cell lines. The breast cancer cells were 
exposed to the same range of concentrations of the NPs (10-100 μg/ml) for 48 h. The bare 
ZnO NPs induced a time dependent toxicity to the MCF-7 and the MDA-MB-231 cells after 
24 and 48 h exposure (Figure 39 and Figure 41, respectively). The increase in the toxicity of 
the bare ZnO NPs after 48 h compared to 24 h was statistically significant (p<0.05) at 
concentrations 20-100 μg/ml in the MCF-7 cells and at 20-60 μg/ml in the MDA-MB-231 
cells (Figure 39 and Figure 41, respectively). The toxicity of the bare ZnO NPs in the MCF-7 
after 48 h exposure was still dose dependent, with an IC50 <20 μg/ml (Figure 40) with more 
than 70% of the cells were dead at 25 μg/ml. On the other hand, cellular death in the MDA-
MB-231 cells treated for 48 h was dose independent at concentrations between 10-60 
μg/ml of the bare ZnO NPs (Figure 41). All concentrations between 10-60 µg/ml of the bare 
ZnO NPs showed almost 50% toxicity to the MDA-MB-231 cells after 48 h exposure, and 
therefore the IC50 of the bare ZnO NPs in the MDA-MB-231 cells could not be measured 
after 48 h exposure. At the concentration of 100 μg/ml, the bare ZnO NPs showed 80% 
toxicity to the MDA-MB-231 cells after 48 h exposure. 
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Figure 39: LDH viability assay of MCF-7 breast cancer cells exposed to bare ZnO NPs for 24 and 48 h at increasing 
concentrations (10-100 μg/ml). The values represent the mean ± SD of three experiments each performed in triplicate. 
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001. 
 
 
Figure 40: LDH dose response curve of MCF-7 cells exposed to the bare ZnO NPs for 48 h, IC50< 20 μg/ml. The values 
represent the mean ± STD of three experiments each performed in triplicate. 
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Figure 41: LDH viability assay of MDA-MB-231 breast cancer cells exposed to bare ZnO NPs at increasing concentrations 
(10-100 μg/ml). The values represent the mean ± SD of three experiments each performed in triplicate. *p ≤ 0.05; **p ≤ 
0.01; ***p ≤ 0.001. 
 The LDH assay was also used to test the sensitivity of the MCF-10-2A cells to the 
bare ZnO NPs. The MCF-10-2A cells were exposed to the bare ZnO NPs at concentrations 10-
100 μg/ml for 24 and 48 h and the percentage toxicity due to the release of LDH from the 
cells was calculated. The bare ZnO NPs showed time, but not dose dependent toxicity to the 
MCF-10-2A cells (Figure 42). After 24 h, the percentage necrosis observed at the highest 
concentration of the bare ZnO NPs tested (100 μg/ml) was <20%. The IC50 of the bare ZnO 
NPs to the MCF-10-2A cells after 24 h exposure could not be measured because the bare 
ZnO NPs were still not toxic to > 80% of the cells at 100μ/ml (Figure 42), therefore the IC50 is 
> 100 μg/ml.  After 48 h exposure, however, the cells were completely dead at the lowest 
concentration tested (10 μg/ml). The higher IC50 of the bare ZnO NPs to the MCF-10-24 cells 
after 24 h exposure compared to the breast cancer cells again has important implications for 
the use of this material in cancer therapy.  
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Figure 42: LDH viability assay of MCF-10-2A breast cancer cells exposed to bare ZnO NPs for 24 and 48 h at increasing 
concentrations (10-100 μg/ml). The values represent the mean ± SD of three experiments each performed in triplicate. 
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. 
 ATP assay 4.2.1.3
The Alamar Blue and LDH assays evaluate the viability of cells based on their metabolic 
activity and cell membrane integrity, respectively. Since after exposure to ZnO NPs, the cells 
could be metabolically inactive, but still maintain their membrane integrity, they could be 
recorded as dead in Alamar Blue, but viable in LDH assay. Furthermore, the Alamar blue 
assay requires a long incubation time with cells, which varies between the cells (i.e. 4, 9, and 
11 h for the MCF-10-2A, MCF-7, and MDA-MB-231, respectively). Although the ZnO NPs 
were washed twice out of the cells at the end of the incubation time, and before the 
addition of the Alamar Blue, some aggregates of the ZnO NPs were observed to still adhere 
to the cells (data not shown). These adhered NPs could continue to exert their toxic effects 
during prolonged incubation of the cells with Alamar Blue reagent, giving false positive 
toxicity. In addition, in the LDH assay, the ZnO NPs were prepared in culture media with 1% 
FBS, as recommended by the manufacturer,  to avoid the high background signal from LDH 
present in FBS, while they were prepared in media with 10% FBS in the Alamar Blue assay. 
All these factors made comparison between the results of two assays difficult. For this 
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reason, the ATP assay was used as another viability assay to evaluate the metabolic activity 
of the cells upon exposure to ZnO NPs.  
 The ATP assay determines the number of viable cells in culture based on 
quantification of the ATP present, which signals the presence of metabolically active cells 
which produce ATP as energy for respiration and other vital processes. The assay is based on 
lysing the cells at the end of exposure to the NPs and consequently, false positive toxicity 
due to long incubation time with the kit is avoided. The MDA-MB-231 cells were used in the 
ATP assay since they showed a dose dependent and linear reduction in the viability after 
exposure to the bare ZnO NPs in the Alamar Blue assay.  Six concentrations of the bare ZnO 
NPs (10, 20, 30, 40, 50, and 100 μg/ml), and three concentrations (20, 30, and 50 μg/ml) of 
the targeted ZnO-HCV-RGD-GFP NPs were tested. Lower range of concentrations of the 
targeted ZnO NPs was tested due to the limited volumes available at the time of the assay.  
 ATP assay of the bare ZnO nanoparticles 4.2.1.3.1
The metabolic activity of the MDA-MB-231 cells after exposure to the bare ZnO NPs at 
concentrations 10-100 μg/ml was evaluated using the ATP assay. To have a better 
comparison to LDH assay, the ZnO NPs (10-100 μg/ml) were prepared in media 
supplemented with 1% FBS before exposure to the cells. The toxicity of the bare ZnO NPs 
against the MDA-MB-231 cells was measured after 24 and 48 h exposure.  
 Figure 42 shows the viability of the MDA-MB-231 cells after 24 and 48 h exposure 
to the bare ZnO NPs. The bare ZnO NPs resulted in a dose and time dependent reduction in 
the viability of the MDA-MB-231 cells at concentrations 10-100 µg/ml (Figure 42). After 24 
h, the reduction in the viability of the cells was significant (p<0.05) at concentrations 50-100 
μg/ml of the bare ZnO NPs, and the viability was reduced to 30% at 100 μg/ml of the bare 
ZnO NPs (Figure 43). The IC50 of the bare ZnO NPs after 24 h of exposure was 36 μg/ml and 
the reduction in viability was almost linear between 10-100 μg/ml (r2=0.99) (Figure 43). This 
linear reduction in the viability of the MDA-MB-231 cells after exposure to the bare ZnO NPs 
was also observed in the Alamar Blue assay, and the IC50 measured from the ATP assay (36 
μg/ml) was the same as that measured from the Alamar Blue assay (Figure 20). The 
reduction in the viability of the MDA-MB-231 cells after 48 h to the bare ZnO was significant 
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(p<0.05) at all tested concentrations 10-100 μg/ml compared to nontreated control (Figure 
43). The cells lost >60% of their viability at all concentrations tested; therefore, the IC50 is < 
10 μg/ml. The viability was completely lost at 100 μg/ml after 48 h exposure to the bare ZnO 
NPs (Figure 43). 
 Figure 44 shows a comparison of the viability of the MDA-MB-231 cells measured 
from the ATP and the Alamar Blue after 24 h exposure to the bare ZnO NPs. The viability 
measured from the ATP assay are comparable to these measured from Alamar Blue, and no 
significant differences were obtained except at 40 and 50 μg/ml (Figure 43). For example, 
the viability measured at 50 μg/ml of the bare ZnO NPs using the Alamar Blue and the ATP 
assays, was 10 and 47 %, respectively (Figure 45). The lower viability of the MDA-MB-231 
cells measured by the Alamar blue at concentrations higher than the IC50 (36 µg/ml) could 
be false positive result due to longer incubation time of the Alamar Blue with the cells 
compared to the ATP, as discussed earlier in the introduction of this chapter.  
 
Figure 43: ATP viability assay of MDA-MB-231 cells exposed to bare ZnO NPs. Experiments were repeated twice (n=2) 
and represented as the mean ± SD. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
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Figure 44: Dose response sigmoidal fit of viability of MDA-MB-231 cells exposed to bare ZnO NPs for 24 h. IC50= 36 
μg/ml. The values represent the mean ± STD of two experiments each performed in triplicate. 
 
Figure 45: Viability of MDA-MB-231 cells exposed to bare ZnO NPs for 24 h measured by Alamar Blue and ATP assays. 
Experiments were repeated twice (n=2) and represented as the mean ± SD. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
 ATP assay of the targeted ZnO-HCV-RGD-GFP nanoparticles 4.2.1.3.2
The viability of the MDA-MB-231 cells after 24 and 48 h exposure to 20, 30 and 50 μg/ml 
ZnO-HCV-RGD-GFP NPs was measured by the ATP assay. Figure 46 shows that the MDA-MB-
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231 cells experienced a dose and time dependent reduction in the viability after exposure to 
the targeted ZnO-HCV-RGD-GFP NPs. Compared to untreated controls, the reduction in the 
viability was statistically significant (p<0.05) at 50 μg/ml ZnO-HCV-RGD-GFP NPs after both 
24 and 48 h exposure to the targeted ZnO NPs (Figure 46). The time dependent reduction in 
the viability of the cells was statistically significant (p<0.05) at 30 and 50 μg/ml of the ZnO-
HCV-RGD-GFP NPs (Figure 46). The IC50 of the ZnO-HCV-RGD-GFP NPs against the MDA-MB-
231 cells measured by the ATP assay was 33.5 and 24.6 μg/ml after 24 and 48 h exposure, 
respectively (Figure 47 and Figure 48).  
 
Figure 46: ATP viability assay of MDA-MB-231 cells exposed to ZnO-HCV-RGD-GFP NPs. Experiments were repeated in 
duplicate (n=2) and represented as the mean ± SD. *P ≤ 0.05, **P ≤ 0.01. 
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Figure 47: Dose response sigmoidal fit of viability of MDA-MB-231 cells exposed to ZnO-HCV-RGD-GFP NPs for 24 h 
measured by ATP assay. IC50= 33.5 μg/ml. The values represent the mean ± STD of two experiments each performed in 
triplicate. 
 
Figure 48: Dose response sigmoidal fit of viability of MDA-MB-231 cells exposed to ZnO-HCV-RGD-GFP NPs for 24 h 
measured by ATP assay. IC50= 24.6 μg/ml. The values represent the mean ± STD of two experiments each performed in 
triplicate. 
 Figure 49 shows the viability of the MDA-MB-231 cells measured by the ATP and 
the Alamar Blue assays after 24 h exposure to 20, 30 and 50 μg/ml ZnO-HCV-RGD NPs. As 
observed with the bare ZnO NPs (Figure 45), the ATP assay recorded a higher viability of the 
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cells compared to the Alamar Blue assay; however, no significant difference was recorded 
between the two assays at any tested concentration (Figure 49). The lower viability 
measured using the Alamar Blue compared to the ATP assay, could be again due to the long 
incubation time with the Alamar Blue reagent as explained earlier. The IC50 measured for 
the ZnO-HCV-RGD-GFP NPs from the Alamar Blue and the ATP assay after 24 h exposure was 
22 and 33.5 μg/ml (Figure 32 and Figure 47), respectively. It should be noted here that only 
three concentrations were tested with the ATP assay and they were not enough to obtain a 
complete dose response curve. An IC50 of 30.6 μg/ml would be obtained from the Alamar 
Blue assay when the dose response curve was constructed from the three concentrations 
(20, 30, and 50 μg/ml). Although the IC50 values measured after 24 h exposure to the Bare 
and targeted ZnO NPs from the Alamar Blue assay were lower than those measured from 
the ATP assay, the rate of change of the value was almost the same for the bare and the 
targeted ZnO NPs in the two assays (36 and 30 μg/ml for the bare ZnO NPs and 33.5 and 22 
μg/ml for the targeted ZnO NPs from ATP and Alamar blue assays, respectively).  
   
Figure 49: Comparison of the viability of MDA-MB-231 cells exposed to ZnO-HCV-RGD-GFP NPs measured by Alamar Blue 
and ATP assay. Experiments were repeated twice (n=2) and represented as the mean ± SD. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 
0.001. No significant difference at any concentration 
 The reduction in the viability of the MDA-MB-231 cells after 24 and 48 h exposure 
to the ZnO-HCV-RGD-GFP NPs was compared to the negative control ZnO-HCV-GGG NPs. 
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Figure 50 shows that the ZnO-HCV-RGD-GFP NPs caused a higher reduction in the viability of 
the cells compared to the ZnO-HCV-GGG NPs after 24 and 48 h and at all tested 
concentrations (20, 30 and 50 µg/ml) (Figure 50). This difference was statistically significant 
(p<0.05) after 24 h exposure to 50 μg/ml of both NPs (Figure 50, a); while more than 70% of 
the MDA-MB-231 cells were dead after exposure to 50 μg/ml of the ZnO-HCV-RGD-GFP NPs, 
only 45% were dead at the same concentration of the ZnO-HCV-GGG NPs. This indicates that 
the RGD-targeting of the NPs was efficient and it could increase the toxicity of the ZnO NPs. 
After 48 h, the ZnO-HCV-RGD-GFP NPs were still more toxic than the negative control (ZnO-
HCV-GGG NPs); however, this was not statistically significant (p>0.05) at all tested 
concentrations. 
 
 
 
 
 
 
 
 
92 
 
 
 
Figure 50: ATP viability assay of MDA-MB-231 cells exposed to ZnO-HCV-RGD-GFP and ZnO-HCV-GGG-GFP for (a) 24 h 
and (b) 48 h.  Experiments were repeated in duplicate (n=2) and represented as the mean ± SD. *P ≤ 0.05, **P ≤ 0.01. 
 To assess the effect of targeting of the ZnO NPs, the viability of the MDA-MB-231 
cells measured by the ATP assay after 24 and 48 h exposure to both the bare and the 
targeted ZnO NPs for 24 and 48 h was compared (Figure 51). At doses smaller than the IC50 
(20 μg/ml), the bare ZnO NPs caused a higher reduction in the viability of the cells compared 
to the targeted ZnO NPs after both 24 and 48 h exposure; however, this difference was not 
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statistically significant (p<0.05). This higher effect of the bare ZnO NPs on the viability of the 
MDA-MB-231 cells could be due to smaller aggregate sizes in the medium used for the ATP 
assay (DMEM+1% FBS) compared to that of the ZnO-HCV-RGD-GFP NPs. The average 
aggregate size of the bare ZnO NPs measured in DMEM+1% FBS medium was 1375 nm 
(Figure 9). The aggregate size of the ZnO-HCV-RGD-GFP NPs in the same medium was not 
measured, due to their limited amount available, but the targeted ZnO-HCV-RGD-GFP NPs 
formed aggregates of higher size than those of the bare ZnO with a high PdI in the confocal 
imaging buffer (Table 4). The smaller size of the bare ZnO NPs could lead to their higher 
uptake by the MDA-MB-231 cells and subsequent higher toxicity. It has been shown that the 
size of the NPs is a critical factor that affects their uptake [171, 172]. The IC50 of the targeted 
ZnO NPs after 24 h exposure to the MDA-MB-231, however, was lower than that measured 
for the bare ZnO NPs (33.5 and 36 μg/ml, respectively). This indicates that RGD targeting 
increased the toxicity of the ZnO NPs, due to enhanced uptake by the cells through binding 
of the ZnO-HCV-RGD-GFP NPs to the integrin αvβ3 receptors.  
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Figure 51: Comparison of ATP viability assay of MDA-MB-231 cells exposed to bare and ZnO-HCV-RGD-GFP NPs for (a) 24 
h and (b) 48 h.  Experiments were repeated in duplicate (n=2) and represented as the mean ± SD. *P ≤ 0.05, **P ≤ 0.01. 
4.2.2 Mode of Cell death by Annexin V-7AAD (necrosis and apoptosis) 
Necrosis and apoptosis are two distinct modes of cell death which differ in morphology, 
mechanism and incidence [163].  Apoptosis is mainly initiated by detachment and shrinkage 
of the cells, separation of blebs (protrusions of the plasma membranes) and finally the 
formation of apoptotic bodies that are packed densely with cellular organelles and nuclear 
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fragments [173]. In vivo, the apoptotic bodies will subsequently be engulfed by 
macrophages or adjacent cells and thus do not go through lysis. In contrast, in vitro, 
apoptotic bodies that are formed will ultimately swell and the apoptotic process proceeds 
to an autolytic necrotic outcome due to the absence of phagocytes [152, 174, 175]. Here, 
the term late apoptosis or secondary necrosis, which is the natural outcome of the complete 
apoptotic program, is used to describe dead cells that have reached this state via apoptotic 
program as named by Wyllie et al. [175, 176]. In apoptosis the cytoplasmic and the 
lysosomal membrane remains intact [175]. Necrosis, on the other hand, has been 
characterized as passive, accidental cell death process that elicit uncontrolled  inflammatory 
cellular responses [153]. The most characteristic features of necrosis are cell swelling, 
lysosomal membrane permeabilization and cell membrane permeabilization [175]. As 
apoptosis is considered to be a regulated and controlled process, its occurrence during 
cancer treatment has received great attention [154, 155]. 
 The biological effects of the ZnO NPs on the breast cancer cell lines were 
investigated in the previous sections of this chapter using the Alamar Blue, the LDH and the 
ATP assays. The Alamar blue assay monitors the metabolic activity of the living cells [177, 
178]. The LDH assay, on the other hand,  is used to quantitate LDH release from lysed cells 
[168]. Therefore in the Alamar Blue both apoptotic and necrotic cells will lose their 
metabolic activity and will be recorded as not viable (dead), while in the LDH assay only 
necrotic cells will release LDH and will be recorded as not viable (or dead) bot not the cells 
in an early apoptosis. The bare ZnO NPs could be inducing different mechanisms of cellular 
death in the MCF-7 and the MDA-MB-231 cells. The bare ZnO NPs may be inducing 
apoptosis in the MDA-MB-231 cells but necrosis in the MCF-7 cells. We based our 
assumption here on the following facts; the bare ZnO NPs are hypothesized to be taken up 
by the cells by clathrin-independent endocytosis, and then end up in the acidic lysosomes of 
the cells where they dissolve to release the zinc ions and labile zinc complexes [10, 49, 124, 
179]. Zinc is reported to cause toxicity in breast cancer cells [180] and this toxicity could be 
related to different modes of cellular death in different cancers [180, 181] . In our study, the 
metabolic collapse, probably due to lysosomal membrane damage, and the high release of 
LDH enzyme measured in the MCF-7 cells are indicative of necrosis [163]. On the other 
hand, the MDA-MB-231 cells showed a linear reduction in the viability after exposure to the 
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ZnO NPs, because their lysosomal membranes were probably still intact and the ZnO NPs 
were still dissolving after their uptake, and they also showed a low LDH release after 24 h of 
exposure, both observations indicate apoptosis. To confirm these assumptions, Annexin 
V/7AAD assay, which measure apoptosis, was conducted. 
 The possible mechanism of death of the MCF-7 and the MDA-MB-231 cells after 
exposure to the ZnO NPs was further explored by Annexin V/ 7AAD assay which measure 
apoptosis. As mentioned at the beginning of this section, the apoptotic program in the cells 
is characterized by certain morphologic features. During early events of apoptosis, the 
externalization of the phospholipid phosphatidylserine (PS) occurs at the cell membrane 
while the membrane integrity remains unchallenged [182]. This translocation of PS to the 
outer leaflet of the lipid bilayer occurs very early in the apoptotic process [174]. The 
exposed PS could be detected by Annexin V, an endogenous human protein that has high 
affinity to bind, in a calcium dependent manner, to PS. This binding of Annexin V to PS can 
be detected using fluorescently labelled Annexin V and a flow cytometer. The 7AAD is a 
standard flow cytometric viability probe and is used to distinguish viable from nonviable 
cells. Viable cells with intact membranes exclude 7AAD, whereas the membranes of dead 
and damaged cells are permeable to 7AAD staining [183]. Therefore, staining with 
Phycoerythrin conjugated Annexin V (PE Annexin V) is typically used in conjunction with 
7AAD.  
 Herein, to distinguish between cells that have undergone apoptotic death versus 
those that have died as a result of a necrotic pathway, apoptosis was first measured over 
time after exposure to the bare ZnO NPs. The breast cancer cells were exposed to the bare 
ZnO NPs for 3, 8, and 12 h concentrations 20, 30 and 50 μg/ml. At 24 h time point, more 
concentrations of the ZnO NPs were tested; 10, 20, 25, 30, 35, 40, 50, 60, and 100 μg/ml to 
have a good comparison with the viability assays in section 4.2.1. After exposure to the bare 
ZnO NPs, the cells were stained with PE Annexin V/7AAD for FACS analysis. Four different 
populations can be gated using PE Annexin V/7AAD; Live, necrotic, apoptotic, and late 
apoptotic cells. A representative plot of gating of the populations of cells after exposure to 
the ZnO NPs is illustrated in Figure 52. In Annexin V/7AAD assay, the cells can be gated into 
four populations; PE Annexin V negative and 7AAD positive cells (necrosis, membrane 
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integrity is lost, Q1), PE Annexin V and 7AAD positive cells (late apoptosis or secondary 
necrosis, Q2), PE Annexin V positive and 7AAD negative cells (apoptosis, membrane integrity 
is present, Q3), and PE Annexin V and 7AAD negative (live, or no measurable apoptosis, Q4).  
It is not simple to distinguish whether the cells that reached Q2 had experienced 
primary necrosis or they are secondary necrotic/Late apoptotic cells. This is because primary 
necrotic cells cannot stain 7AAD positive and Annexin V negative; upon lysis, the cell 
becomes permeable to both 7AAD and Annexin V inside the cell, Annexin V could bind PS 
and consequently the cell will stain Annexin V positive/7AAD positive and will appear in Q2. 
Furthermore, apoptotic cells have short half-life [163]; in in vitro cultured cells, when 
massive apoptosis occurs and phagocytosis is limited, the apoptotic cells will lyse (become 
necrotic) and they will be stained double positive for Annexin V/7AAD and will appear in Q2. 
However, if the PS is lost in one of the previous cases, the cell will stain 7AAD positive and 
Annexin V negative and will appear in Q1. 
   Because we assumed that the different effects of the ZnO NPs on the viability of 
the MCF-7 and the MDA-MB-231 cells could be related to the release of zinc ions, the effect 
of ionic zinc from ZnCl2 on the mode of cell death was also investigated using Annexin 
V/7AAD assay. The MCF-7 and the MDA-MB-231 cells were exposed to 16, 24, and 40 μg/ml 
of ionic zinc (Zn2+) from ZnCl2 for 3, 8, 12 and 24 h, and the cells were processed in the same 
way as with the ZnO NPs. These concentrations of ionic zinc are equivalent to the ionic zinc 
contents of 20, 30, and 50 μg/ml ZnO NPs, respectively. 
 
Figure 52: A representative flow cytometric density dot showing gating of necrotic (Q1), late apoptotic (Q2), apoptotic 
(Q3), and live (Q4) MCF-7 cells exposed to 50 μg/ml bare ZnO NPs for 3 h. Cells were exposed to the bare ZnO Ps and 
then stained with Annexin V-PE and 7AAD.  
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 The percentage of the different populations of the cells; live, apoptotic, late 
apoptotic, and necrotic, after exposure to either the bare ZnO NPs or ionic zinc, was 
calculated after each exposure time. A representative FACS analysis after 24 h exposure of 
the MCF-7 and the MDA-MB-231 cells to both the bare ZnO NPs and ZnCl2 from one 
experiment is illustrated in Figure 53 (a-d). It can be clearly observed from the flow 
cytograms in Figure 53 that the cells experienced a dose and time dependent reduction in 
the live cell population compared to untreated controls. Whether this reduction in the cell 
viability is due to apoptotic cell death or not will be discussed here.  
 
 
Figure 53 (a): Flow cytogram images of MCF-7 cells treated with 20, 30 and 50 μg/ml bare ZnO NPs for 3, 8, 12 and 24 h 
NPs. Representative figures show population of viable (Annexin V-/7AAD-), apoptotic (Annexin V+/7AAD-), late 
apoptotic (Annexin V+/7AAD+) and necrotic (Annexin V-/7AAD+). 
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Figure 52 (b): Flow cytogram images of MCF-7 cells treated with 16, 24, and 40 μg/ml ZnCl2 for 3, 8, 12 and 24 h. 
Representative figures show population of viable (Annexin V-/7AAD-), apoptotic (Annexin V+/7AAD-), late apoptotic 
(Annexin V+/7AAD+) and necrotic (Annexin V-/7AAD+). 
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Figure 52 (c): Flow cytogram images of MDA-MB-231 cells treated with 20, 30 and 50 μg/ml bare ZnO NPs for 3, 8, 12 and 
24 h. Representative figures show population of viable (Annexin V-/7AAD-), apoptotic (Annexin V+/7AAD-), late 
apoptotic (Annexin V+/7AAD+) and necrotic (Annexin V-/7AAD+). 
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Figure 52 (d): Flow cytogram images of MDA-MB-231 cells treated with 16, 24, and 40 μg/ml ZnCl2 for 3, 8, 12 and 24 h. 
Representative figures show population of viable (Annexin V-/7AAD-), apoptotic (Annexin V+/7AAD-), late apoptotic 
(Annexin V+/7AAD+) and necrotic (Annexin V-/7AAD+). 
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Figure 54 shows the change in the percentage of apoptotic cells within the MCF-7 
and the MDA-MB-231 cells over time of 3, 8, 12 and 24 h, to three concentrations of the 
bare ZnO NPs (20, 30 and 50 μg/ml). The MDA-MB-231 cells showed a very significant 
increase (p<0.05) in the apoptotic population over time (3, 8, 12, and 24 h) at all tested 
concentrations (Figure 54, a). The MCF-7 cells, on the other hand, did not show any 
significant increase in the apoptotic population over time at all tested concentrations 
(Figure 54, b). The highest percentage of the apoptotic population in the MCF-7 cells 
exposed to 50 μg/ml ZnO NPs was observed at the lowest exposure time i.e. 3 h (Figure 54, 
b). Interestingly, the MDA-MB-231 cells treated for 3 h with small doses of 20 and 30 μg/ml 
of the bare ZnO NPs showed a reduction in the apoptosis compared to nontreated control; 
however, that was not the case in the MCF-7 cells (Figure 54). This effect of the bare ZnO 
NPs on apoptosis could be related to the release of ionic zinc from the NPs inside the cells. 
Ionic zinc has been reported to either reduce or induce apoptosis in the same cell line 
depending on the dose of exposure [184]. 
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Figure 54: FACS analysis of cells undergoing apoptosis (Annexin V +/7AAD - (Q3)) from (a) MDA-MB-231 and (b) MCF-7 
cells treated for 3, 8, 12, and 24 h with 20, 30, and 50 μg/ml ZnO NPs. At each time point, the apoptotic population from 
the untreated control was subtracted from that in the treated cells at each concentration. Experiments were performed 
in triplicate in three independent experiments. Bars are presented as mean ± SD (n=3). ****p ≤ 0.0001. 
 Figure 55 shows the effect of different concentrations of zinc ions from ZnCl2 on 
the apoptotic population of the MCF-7 and the MDA-MB-231 cells over time. The ionic zinc 
had the same effects on the apoptotic population of both breast cancer cell lines as those of 
the bare ZnO NPs. In the MDA-MB-231 cells, zinc ions induced a significant increase (p<0.05) 
in apoptosis with time at all tested concentrations of zinc ions. In MCF-7, however, there 
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was no significant increase in apoptosis (p>0.05) except at 24 μg/ml Zn2+. The same 
observation of the reduction in the apoptosis of the MDA-MB-231 cells after 3 h exposure to 
the bare ZnO NPs was recorded here at 16, 24, and 50  μg/ml ZnCl2 compared to untreated 
control (Figure 55, a). Such reduction in apoptosis was not observed in the MCF-7 cells 
(Figure 55, b). This could be due to different effects of zinc on apoptosis at such short 
exposure time, as discussed earlier. 
 Comparing the bare ZnO NPs and ZnCl2 results obtained by Annexin V/7AAD 
indicated no statistical difference (p>0.05) between the effect of the ZnO NPs and the ionic 
zinc on the apoptotic cell population in the MCF-7 cells at all tested concentrations. In the 
MDA-MB-231 cells, however, there was a significant difference (p<0.05) between the ZnO 
NPs and the zinc ions from ZnCl2 at all tested concentrations after 3 h , and at all time- 
points at 30 μg/ml ZnO NPs (24 μg/ml ZnCl2).  
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Figure 55: FACS analysis of cells undergoing apoptosis (Annexin V +/7AAD -, (Q3)) from (a) MDA-MB-231 and (b) MCF-7 
cells treated for 3, 8, 12, and 24 h with 16, 24, and 40 μg/ml Zn
2+
 from ZnCl2 (equivalent Zn
2+
 concentrations from 20, 30, 
and 50 μg/ml ZnO NPs). At each time point, the apoptotic population from the untreated control was subtracted from 
that in the treated cells at each concentration. Experiments were performed in triplicate in three independent 
experiments. Bars are presented as mean ± SD (n=3). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001, ****p ≤ 0.0001. 
 The apoptotic and late apoptotic populations of the MCF-7 and the MDA-MB-231 
cells after 24 h exposure to the ZnO NPs measured from Annexin V/7AAD assay were 
compared (Figure 56). In the MDA-MB-231 cells, compared to untreated control, there was 
a significant increase (p<0.05) in the apoptotic and late apoptotic populations at 
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concentrations 10-100 μg/ml and 20-100 μg/ml ZnO NPs, respectively (Figure 56, a). The 
MCF-7 cells, on the other hand, showed a significant increase (p<0.05) in the apoptotic and 
late apoptotic population only at 35-100 μg/ml and 20-35 μg/ml ZnO NPs, respectively 
(Figure 56, b). There was no statistical difference (p>0.05) between apoptotic cell 
population in the MCF-7 and the MDA-MB-231 cells after 24 h exposure to 10-100 μg/ml 
ZnO NPs. 
 
 
 
 
 
 
 
 
 
 
107 
 
 
 
Figure 56: FACS analysis of percentage necrosis, apoptosis and late apoptosis results of (a) MDA-MB-231 and (b) MCF-7 
cells treated for 24 h with 10, 20, 25, 30, 35, 40, 50, 60 and 100 μg/ml ZnO NPs. Experiments were repeated in triplicate 
in three independent experiments. Bars are presented as mean ± SD (n=3). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001, ****p ≤ 
0.0001. 
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4.3 Summary and conclusions 
The results of the viability assays showed that the bare and the targeted ZnO NPs were toxic 
to the breast cancer MDA-MB-231 and MCF-7 cells. The ZnO NPs (both bare and targeted) 
caused a reduction in the metabolic activity, as well as cellular membrane damage in the 
MCF-7 and the MDA-MB-231 cells. The IC50 values obtained for the bare and the targeted 
ZnO NPs to the MDA-MB-231 and the MCF-7 breast cancer cells, as well as the healthy 
epithelial MCF-10-2A cells, at different exposure times are summarized in Table 6. 
Significant differences in the responses of the MCF-7 and MDA-MB-231 cells after exposure 
to the bare ZnO NPs were observed in the Alamar Blue and the LDH assays. This could 
indicate that ZnO NPs induce a variety of cellular damage responses in both cell lines that 
influence the final outcome.  
 Taking all the results of this chapter into account, we proposed that the ZnO NPs 
(both bare and targeted) could probably induce necrosis in the MCF-7, but apoptosis in the 
MDA-MB-231 cells at concentrations 10-60 μg/ml. The MCF-7 showed signs of necrosis, 
which includes the sudden drop in the metabolic activity at concentrations around the 24 h 
IC50, and cell lysis with high release of LDH. The MDA-MB-231 cells, on the hand, showed 
signs of apoptosis after 24 h exposure to the bare and targeted ZnO NPs, which includes the 
linear reduction in the metabolic activity and the low release of LDH. These findings were 
further confirmed by Annexin V/7AAD assay; the MDA-MB-231 cells showed significant time 
and dose dependent increase in the apoptotic population, while the MCF-7 cells, on the 
hand, did not show any increase in the apoptotic population compared to untreated control 
at any tested concentration (20, 30, and 50 μg/ml). It has been reported that MCF-7 cells 
lack caspase-3, which is required for DNA fragmentation and morphological changes 
associated with apoptosis [170]. However, Sasidharan et al. [11] showed that incubation of 
ZnO nanocrystals (NCs) (5 nm) with MCF-7 breast cancer epithelial cells lead to significant 
impairment of metabolic function of the cancer cells that took place within 12 h of 
incubation with ZnO NCs. The same study showed no significant LDH leakage within 12 h 
and only after 24 h did the cancer cells treated with ZnO NCs showed LDH leakage. The IC50 
of ZnO NCs in MCF-7 cells after 24 h determined in [11] was ~150 μM (12.21 μg/ml) and 
they suggested that the delayed occurrence of plasma membrane permeabilization is a 
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signature of late stage apoptosis. The same study investigated the toxicity of ZnO NCs in 
normal breast epithelial cells and highly invasive breast cancer cells, MDA-MB-231, and they 
concluded that ZnO NCs were toxic to cancer cells but not normal epithelia cells. However, 
only metabolic activity assay, MTT, was used to determine the effect of ZnO NCs on viability 
of MDA-MB-231 and normal breast epithelial cells and no apoptotic assay was performed to 
confirm the mechanism of toxicity induced by ZnO NCs. It has been reported that cellular 
responses like apoptosis in the presence of ZnO NPs require the potent tumor suppressor 
p53 as the molecular master switch towards apoptosis [185]. It has been reported that he 
p53 pathway was activated in BJ cells (skin fibroblasts) upon ZnO NPs treatment with a 
concomitant decrease in cell numbers [185]. Furthermore, in the wild type form, p53 aides 
in inhibiting growth of cancerous cells, but this is not the effect seen in mutant p53 [186]. 
Therefore, the differences observed in the responses of the MCF-7 and the MDA-MB-231 
cells to the ZnO NPs could be due to the fact that MCF7 expresses wild type p53 and MDA-
MB-231 expresses hyperactive, mutant p53 [186].  
 The bare and the RGD-targeted ZnO NPs showed different cytotoxicity to each 
breast cancer cell line. The RGD-targeted ZnO NPs were more toxic to the breast cancer cells 
than the bare NPs; however, this difference was not highly manifested after 3 h exposure in 
the MDA-MB-231 cells. Herein, the effect of the bare and the targeted ZnO NPs on the 
breast cancer cells was compared based on the IC50 values obtained for each NPs from the 
Alamar Blue (Table 6). In the MDA-MB-231 cells, the targeted ZnO NPs showed 3% increase 
in the toxicity compared to the bare NPs after 3 h exposure. After 24 h exposure, however, 
the RGD-targeted ZnO NPs were 27% more toxic to the MDA-MB-231 cells than the bare 
NPs. This higher toxicity of the targeted ZnO NPs compared to the bare ZnO NPs after 24 h 
exposure could be probably due to the higher binding of the targeted ZnO NPs to the 
integrin αvβ3 receptors of the MDA-MB-231 cells, which showed 42% expression of these 
receptors, and therefore higher internalisation and toxicity. The lower difference in the 
toxicity of the bare and targeted ZnO NPs in the MDA-MB-231 cells after 3 h exposure could 
indicate that the RGD-binding to the integrin αvβ3 receptor and then internalisation require 
time that could be >3 h, or that the intracellular processing and dissolution of the RGD-
targeted ZnO NPs, after their internalisation, requires time that is >3 h. These assumptions 
could be further supported by the observation that the toxicity of the targeted ZnO NPs to 
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the MDA-MB-231 cells was increased by 33% after 24 h compared to 3 h exposure. In the 
MCF-7 cells, neglecting the unexplained higher cytotoxic effects of the bare ZnO NPs after 3 
h compared to 24 h exposure, the targeted ZnO NPs were 24 and 56 % more toxic to the 
cells than the bare ZnO NPs after 3 and 24 h exposure, respectively. The targeted ZnO NPs, 
however, did not show any time dependent increase in the toxicity after 3 and 24 h 
exposure to the MCF-7 cells (i.e. the IC50 was the same at the two time points). The higher 
toxicity of the targeted ZnO NPs in the MCF-7 cells compared to the bare ZnO NPs could be 
still related to the higher binding of the targeted ZnO NPs to the integrin αvβ3 receptors, 
which were expressed by 19% of the MCF-7 cells. The unchanged toxicity of the targeted 
ZnO NPs to the MCF-7 cells after 24 h compared to 3 h exposure could indicate that the 
targeted NPs are internalised and dissolve inside the MCF-7 cells shortly after their binding 
to the cell surface.   
 The reduction in the metabolic activity after exposure to the ZnO NPs (bare and 
RGD-targeted) could be related to the toxic Zn2+ released from the bare and targeted ZnO 
NPs after their intracellular dissolution. It has been reported that Zn2+ has many effects on 
cancer cells, which includes alteration in gene expression, reduction in cellular metabolism 
and induction of apoptosis [5]. The release of Zn2+ ions, following incubation of ZnO 
nanocrystals (NCs) (5 nm) with MCF-7 breast cancer epithelial cells lead to significant 
impairment of metabolic function of the cancer cells and caused damage to the plasma 
membrane [11]. In this study, the apoptotic population in the MCF-7 cells showed no 
statistical difference (p>0.05) after exposure to the bare ZnO NPs and equivalent 
concentrations of Zn2+ from ZnCl2. In the MDA-MB-231 cells, however, there was significant 
difference in the apoptotic populations resulted from ZnCl2 and the bare ZnO NPs exposures 
at the 24 h IC50 of the bare ZnO NPs (i.e. 30 μg/ml). Based on these results, the different 
mechanisms of death induced by the ZnO NPs in the MCF-7 cells could be related to the 
effects of zinc ions. In the MDA-MB-231 cells, however, in addition to the effects of the 
released zinc ions, the ZnO NPs could be initiating other types of cell injury that contribute 
to its cytotoxicity. 
 The toxicity of the bare ZnO NPs to the cells used in this study, based on the 3 h 
exposure IC50 obtained from the Alamar Blue assay, could be suggested in the following 
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order; MCF-7> MDA-MB-231> MCF-10-2A cells. The bare ZnO NPs showed a selective 
toxicity to the breast cancer cell lines compared to the healthy breast epithelial cells at 
concentrations 25-40 μg/ml of the bare ZnO NPs after 3 h exposure. A dose of 35 μg/ml of 
the bare ZnO NPs could be used as a toxic dose to the breast MCF-7 and MDA-MB-231 
cancer cells with minimal toxic effects on the healthy breast MCF-10-2A cells, which showed 
>65% viability at this concentration. The ability of the targeted ZnO NPs to selectively kill the 
breast cancer cells but not the healthy epithelial cells, as well as its ability to effectively kill 
the triple negative MDA-MB-231 breast cells, which account for a high proportion of breast 
cancer mortality due to the lack of effective therapies [64], will open new options for this 
material in cancer therapy.  
 Both breast cancer cell lines expressed the integrin αvβ3 receptor, while the 
healthy epithelial breast cells MCF-10-2A showed almost negligible expression of these 
targeted receptors. Therefore, with the combination of the right dose and exposure time, 
and effective targeting, ZnO NMS would have potential for clinical applications in breast 
cancer therapy.  
 The RGD targeting of the ZnO NPs to the integrin αvβ3 receptors, which are 
selectively expressed on breast cancer cells, but not on healthy breast epithelial cells, 
together with the EPR effect of the tumor tissues, will increase the local concentrations of 
these NPs at the tumor site in vivo. In addition, the fact that the targeted ZnO NPs do not 
dissolve at neutral pH of 7.4 but completely dissolve in the acidic pH (in tumor 
microenvironment or inside the lysosomes of tumor cells) will increase the relevancy of our 
in vitro findings that the targeted ZnO NPs are more toxic to breast cancer cells than normal 
breast epithelial cells. 
 Finally, careful decisions should be made regarding the choice of the suitable 
viability assays to be used to assess the toxic effects of NMS to cells. These viability assays 
are originally designed to test the toxicity of chemicals, and not NMS, and therefore they 
could have different interactions with NMS that might affect their outcomes. In this study, 
we can conclude that ATP and LDH but not Alamar Blue assays could be used effectively to 
test the toxicity of ZnO NMS.  
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Table 6: A summary of IC50 values obtained for MCF-7, MDA-MB-231 breast cancer cell lines, and the healthy epithelial 
MCF-10-2A breast cells after exposure to bare and targeted ZnO NPs as determined from the viability assays. 
  
   
  
  
 
   
 
Assay 
 
Cells 
IC50 (μg/ml) 
Bare ZnO-NPs ZnO-HCV-RGD-GFP NPs 
3 h 24 h 48 3 h 24 h 48 h 
Alamar blue 
 MCF-7 21 36 NA 16 16 NA 
 MDA-MB-231  34 30 NA 33 22 NA 
 MCF-10-2A 45 NA NA NA NA NA 
LDH 
 MCF-7 NA 48 <20 NA NA NA 
 MDA-MB-231 NA Dose 
independent 
>100 
Dose 
independent ≤ 
10 
NA NA NA 
 MCF-10-2A NA >100 Dose 
independent  
(could not be 
measured) 
NA NA NA 
ATP 
 MCF-7 NA NA NA NA NA NA 
 MDA-MB-231 NA 36 <10 NA 33.5 24.6  
 MCF-10-2A NA NA NA NA NA NA 
NA: not measured 
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5 Uptake and intracellular dissolution of bare and RGD-targeted zinc 
oxide nanoparticles in breast cancer cells 
The design of smart multifunctional platforms for intracellular imaging and targeted 
therapeutic applications requires a thorough understanding of the uptake and bioreactivity 
of the NMS. Several studies have been conducted recently on the toxicity of ZnO NMS to 
different mammalian cells lines [49, 53, 65, 187], and its potential applications for imaging 
and targeted therapeutics [12]. ZnO NMS have been found to be toxic to different 
mammalian cells [53, 65, 67, 69, 187]. In many reports, the cytotoxicity of ZnO NMS to 
cancer cells has been attributed to free zinc ions and zinc complexes released upon 
dissolution of ZnO [10, 11]. However, only few reports on the cellular uptake of ZnO NMs 
are available [10, 49, 58]. It has been reported, by confocal microscopy, that ZnO NPs 
remnants are internalised by caveolae mediated uptake in BEAS-2B cells and toxic Zn2+ has 
been shown to accumulate in the lysosomal compartment in mouse macrophages (RAW 
264.7) [49]. It has also been shown that a pH-triggered controlled doxorubicin release from 
mesoporous silica NPs was achieved via intracellular dissolution of ZnO nanolids [44]. Only 
one study provided transmission electron microscopy (TEM) imaging data of binding of ZnO 
NPs to Human Bronchial Epithelial (BEAS-2B) Cells [124]. Lin W., et al. also showed 
agglomerates of ZnO NPs in endosomes in bronchoalveolar carcinoma- derived cells (A549) 
after 24 h exposure to 12 μg/ml ZnO NPs [161], however, their study lacks EDX data to 
confirm the presence of ZnO NPs. Therefore, there is still much debate around whether the 
ZnO NMS are taken up by cells and then dissolve only intracellularly or whether they 
dissolve in the extracellular matrix releasing ionic zinc which diffuses into the cells. One 
study has successfully targeted fluorescent ZnO NWs to tumours in vivo by targeting the 
integrin αvβ3 [12]. Again this study did not demonstrate whether the NWs are internalised 
by cells and where the zinc dissolves and exert its toxic effects. A summary of the size and 
zeta potential of ZnO NMS used in these studies is shown in Table 7. 
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Table 7: Primary and hydrodynamic size of ZnO NMs used in literature. Blank cells represent information that is not 
given in the specific publication. 
 
 
Reference 
 
 
Cells 
tested 
ZnO NMS 
 
Shape  
 
Primary size 
 
Hydrodynamic size (nm) Zeta potential (mV) 
DMEM BEGM Ham’s F-12 DMEM BEGM 
Xia et al. 
[49] 
RAW 
264.7 
BEAS-2B 
NPs 11 nm 36
a
 184
b
  -5
 a
 -16
 b
 
Gilbert et 
al. 
[124] 
BEAS-2B NPs 20 nm (no 
Fe) 
10 nm (Fe 
doped) 
 aggregated
c
  
100, 1000, 
>1000  
   negative  
Lin et al. 
[161] 
A549 NPs  70 nm, 420 
nm 
  ≈300 nm
d
   
Hong et al. 
[12] 
U87MG 
 
NWs 20-50 nm in 
diameter and 
0.5-1 μm in 
length 
     
RAW 264.7: Mouse leukaemic monocyte macrophage cell line, BEAS-2B: Normal human bronchial epithelial cells, A549: 
Human bronchoalveolar carcinoma-derived cells, U87MG: Human glioblastoma cells. 
DMEM: Complete Dulbecco’s modified eagle media. BEGM: Bronchial epithelial growth medium, 
a
: contains 10% fetal 
FBS. 
b
The medium contains growth factors, cytokines, and supplements (no serum). 
c 
The medium contains 2 mg/mL bovine 
serum albumin (BSA). 
 
d 
The medium contains 5% FBS. 
 
 Internalisation of NPs into living cells is a two-step process, which involves binding 
of the NPs to the surface of the cells and then their uptake by cells [10]. ZnO nanostructures 
are known to dissolve under acidic conditions. The phase-solubility diagram of ZnO [188] 
indicates that ZnO NPs will dissolve at pH below 6.7 at physiological temperature, and it will 
rapidly dissolve in the acidic pH of the lysosomes (pH 5.7) after their uptake. It is 
hypothesized that ZnO NPs can be targeted to cancer cells and specifically kills, by releasing 
Zn2+ ions inside these cells independently of their metabolic rate. It has been previously 
shown that the release of Zn2+ ions, following incubation of bare 5 nm ZnO NPs with MCF-7 
breast cancer epithelial cells, lead to generation of reactive oxygen species, resulted in 
damage to the plasma membrane and mitochondria leading to apoptosis [11]. However, in  
115 
 
ref. [11], they did not directly image whether the particles are internalised by the cells or 
where dissolution of ZnO NPs occurs. It is also likely that the ZnO NPs used in ref. [11] 
dissolved in the cell culture media due to their small size. The tendency of ZnO NPs to 
dissolve in aqueous solutions, especially biological fluids, has been well documented [10, 
117], but direct identification of the chemical form of zinc taken up (i.e. whether the ZnO 
NPs dissolve in the extra and intracellular environments), has not yet been shown.   
 It is extremely challenging to assess the relative contributions of nanoparticulate 
and dissolved zinc to the uptake, subcellular localization, and mechanism(s) of toxicity. 
Sasidharan et al. suggested that rapid dissolution of ZnO NCs in acidic cancer 
microenvironment is the main cause of apoptosis in cancer cells [11]. However, a study by 
Muller et al. used zinc sensitive dyes to show that zinc oxide NWs dissolution only occurs 
inside macrophage cells and that raised Zn2+ ion concentrations can be correlated directly to 
cell death [10]. Gilbert et al. combined high resolution X-ray spectromicroscopy and high 
elemental sensitivity X-ray microprobe analyses to determine the fate of ZnO and less 
soluble iron-doped ZnO NPs following exposure to cultures of human bronchial epithelial 
cells (BEAS-2B) [124]. The data suggested cellular uptake of ZnO NPs and a mechanism of 
zinc accumulation; following uptake, ZnO NPs dissolved completely generating intracellular 
Zn2+ complexed by molecular ligands [124]. A combination of atomic force microscopy and 
scanning transmission x-ray microscopy (STXM) were used to prove this question, however 
these techniques do not probe depth information [124] and the STXM data did not 
demonstrate significant changes in the zinc absorption edge in the cells exposed to ZnO NPs. 
Therefore conclusions cannot be drawn from this work.  In cancer cells, direct identification 
of the chemical format of zinc taken up by cells exposed to ZnO NPs, and its intracellular 
fate, has not yet been achieved.  
 To track binding, cellular uptake and intracellular dissolution of the ZnO NPs and 
death of the breast cancer cells, confocal microscopy of live cells was utilized to generate 
real time information about these processes. The confocal microscope does not have the 
spatial resolution to detect individual ZnO NMs, therefore correlative confocal and electron 
microscopy imaging and analysis of exactly the same cells imaged in the confocal and 
transmission electron microscopes, was used to confirm that the particles are internalised 
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by the cells and to assess their morphology inside the cells. Electron microscopy was also 
used to study how the ultrastructure of the cells was altered by the ZnO NPs to provide 
clues about the mode of cell death.  
It was shown in Chapter 4 of this study that a higher amount of integrin αvβ3 is 
expressed on breast cancer cells, compared to healthy breast epithelial cells. Therefore, it 
was hypothesized that RGD-ZnO NPs, will selectively target and destroy breast cancer cells, 
compared to healthy cells, and that these effects will follow the order MDA-MB-231 > MCF-
7> MCF-10-2A cells.  
The aim of this chapter is to correlate and compare targeting, intracellular 
destination and local dissolution of the bare and RGD-ZnO NPs directly with their toxicity 
mechanisms. 
5.1 Materials and methods 
5.1.1 Chemicals  
Propidium iodide (PI) was purchased from Sigma, UK. CellMask™ Deep Red Plasma 
membrane Stain, Hoechst 33342, and FluoZin3-AM from were purchased from Invitrogen. 
Zinquin-AM was purchased from Interchim, France. CaCl2 was from Sigma Aldrich Ltd, UK. 
PIPES (piperazine-N, N′bis [2-ethanesulfonic acid]) and MgCl2 were purchased from Fisher 
scientific Ltd, UK. MES was purchased from ACROS Organics, US. Accutase and Versene were 
purchased from Gibco (Life Technologies Ltd, UK). CD24-FITC was purchased from MACS 
(Miltenyi Biotech, UK, Cat. No., 120-008-097) and CD44-PE was from Biolegend, UK (Cat. No. 
338802; mouse monoclonal (BJ18). CD90-PE-Cy 5 (Cat. No. 555597), EpCAM-PE-CY5 (Cat. 
No. 347199) and the isotype control IgG1 were purchased from BD Bioscience, UK. Sodium 
cacodylate trihydrate (≥98%) was purchased from Sigma Aldrich Ltd, UK. PIPES (piperazine-
N, N′bis [2-ethanesulfonic acid]). 
5.1.2 Cell Culture 
The cells were cultured as described in section 4.1.1. 
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5.1.3 Confocal microscopy of breast cells exposed to targeted and bare ZnO 
nanoparticles  
 Correlation of uptake and dissolution of the targeted ZnO NPs by MDA-MB-231 5.1.3.1
cells 
 Uptake of ZnO-HCV-RGD-GFP NPs by live MDA-MB-231 cells 5.1.3.1.1
1. Live cells nuclei staining using Hoechst 33342 
The MDA-MB-231 cells were cultured for 48 h on 35 mm glass-based culture dishes (Nest 
Biotech Co, LTD, 35X12 mm style, 20 mm glass bottom) at 6x104 cells/cm2. The cells were 
rinsed once with the HEPES confocal imaging buffer at pH 7.4, 37°C. The cells were loaded 
with 5 μg/ml Hoechst 33342 in 1 ml of the HEPES confocal imaging buffer for 30 min at 37°C. 
At the end of incubation time, the cells were washed twice with imaging buffer (at 37°C). PI 
(20 μg/ml) was prepared in 1 ml of the HEPES confocal imaging buffer and added to the cells 
(the final concentration incubated with the cells was 10 μg/ml). PI is a cell impermeable dye 
and excluded from viable cells. Upon destruction of the plasma cell membrane, PI 
penetrates the cell, and upon binding DNA and RNA, its fluorescence intensity is enhanced 
20-30 fold. The targeted ZnO-HCV-RGD-GFP NPs stock dispersion, prepared in 50 mM 
HEPES+100 mM NaCl buffer at pH 7.5, was sonicated for 30 s on a bench sonicator. Then 1 
ml of 300 μg/ml ZnO-HCV-RGD-GFP NPs prepared in the HEPES confocal imaging buffer was 
added to the cells, just before imaging (the final concentration was 150 μg/ml). Confocal live 
imaging was started immediately after addition of the ZnO-HCV-RGD-GFP NPs dispersion to 
the cells using a Zeiss LSM 710 confocal microscope, with the environmental chamber set to 
37°C. Bright field confocal imaging was used to view changes in the cell morphology and to 
track the uptake of the targeted NPs across the cell membrane. Images were processed 
using ZEN 2009 Confocal Software. 
 The 405 nm laser line was used to excite Hoechst 33342 (λexc\λem= 355/461 nm), 
the 561 nm laser was used to excite PI (λexc\λem= 538/617 nm) and the 488 nm laser was 
used to track the GFP labelled ZnO-HCV-RGD (λexc\λem=488/509 nm). Images were 
acquired over a time period of 3-4 h to track the uptake of the particles (1 frame/2 min) 
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using a 20x objective/0.8 numerical aperture (NA), and the pinhole was set at 1 AU. Images 
were processed using ZEN 2009 Confocal Software. 
 To obtain 3D images of the targeted NPs inside the cells after their uptake, and to 
assess the viability of the cells, the experiment described above was repeated and images 
were acquired at different Z-stacks over a time period of 8-9 h (1 frame/1.5 min) using a 20x 
objective/0.8 NA. The cells were incubated at 37°C with the targeted NPs up to 18 h 
exposure and the cells were then imaged to assess the viability of the cells. 
2. Plasma membrane staining of live MDA-MB-231 cells using CellMask Deep Red   
CellMask Deep Red is a convenient marker of the plasma membrane and can be utilized to 
track the translocation of ZnO-HCV-RGD-GFP NPs across the plasma membrane. CellMask™ 
Deep Red is an amphipathic molecule providing a lipophilic moiety for excellent membrane 
loading and a negatively charged hydrophilic dye for “anchoring” of the probe in the plasma 
membrane.   
 To track the internalisation of ZnO-HCV-RGD-GFP NPs by the cells, the MDA-MB-
231 cells were cultured for 48 h on 35 mm glass-based culture dishes (Nest Biotech Co, LTD, 
35X12 mm style, 20 mm glass bottom) at 6x104 cells/cm2. At the end of incubation time, the 
cells were rinsed once with the HEPES confocal imaging buffer at 37°C. The cells were then 
loaded with 5 μg/ml CellMask Deep Red plasma membrane stain for 5 min at 37°C. The cells 
were washed twice with the imaging buffer and incubated in 1 ml imaging buffer at 37°C. 
The targeted ZnO-HCV-RGD-GFP stock dispersion, prepared in 50 mM HEPES+100 mM NaCl 
buffer at pH 7.5, was sonicated for 30 s on a bench sonicator. Then 1 ml of 300 μg/ml ZnO-
HCV-RGD-GFP NPs prepared in the HEPES confocal imaging buffer was added to the cells, 
just before imaging (the final concentration was 150 μg/ml). Confocal live imaging was 
started immediately after addition of the ZnO-HCV-RGD-GFP NPs dispersion to the cells 
using a Zeiss LSM 710 confocal microscope, with the environmental chamber set to 37°C. 
Images were processed using ZEN 2009 Confocal Software. 
 The 561 nm laser line was used to excite CellMask Deep Red plasma membrane stain and 
the 488 nm laser was used to track the ZnO-HCV-RGD-GFP NPs. Confocal live imaging was 
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carried out for 10 h (1 frame/2min) using 20x objective/0.8 NA, and the pinhole was set at 1 
AU. Images were processed using ZEN 2009 Confocal Software.  
 Dissolution kinetics of ZnO-HCV-RGD-GFP nanoparticles inside live MDA-MB-5.1.3.1.2
231 cells  
The MDA-MB-231 cells were cultured for 48 h on 35 mm glass-based culture dishes (Nest 
Biotech Co, LTD, 35X12 mm style, 20 mm glass bottom) at 6x104 cells/cm2. The cells were 
then rinsed once with the HEPES confocal imaging buffer at pH 7.4 and 37°C. The cells were 
then loaded with 10 μM of the cell-permeant Zn2+ indicator Zinquin-AM in 1 ml of the HEPES 
confocal imaging buffer for 30 min at 37°C. After rinsing the cells twice with imaging buffer 
at 37°C to remove any dye that is non-specifically associated with the cell surface, the cells 
were incubated for a further 30 min to allow complete de-esterification of intracellular AM 
esters of Zinquin. PI (20 μg/ml) was prepared in 1 ml HEPES confocal imaging buffer and 
added to the cells (the final concentration incubated with the cells was 10 μg/ml). Then 300 
μg/ml ZnO-HCV-RGD-GFP NPs were prepared in 1 ml HEPES imaging  buffer and was added 
to the cells just before imaging (final concentration exposed to the cells is 150 μg/ml). 
Confocal live imaging was started immediately after addition of the ZnO-HCV-RGD-GFP NPs 
dispersion to the cells using a Zeiss LSM 710 confocal microscope with the environmental 
chamber set to 37°C. A control MDA-MB-231 cells were incubated with 1 ml of the HEPES 
confocal imaging buffer alone.  
 The 405 nm laser line was used to excite Zinquin (λexc\λem = 344/385 nm), 561 nm 
laser was used to excite PI (λexc\λem= 538/617 nm) and the 488 nm laser was used to 
excite GFP labelled ZnO-HCV-RGD (λexc\λem=488/509 nm). Images were acquired over a 
time period of 24 h (1 frame/4 min) using a 20x objective/0.8 NA and the pinhole was set at 
1 AU. To monitor the dissolution of ZnO-HCV-RGD-GFP NPs inside the cells and subsequent 
cell death, the intensity of Zinquin and PI was tracked for 20 cells in the imaging frame over 
24h. Images were processed using ZEN 2009 Confocal Software. 
 Uptake of ZnO-HCV-RGD-GFP nanoparticles by live MCF-7  5.1.3.2
The MCF-7 cells were cultured for 48 h on 35 mm glass-based culture dishes (Nest Biotech 
Co, LTD, 35X12 mm style, 20 mm glass bottom) at 9x104 cells/cm2. The cells were then 
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rinsed once with the HEPES confocal imaging buffer at pH 7.4 and 37°C. The cells were then 
loaded with 5 μg/ml Hoechst 33342 in 1 ml of the HEPES confocal imaging buffer for 30 min 
at 37°C. At the end of incubation time, the cells were washed twice with HEPES confocal 
imaging buffer at 37°C. PI (20 μg/ml) was prepared in 1 ml HEPES confocal imaging buffer 
and added to the cells (the final concentration was 10 μg/ml). Then 150 μg/ml of the ZnO-
HCV-RGD-GFP NPs were prepared in 1 ml HEPES confocal imaging buffer and was added to 
the cells just before imaging (the final concentration was 75 μg/ml). Confocal imaging of live 
cells was started immediately after addition of the ZnO-HCV-RGD-GFP NPs dispersion to the 
cells using a Zeiss LSM 710 confocal microscope with the environmental chamber set to 
37°C. A control experiment was performed, in which the MCF-7 cells were incubated with 1 
ml of the HEPES confocal imaging buffer alone.  
 The 405 nm laser line was used to excite Hoechst 33342 (λexc\λem = 355/461 nm), 
the 561 nm laser was used to excite PI (λexc\λem= 538/617 nm) and the 488 nm laser was 
used to excite GFP labelled ZnO-HCV-RGD (λexc\λem=488/509 nm). Images were acquired 
over a time period of 13 h to track the uptake of the particles and viability of the cells (1 
frame/2 min) using a 20x objective/0.8 NA, and the pinhole was set at 1 AU. Images were 
processed using ZEN 2009 Confocal Software. 
 Uptake of ZnO-HCV-RGD-GFP nanoparticles by Live MCF-10-2A cells  5.1.3.3
The MCF-10-2A cells were cultured for 48 h on 35 mm glass-based culture dishes (Nest 
Biotech Co, LTD, 35X12 mm style, 20 mm glass bottom) at 9x104 cells/cm2. The cells were 
then treated using the same method described in section 5.1.3.2. Confocal imaging of live 
cells was started immediately after addition of the ZnO-HCV-RGD-GFP NPs dispersion to the 
cells using a Zeiss LSM 710 confocal microscope with the environmental chamber set to 
37°C. 
 The 405 nm laser line was used to excite Hoechst 33342 (λexc\λem = 355/461 nm), the 561 
nm laser was used to excite PI (λexc\λem= 538/617 nm) and the 488 nm laser was used to 
excite GFP labelled ZnO-HCV-RGD (λexc\λem=488/509 nm)Images were acquired over 24 h 
to track the uptake of the particles and viability of the cells (1 frame/4 min) using a 20x 
objective/0.8 NA, and the pinhole was set at 1 AU. A control experiment was performed, in 
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which the MCF-10-2A cells were incubated with 1 ml of the HEPES confocal imaging buffer 
alone. Images were processed using ZEN 2009 Confocal Software. 
 Correlation of uptake and dissolution of bare ZnO nanoparticles by MDA-MB-231 5.1.3.4
cells 
The MDA-MB-231 cells were cultured for 48 h on 35 mm glass-based culture dishes (Nest 
Biotech Co, LTD, 35X12 mm style, 20 mm glass bottom) at 6x104 cells/cm2. The cells were 
then rinsed once with the HEPES confocal imaging buffer at pH 7.4, 37°C. The cells were 
then loaded with 5 μM of the cell-permeant Zn2+ indicator FluoZin3-AM (Invitrogen, UK) in 1 
ml HEPES confocal imaging buffer for 20 min at 37°C. After rinsing the cells twice with 
imaging buffer (37°C), to remove any dye that was nonspecifically associated with the cell 
surface, the cells were incubated for a further 30 min to allow complete de-esterification of 
intracellular AM esters of FluoZin. Then, 150 μg/ml of the bare ZnO NPs were prepared in 2 
ml HEPES confocal imaging buffer and PI was added to the ZnO dispersion just before 
imaging at a final concentration of 10 μg/ml. Finally, the ZnO/PI dispersion was added to the 
cells and live imaging was started immediately after addition of the bare ZnO NPs using a 
Zeiss LSM 710 confocal microscope with the environmental chamber set to 37°C. A control 
experiment was performed, in which the MDA-MB-231 cells were incubated with 1 ml of the 
HEPES confocal imaging buffer alone.  
 The 488 nm laser line was used to excite FluoZin3 (λexc\λem= 494/516 nm) and the 
561 nm laser was used to excite PI (λexc\λem= 538/617 nm). Images were acquired over a 
time period of 16 h (1 frame/2 min) using a 20x objective/0.8 NA and the pinhole was set at 
1 AU. Images were processed using ZEN 2009 Confocal Software. 
5.1.4 Cellular uptake of ZnO nanoparticles and their effects on cell structure by electron 
microscopy  
 SEM imaging and analysis of bare ZnO nanoparticles binding in MDA-MB-231 5.1.4.1
cells  
To examine binding of the bare ZnO NPs to the MDA-MB-231 cells and their distribution 
around the cells, the MDA-MB-231 cells were grown on 10 mm φ Melinex coverslips (Agar 
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Scientific) coated with 20 μg/ml Poly-L-ornithine (PLO) at a density of 6x104 cells/cm2 for 24 
h at 37°C in 5% CO2 humidified environment. The cell culture medium was then removed 
and the cells were washed once in the medium. The cells were then incubated with 30 
μg/ml of the bare ZnO NPs for 4 h at 37°C in 5% CO2 humidified environment. The cells were 
then fixed with 2% formaldehyde and 2% glutaraldehyde prepared in 0.1 M PIPES buffer at 
pH 7.4 for 1 h at 4°C. This cocktail has been shown to preserve cell structure and chemistry 
for elemental analysis [189]. The cell culture medium and the fixative was aspirated off the 
cells and the cells were then washed three times with deionised water and allowed to dry at 
RT before SEM imaging and analysis. The cells were carbon coated and SEM was carried out 
with a Magellan 400 FEG SEM. Images were acquired with an accelerating voltage of 2 kV 
and EDX was performed at 20 kV.  
 TEM imaging and analysis of bare and targeted ZnO NPs uptake  5.1.4.2
The uptake of the bare ZnO NPs by the MCF-7 and MDA-MB-231 cells was investigated using 
TEM. The MDA-MB-231 cells were tested with the ZnO-HCV-RGD NPs for binding because 
our experimental results showed that the MDA-MB-231 cells express a higher percentage of 
the RGD-targeting receptor (integrin αvβ3). 
 Bare ZnO nanoparticles 5.1.4.2.1
The MDA-MB-231 and MCF-7 were seeded on 60 mm tissue culture dishes (CELLTREAT, 
China) for 24 h, at a density of 6x104 and 9x104 cells/cm2, respectively. The cell culture 
medium was then removed and the cells were washed once in the medium. The bare ZnO 
NPs ethanolic stock dispersion was sonicated for 20 min on a bench sonicator. The cells 
were then incubated with 20 μg/ml of the bare ZnO NPs, prepared in CDMEM medium, for 6 
and 24 h at 37°C in 5% CO2 humidified environment. After exposure, the cells were rinsed 
with 0.1M cacodylate buffer (pH=7.4), and were then fixed with 2.5% glutaraldehyde/0.1 M 
cacodylate buffer pH 7.4 for 1 h at 4°C. The samples were bulk stained using a cocktail of 1% 
OsO4, 0.15% potassium ferricyanide, and 2 mM CaCl2 in 0.1 M cacodylate buffer for 1 h at 
RT. The samples were washed several times with 0.1 M cacodylate buffer at pH 7.4. 
Dehydration of the samples in graded solutions of ethanol (30, 50, 70, 90, 95, and 100%), 
and infiltration in graded solutions (30, 50, 70, and 100%) of Spurr’s resin in acetone was 
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carried out using a Leica EM TP tissue processor (Leica Biosystems, UK). The samples were 
then embedded in Spurr’s Epoxy resin (Ted Pella, USA). Ultrathin sections (80-120 nm) of 
the cell pellets were prepared by ultramicrotomy using a 35° diamond knife and collected 
onto 300 mesh copper grids (TED PELLA, USA) in a water bath. The sections were post-
stained for 2 min in lead citrate. Images were acquired using a FEI Tecnai T12 TEM (Tecnai 
bio Twin, FEI Company, Hillsboro, OR) operated at 120 kV, unless otherwise specified. 
Images were recorded on a 2k x 4K CCD camera (Gatan Inc., Pleasanton, CA). 
 ZnO-HCV-RGD-GFP nanoparticles 5.1.4.2.2
 To determine the best incubation time for binding and uptake of the targeted ZnO NPs by 
the MDA-MB-231 cells, confocal microscopy of live cells incubated with the particles was 
conducted prior to TEM. The MDA-MB-231 cells were cultured for 48 h on 35 mm glass-
based culture dishes (Nest Biotech Co, LTD, 35X12 mm style, 20 mm glass bottom) at a 
density of 6x104 cells/cm2. The cells were then rinsed once with the HEPES confocal imaging 
buffer at 37°C. The cells were then loaded with 1 μg/ml of the cell permeable nucleus stain 
Hoechst 33342 in 1 ml HEPES confocal imaging buffer for 30 min at 37°C. After rinsing the 
cells twice with imaging buffer (at 37°C), PI was added to the cells in 1 ml of the same buffer 
(final concentration 10 μg/ml). The targeted ZnO-HCV-RGD-GFP stock dispersion, prepared 
in 50 mM HEPES + 100 mM NaCl buffer at pH 7.5, was sonicated for 30 s on a bench 
sonicator. Finally, ZnO-HCV-RGD-GFP NPs were prepared in 1 ml HEPES confocal imaging 
buffer (to a final concentration 150 μg/ml) and 3D imaging of live cells was started 
immediately after addition of the sample solution, using a Zeiss LSM 710 confocal 
microscope with an environmental chamber set to 37°C. The 405 nm laser line was used to 
excite Hoechst 33342 (λexc\λem=355/461 nm), 561 nm laser was used to excite PI 
(λexc\λem=535/617 nm) and the 488 nm laser was used to track GFP labelled ZnO-HCV-RGD 
NPs. The pinhole was set at 1 AU and imaging was started (1 frame/2 min) using a 20x 
objective/0.8 NA. Images were processed using ZEN 2009 Confocal Software. 
  Once the ZnO-RGD-HCV-GFP NPs were bound to the surface of the cells (after 22 
min exposure), confocal live imaging was stopped and the cells were immediately fixed with 
4% glutaraldehyde in 0.1 M cacodylate buffer at pH 7.4. Cells were then rinsed, pre-
embedded in gelatin 10% and infiltrated in 2.3 M sucrose, prepared in 0.1 M HEPES buffer at 
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pH 7.4, overnight at 4°C. Sucrose infiltrated samples were then frozen by immersion into 
liquid nitrogen for 3 s. 90 nm ultrathin sections were cut using an ultramicrotome at -110°C 
using diamond knife and collected using a drop of MS (1% methyl cellulose and 1.15 M 
sucrose) held on a wire loop, and transferred to 300 mesh copper grids (TED PELLA, USA). 
Cells were then imaged and analysed in Titan ST operated at 300 kV. Because the Cu grid 
interfered with the EDX energy peaks of Zn, new sections were prepared the same way but 
collected onto a gold grid. Pre-embedding in gelatin, infiltration, and sectioning of the cells 
was carried out with the help of Dr. Rachid Sougrat and Guangchao Wang at KAUST. 
5.1.5 Cancer stem cell markers 
For analysis of the cancer stem cell surface markers, the MCF-7 and the MDA-MB-231 cells 
were plated for 24 hours in 12-well plates to 80 % confluency. The cells were then detached 
using ice cold EDTA (0.48 mM Versene) solution. The cells were counted and then washed 
with Hank’s Balanced Salt Solution (HBSS). A total of 2X106 cells were incubated with 
specific antibodies for 30 min at 4°C in the dark. Unbound antibody was washed out through 
two cycles of washing with HBSS and the cells were analysed on a BD FACSCanto II flow 
cytometer (BD bioscience, Franklin lakes, NJ). The data were analysed using FlowJo 7.6.1 
and at least 50,000 events per sample was collected. The antibodies used were anti-CD44 
[phycoerythrin (PE)], anti CD24 [FITC], anti CD90 [PE-Cy5], anti EpCAM [PerCP-Cy™5.5+, and 
IgG1 was used an isotype control.  
5.2 Results and Discussion 
5.2.1 Confocal microscopy of live MDA-MB-231, MCF-7 and MCF-10-2A cells exposed to 
bare and RGD-targeted ZnO nanoparticles  
Binding, uptake, dissolution and cytotoxicity of the targeted ZnO NPs in the breast cancer 
MDA-MB-231 and MCF-7 cell lines were investigated. The MDA-MB-231 cells were chosen 
as a model of estrogen receptor-negative and highly invasive cells that shown to express the 
integrin αvβ3 [157]. The MCF-7 cells are used here as a model of an ER+ and non-metastatic 
breast cells that shows lower expression of these receptors [190].  
In MDA-MB-231 cells, Imaging was carried out using confocal microscopy of live cells 
exposed to the targeted ZnO-HCV-RGD-GFP NPs. The first objective was to track binding, 
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uptake and intracellular distribution of these NPs and subsequent death of the breast 
cancer cells. To achieve these goals, the targeted ZnO-HCV-RGD NPs were labelled with the 
GFP, and the nucleus or the plasma membrane of the cells was labelled with fluorescent 
probes. The second objective was directed to study the dissolution of the targeted ZnO-
HCV-RGD-GFP NPs inside the cells and correlate ZnO-HCV-RGD-GFP NPs uptake directly to 
rise of intracellular Zn2+ and cell death. Zinc-sensitive and cell permeable fluorescent probes 
were used to track the dissolution of the ZnO-HCV-RGD-GFP NPs inside the cells. PI, which is 
excluded by the intact cell membrane of live cells, was used as a viability indicator. 
 Since the MDA-MB-231 cells and the MCF-7 cells showed different responses to the 
ZnO-HCV-RGD-GFP NPs in the Alamar Blue and the ATP assays (Table 6), and they also 
expressed different percentage of the integrin αvβ3 targeted receptor (Figure 29), the 
cellular responses to the targeted ZnO-HCV-RGD-GFP NPs in the MDA-MB-231 cells were 
compared to those in the MCF-7 cells. The cellular responses of the healthy breast MCF-10-
2A cells after exposure to the ZnO-HCV-RGD-GFP NPs were also studied.  
The efficiency of targeting and mechanisms of uptake of the targeted ZnO-HCV-RGD-
GFP NPs, as well as intracellular rise of Zn2+ in the MDA-MB-231 cells were compared to 
those of the bare ZnO NPs. Finally, the intracellular rise of Zn2+ after exposure of the MDA-
MB-231 cells to ZnCl2 was also investigated.  
 A number of fluorescent dyes were used for confocal microscopy imaging of the 
cells; a list of these is shown in  
Table 8. Hoechst 33342 is a cell permeable dye that fluoresce blue upon binding the DNA of 
live nuclei. FluoZin3-AM and Zinquin-AM were used as Zn2+- sensitive probes. FluoZin 
fluoresces green while Zinquin fluoresces blue when complexed with Zn2+; therefore the 
latter was used with the green fluorescent RGD-targeted NPs. Both FluoZin3-AM and 
Zinquin-AM probes are cell-permeable fluorescent esters which are cleaved by cytosolic 
esterases to a cell-impermeant FluoZin and Zinquin that carry a negative charge, preventing 
their efflux across the plasma membrane. They also exhibit high Zn2+-binding affinity that is 
unperturbed by Ca2+ concentrations up to at least 1 μM *40+. A schematic representation of 
the confocal microscopy experiments performed in this study is shown in Figure 57. 
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Table 8: Fluorescent dyes used for confocal imaging.  
Dye used Excitation 
wave length 
(λexc)* (nm) 
Emission wave 
length (λem)** 
(nm) 
Excitation wave 
length used 
(nm) 
Function Fluorescent 
colour 
Hoechst 33342 355 461 405 Live cells nuclei stain blue 
PI 538 617 561 Viability indicator red 
FluoZin3-AM 494 516 488 Zinc ions sensitive dye green 
Zinquin-AM 344 385 405 Zinc ions sensitive dye blue 
GFP  488 509 488 Label for ZnO-HCV-
RGD NPs 
green 
CellMask Deep Red  649 666 561 Plasma membrane 
stain 
red 
*λexc: excitation wave length, **λem: emission wave length 
 
 
 
Figure 57: A schematic representation of the confocal microscopy experiments performed in this study.  
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 Correlation of uptake and dissolution of ZnO-HCV-RGD-GFP nanoparticles by live 5.2.1.1
MDA-MB-231 cells 
 Uptake of ZnO-HCV-RGD-GFP NPs into live MDA-MB-231 cells 5.2.1.1.1
1. Live cells nuclei staining using Hoechst 33342 
2D cell imaging of uptake of ZnO-HCV-RGD-GFP NPs into live MDA-MB-231 cells 
The MDA-MB-231 cells were loaded with the live nuclei stain Hoechst 33342, and were then 
incubated with the ZnO-HCV-RGD-GFP NPs. Images were acquired over a time period of 3-4 
h every 2 min. PI was used to stain the nuclei of dead cells. Bright field imaging was used to 
view the changes in cell morphology and to track the uptake of the NPs. The results are 
summarised in the following sections. 
I. Changes in cell morphology upon exposure to ZnO-HCV-RGD-GFP NPs 
Figure 58 shows the changes in the MDA-MB-231 cells’ morphology upon exposure to the 
ZnO-HCV-RGD-GFP NPs. Before exposure to the ZnO-HCV-RGD-GFP NPs, the MDA-MB-231 
cells had a healthy morphology, and were elongated with large intercellular spaces and they 
were adhered to the culture plate (Figure 58, a). Some circular cells had grown on the top of 
the elongated cells (Figure 58, a). All cells were viable as indicated by Hoechst stain of their 
nuclei and the absence of PI staining (Figure 58, a). After exposure to the ZnO-HCV-RGD-GFP 
NPs, the cells changed their morphology and became round as soon as they were incubated 
with the particles (Figure 58, b-d). It has been recently reported that Zn2+ (0.654-3.27 μg/ml) 
induced a dose-dependent inhibition of cell adhesion of MDA-MB-231 cells to fibronectin 
used as an extracellular matrix [191]. In this study, the targeted ZnO-HCV-RGD-GFP NPs 
dispersions released about 0.35 μg/ml of ionic zinc (Zn2+) in the confocal imaging buffer as 
indicated by the ICP dissolution experiment of the NPs (Figure 19). Therefore, it is possible 
that this alteration in morphology arose due to the release of a small amount of soluble Zn2+ 
in the imaging buffer. Large green aggregates of the ZnO-HCV-RGD-GFP NPs could also be 
observed around the cells (Figure 58, b-d). 
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Figure 58: Confocal and bright field images of MDA-MB-231 cells incubated with ZnO-HCV-RGD-GFP NPs (green). (a) 
MDA-MB-231 cells before exposure to the NPs. (b, c, d) MDA-MB-231 cells after 20, 30 and 60 min exposure to the 
targeted ZnO NPs, respectively. The cells nuclei were stained with Hoechst 33342 (blue).  
II. Binding and uptake of ZnO-HCV-RGD-GFP nanoparticles by MDA-MB-231 cells 
Binding and uptake of the ZnO-HCV-RGD-GFP NPs by the MDA-MB-231 cells were followed 
over time (Figure 59). Upon exposure to the targeted ZnO NPs, the MDA-MB-231 cells lost 
their shape rapidly (Figure 59, a-h). Large projections from the plasma membrane of the 
cells that extend into the matrix have developed (Figure 59, a-n). These projections 
surrounded the ZnO-HCV-RGD-GFP NPs (white arrows) and fused together so that the ZnO-
HCV-RGD-GFP NPs has become completely engulfed (Figure 59, a-n). Other ZnO-HCV-RGD-
GFP NPs bound to the cell membrane possibly through a receptor-mediated process (Figure 
59, f, arrow heads). Blebbing (Figure 59, o, black arrows) of the MDA-MB-231 cells, which is 
a marker of apoptosis, was observed at 78 min exposure to the ZnO-HCV-RGD-GFP NPs. 
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  Figure 60 shows binding of the ZnO-HCV-RGD-GFP NPs (white arrows in a-c) to the 
cell membrane possibly through a receptor-mediated process. After 2 h exposure, the MDA-
MB-231 cells were coated by almost a complete layer of ZnO-HCV-RGD-GFP and diffuse 
green fluorescence from the GFP could be observed inside the cells (Figure 60, d, white 
arrow). This diffuse green fluorescence could be present due to dissolution of the ZnO-HCV-
RGD-GFP NPs inside the highly acidic compartments of the lysosomes. Figure 61 shows a 
more clear presentation of the diffuse layer of GFP (white arrows) inside the MDA-MB-231 
cells. A video that shows the binding and uptake of the ZnO-HCV-RGD-GFP into live MDA-
MB-231 cells is attached (Video 1, MDA-MB-231 cells, ZnO-HCV-RGD-GFP NPs, uptake). 
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Figure 59: Confocal images showing binding and uptake of ZnO-HCV-RGD-GFP NPs to live MDA-MB-231 cells. The MDA-
MB-231 cells were exposed to 150 μg/ml ZnO-HCV-RGD-GFP NPs (green) and confocal imaging was carried out for 3-4 h. 
ZnO-HCV-RGD-GFP NPs (white arrows) binds to the cells soon after incubation. Blebbing (black arrows in O) of the MDA-
MB-231 cells was observed after 78 min exposure to the NPs. Hoechst (blue) was used to stain live cells nuclei blue. 
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Figure 60: Confocal images showing binding and uptake of ZnO-HCV-RGD-GFP NPs by live MDA-MB-231 cells. The MDA-
MB-231 cells were exposed to 150 μg/ml ZnO-HCV-RGD-GFP NPs (green) and confocal imaging was carried out for 3-4 h. 
ZnO-HCV-RGD-GFP NPs (white arrows in a-c) bound to the surface of the cells. A diffuse green layer of GFP (white arrow 
in d) could be observed inside the cells. Hoechst (blue) was used to stain live cells nuclei blue. 
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Figure 61: Confocal image showing a diffuse layer of GFP (white arrows) inside the cells MDA-MB-231 cells after 2 h 
exposure to ZnO-HCV-RGD-GFP NPs. The MDA-MB-231 cells were exposed to 150 μg/ml ZnO-HCV-RGD-GFP NPs (green) 
and confocal imaging was carried out for 3-4 h. Hoechst (blue) was used to stain live cells nuclei blue. 
 The binding of the ZnO-HCV-RGD-GFP NPs to the cell membrane of the MDA-MB-
231 cells seemed to be heterogeneous (Figure 62). A single channel of the GFP, after 1.5 h 
exposure to the ZnO-HCV-RGD-GFP NPs, shows difference in the GFP colour between 
individual cells (Figure 62, right image). This indicates systematic variations between NPs 
association levels due to phenotypic variations in ZnO-HCV-RGD-GFP NPs uptake and/or 
processing by the MDA-MB-231 cells (as will be discussed in section 5.2.3). This observation 
could also be due to different levels of expression of the integrin αvβ3 by the MDA-MB-231 
cells. 
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Figure 62: Confocal images showing binding of ZnO-HCV-RGD-GFP NPs to live MDA-MB-231 cells. The MDA-MB-231 cells 
were exposed to 150 μg/ml ZnO-HCV-RGD-GFP NPs (green) and confocal imaging was carried out for 3-4 h. ZnO-HCV-
RGD-GFP (white arrows) bound to the cells very rapidly after incubation. The difference in the GFP colour between 
individual cells indicates systematic variations between NP association levels due to phenotypic variations in NP uptake 
and/or processing by the cells. Hoechst 33342 was used as live nuclei stain. PI was used as a viability indicator 
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3D live cell imaging of uptake of ZnO-HCV-RGD-GFP nanoparticles by MDA-MB-231 cells 
To check for uptake into 3D volume of the cells, the previous experiment was repeated 
under the same conditions except images were acquired at different Z-height through the 
cell at each time point, and images were acquired every 1.5 min for 8-9 h. To check for cell 
viability, the cells were then stored at 37°C and reimaged after 18 h exposure. 
The MDA-MB-231 cells showed the same behaviour upon exposure to the ZnO-HCV-
RGD-GFP NPs in 3D imaging. This includes; the development of large projections from the 
plasma membrane of the cells that extend into the matrix (Figure 63, b, white arrows), 
changes in the cell morphology (Figure 63, a-f), binding and uptake of the ZnO-HCV-RGD-
GFP (Figure 63, b-d, arrow heads). Some agglomerates of the ZnO-HCV-RGD-GFP NPs, 
however are bound to the surface of the cells without being taken up by the cells. It has 
been reported that after binding of NPs to their receptors, the receptors associated with 
their ligands are engulfed to a coated pit, and the assembled vesicle is then pinched off from 
the plasma membrane [48]. Therefore, it is most probably that these agglomerates of the 
ZnO NPs are too big for integrin αvβ3 receptor mediated uptake. Because the cells were 
imaged for longer time, cellular death could be tracked. After 270 min of incubation with 
the ZnO-HCV-RGD-GFP NPs, the MDA-MB-231 cells started to undergo apoptosis as 
indicated by blebbing (Figure 63, g and h, black arrows). After blebbing, the MDA-MB-231 
cells lost their cell membrane integrity as indicated by the intracellular penetration of PI and 
the double staining of their nuclei (Figure 63, i). A single channel of Hoechst 33342 and PI 
staining of the nucleus is shown in Figure 64.  
 An orthogonal view through a stack of images of the MDA-MB-231 cells shows the 
ZnO-HCV-RGD-GFP NPs inside the cells at the same focal plane of the nucleus (Figure 65). 
Furthermore, 3D confocal images of the MDA-MB-231 cells after 13.5, 16.5, and 19.5 min 
exposure to ZnO-HCV-RGD-GFP NPs show the NPs inside the cells at a Z height within the 
cell that is at the same focal plane of the nucleus (Z2) but not at the other Z planes just 
below and above Z2 separated by 1.28 μm (Figure 66). However, after 22.5 min exposure to 
the ZnO-HCV-RGD-GFP NPs, the intensity of the GFP at Z2 was reduced and a more diffused 
green colour could be observed, which could probably indicate the dissolution of the NPs 
inside the cells (Figure 66). This indicates that the targeted ZnO-HCV-RGD-GFP ZnO NPs are 
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internalised, then dissolve inside the cells and cause cytotoxic responses in the MDA-MB-
231 cells. A video that shows the uptake of the ZnO-HCV-RGD-GFP NPs by live MDA-MB-231 
cells is attached (Video 2, MDA-MB-231 cells, ZnO-HCV-RGD-GFP NPs, uptake). 
 
Figure 63: Confocal images showing binding and uptake of ZnO-HCV-RGD-GFP NPs by live MDA-MB-231 cells. The MDA-
MB-231 cells were exposed to 150 μg/ml ZnO-HCV-RGD-GFP NPs (green) and confocal imaging was carried out for 8-9 h, 
the cells were then incubated at 37°C and imaged after 18 h exposure. (a-d) Extensions of large projections from the 
plasma membrane (white arrows) were developed to engulf ZnO-HCV-RGD-GFP (white arrow heads). (e,f) Shrinkage in 
cell size after exposure to the ZnO-HCV-RGD-GFP NPs. (g, h) Blebbing (black arrows) of the cells in process of apoptosis. 
(i) Cell death as indicated by red staining of the nucleus (n). Hoechst (blue) was used to stain live cells nuclei blue. PI 
(red) was used as a viability indicator. 
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Figure 64: Confocal image of MDA-MB-231 cells after 18 h exposure to ZnO-HCV-RGD-GFP NPs. MDA-MB-231 cells were 
exposed to 150 μg/ml ZnO-HCV-RGD-GFP NPs (green) for 18 h at 37°C. (a) A dead MDA-MB-231 cell imaged after 18 h of 
incubation with the NPs, showing the nucleus stained with both Hoechst 33342 and PI. (b) Nucleus of the cell in image a, 
stained with Hoechst 33342 (blue) and PI (red). (c) and (d) are Hoechst 33342 and PI staining of the nucleus, respectively.  
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Figure 65: A Z-Stack image in an orthogonal view of ZnO-HCV-RGD-GFP NPs penetrating the cytoplasm of MDA-MB-231 
cells (green=ZnO-HCV-RGD-GFP, blue=nuclei, green line= XZ plane, red line =YZ plane, blue line=XY ). MDA-MB-231 cells 
were incubated with 150 μg/ml ZnO-HCV-RGD-GFP NPs. Hoechst 33342 was used as viable nuclei stain. Scale bar is 5 
μm. 
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Figure 66: Confocal images of MDA-MB-231 cell exposure to ZnO-HCV-RGD-GFP NPs (green) showing the NPs inside the 
cell at Z2-height within the cells (white arrows) after different exposure time points. The NPs were observed at the same 
focal plane of the nucleus, and were not observed at Z heights just below and above Z2. MDA-MB-231 cells were 
incubated with 150 μg/ml ZnO-HCV-RGD-GFP NPs. Hoechst 33342 was used as viable nuclei stain (blue). 
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2. Plasma membrane staining of live MDA-MB-231 cells using CellMask Deep-Red   
To further confirm the uptake of the ZnO-HCV-RGD–GFP NPs by the MDA-MB-231 cells, the 
plasma membrane of the MDA-MB-231 cells was stained with the CellMask™ Deep Red 
(Figure 67), and the uptake of the ZnO-HCV-RGD–GFP NPs by the cells was tracked over 
time. Figure 68 shows that binding of the particles to the plasma membrane of the cells was 
started shortly after incubation of the cells with the targeted ZnO NPs. Figure 68 also shows 
that the ZnO-HCV-RGD-GFP NPs had become internalised inside the cells (white arrow 
heads) and possibly dissolved inside the cells. At the end of imaging time (≈ 10 h), the cell 
membrane was surrounded by almost a complete layer of the ZnO-HCV-RGD-GFP NPs 
(Figure 68). A video that shows the uptake of the ZnO-HCV-RGD-GF NPs by live MDA-MB-
231 cells is attached (Video 3, MDA-MB-231 cells, ZnO-HCV-RGD-GFP NPs, CellMask deep 
red). 
 
Figure 67: Confocal image of CellMask Deep Red staining of the plasma membrane of MDA-MB-231 cells before 
exposure to ZnO-HCV-RGD-GFP NPs. MDA-MB-231 cells were loaded with 5 μg/ml CellMask™ Deep Red plasma 
membrane stain in confocal imaging buffer for 5 min at 37°C.  
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Figure 68: Confocal images showing uptake of ZnO-HCV-RGD-GFP by live MDA-MB-231 cells. The plasma membrane of 
the cells was stained with CellMask deep red stain (white arrow) and ZnO-HCV-RGD-GFP NPs were added to the cells at 
a final concentration of 150 μg/ml. The ZnO-HCV-RGD-GFP NPs (white arrow heads) started to bind to the plasma 
membrane, internalised, and dissolved inside the cell. The CellMask plasma membrane stain started to penetrate the 
cytoplasm after 30 min of incubation with the cells. 
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 Dissolution of ZnO-HCV-RGD-GFP nanoparticles in MDA-MB-231 cells and rise 5.2.1.1.2
of intracellular Zn2+  
The results illustrated in section 5.2.1.1.1 showed that the ZnO-HCV-RGD-GFP NPs bind to 
and are taken up by the MDA-MB-231 cells. After internalisation of the GFP labelled NPs, a 
diffuse green area could be observed inside the cells indicating that the particles could have 
dissolved. Figure 19 showed that the solubility of the ZnO-HCV-RGD-GFP NPs in the HEPES 
confocal imaging buffer at pH 7.4 was < 0.6 μg/ml Zn2+. Therefore, any rise in intracellular 
Zn2+ upon exposure to ZnO-HCV-RGD-GFP NPs must be due to the acidic dissolution of these 
NPs inside the lysosomes and the local release of toxic Zn2+ ions after their internalisation. 
To confirm that dissolution of the RGD-targeted NPs inside the MDA-MB-231 cells had 
occurred, confocal imaging of cells incubated with 150 μg/ml of the ZnO-HCV-RGD-GFP NPs 
was carried out for 24 h using Zinquin- a dye sensitive to zinc ions. PI was used as a viability 
indicator. Bright field imaging was used to view the changes in cell morphology and to track 
uptake of the NPs by the cells. 
 Figure 69 shows that after 2 h exposure of the MDA-MB-231 cells to the ZnO-HCV-
RGD-GFP NPs, the NPs were bound to the surface of the MDA-MB-231 and formed almost a 
complete layer around the cell. After uptake, the ZnO-HCV-RGD-GFP NPs dissolved in the 
highly acidic compartments of the lysosomes releasing zinc ions (Zn2+) (Figure 70). This 
release of ionic zinc (Zn2+) was accompanied by the increase in the intensity of Zinquin inside 
the cells (Figure 70), which was clear after 4 h of exposure (Figure 70, b). This rise in the 
intracellular zinc was toxic to the cells and resulted in cell death as indicated by the 
penetration of PI into the cells and the rise of its intracellular concentration (Figure 70, c and 
d). The rise of intracellular zinc ions over time was followed for 20 cells and a representative 
example is illustrated in Figure 71 (b and c). Analysis of the cells after exposure to the 
targeted ZnO-HCV-RGD-GFP showed that 20% of the cells in the imaging field died as early 
as 6 h exposure and almost 80% of the cells died after 12 h exposure.  
 The control elongated MDA-MB-231 cells, imaged under the same conditions, 
survived the laser, and did not show any morphological changes throughout the 24 h 
imaging time (Figure 72). Some cells, however, especially the round cells grown on the top 
of the elongated cells, died after 24 h of imaging. The change in the intensity of Zinquin 
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inside individual cells was not easy to track as the cells were alive and moving during 
imaging, therefore, the mean fluorescent intensity of Zinquin and PI was measured from 
different regions in the imaging field. The cells did not show any increase in intracellular zinc 
throughout the experiment (Figure 70, a). This confirms that the Zn2+ indicator did not 
fluoresce over time, in the absence of zinc. A video of intracellular dissolution of the 
targeted ZnO-HCV-RGD-GFP NPs by live MDA-MB-231 cells is attached (Video 4, MDA-MB-
231 cells, ZnO-HCV-RGD-GFP NPs, Zinquin). 
 
Figure 69: Confocal images of MDA-MB-231 cells showing binding of the ZnO-HCV-RGD-GFP NPs. (a) Bright field image of 
the MDA-MB-231 cells showing the bound ZnO-HCV-RGD-GFP NPs. (b) Green fluorescent channel image of ZnO-HCV-
RGD-GFP NPs after 2 h of incubation with MDA-MB-231 cells. The targeted ZnO NPs were bound to the surface of the 
cells (white arrows in b).  
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Figure 70: Confocal images showing dissolution of ZnO-HCV-RGD-GFP NPs after uptake by MDA-MB-231. The MDA-MB-
231 cells were incubated with 150 μg/ml ZnO-HCV-RGD-GFP NPs, Zinquin (blue) was used as a cellular permeant Zn
2+
-
selective indicator, and confocal imaging was carried out for 24 h. PI (red) was used as a viability indicator. The ZnO-
HCV-RGD-GFP NPs dissolved inside the cells over time and released Zn
2+
, which was accompanied by the increase in the 
intensity of Zinquin (blue). Toxic levels of Zn
2+
 ions inside the cell resulted in loss of cell membrane integrity and cellular 
penetration of PI.  
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Figure 71: Intensity curves of Zinquin and PI in MDA-MB-231 cells after exposure to ZnO-HCV-RGD-GFP NPs. MDA-MB-
231 cells were loaded with the cell-permeant Zn
2+
 indicator Zinquin-AM prior to incubation with (a) imaging buffer 
(nontreated control), (b, c) 150 μg/ml ZnO-HCV-RGD-GFP NPs. Zinquin fluoresces blue upon binding ionic zinc (Zn
2+
). PI 
was included to stain the nuclei of dead cells (red). The insets in b and c are showing the gradual increase in FluoZin 
intensity over time. Images were acquired over a time course of 24 h. Fluorescent intensities were measured within a 
representative region of interest (ROI).  
145 
 
 
Figure 72: Confocal images of MDA-MB-231 cells incubated with HEPES confocal imaging buffer (pH 7.4) for 24 h showing 
the healthy morphology of the cells.  
 Uptake of ZnO-HCV-RGD-GFP nanoparticles into live MCF-7 cells 5.2.1.2
Binding and uptake of the ZnO-HCV-RGD-GFP NPs were also tracked over time in the ER+ 
and non-metastatic MCF-7 cells by 3D confocal microscopy. For this purpose, the cells were 
loaded with the live nuclei stain Hoechst 33342, and they were then incubated with the 
RGD-targeted ZnO NPs and images were acquired over a time period of 13 h. The red 
fluorescent viability dye PI was used to stain the nuclei of dead cells. Bright field imaging 
was used to view the changes in cell morphology and to track the uptake of the ZnO-HCV-
RGD-GFP NPs. 
The MCF-7 cells showed a lower expression of the integrin αvβ3 compared to the 
MDA-MB-231 cells (Figure 29). Therefore, the uptake of the targeted ZnO-HCV-RGD-GFP in 
the MDA-MB-231 cells was compared to that of the MCF-7 cells. As the MCF-7 cells showed 
almost 90% reduction in the viability after 3 h exposure to 100 μg/ml ZnO-HCV-RGD-GFP 
NPs using Alamar Blue assay (Figure 33), a lower dose of 75 μg/ml of the ZnO-HCV-RGD-GFP 
NPs was used for confocal microscopy. This dose was chosen in order to track the uptake of 
the targeted NPs before initiation of cellular death. The MCF-7 cells were exposed to 75 
μg/ml ZnO NPs at 37°C for 13 h with images acquired at different Z-heights through the cell.  
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 Before exposure to ZnO-HCV-RGD-GFP NPs, the MCF-7 cells had a healthy 
morphology and tended to grow in clusters (Figure 73, a). They were relatively consistent in 
size and shape in monolayer proliferation, and had big nuclei (Figure 73, a). All cells were 
viable as indicated by Hoechst stain of their nuclei and the absence of PI staining (Figure 73, 
a). Upon exposure to the ZnO-HCV-RGD-GFP NPs, and unlike the MDA-MB-231 cells, there 
was no obvious change in shape or shrinkage of the cell. On the contrary, the MCF-7 cells 
showed some swelling after 1 h exposure to the NPs (Figure 73, e). Extensions of large 
projections from the plasma membrane of the cells that extend into the matrix have 
developed (Figure 73, b (black arrows)). These projections surrounded the ZnO-HCV-RGD-
GFP NPs and fused together so that the ZnO-HCV-RGD-GFP NPs has become completely 
engulfed (Figure 73, c-f). In contrast to the MDA-MB-231 cells, a lower binding of the ZnO-
HCV-RGD-GFP NPs could be seen quantitatively for the MCF-7 cells. This is most probably 
due to the lower expression of the integrin αvβ3 on the surface of the cell membrane of the 
MCF-7 cells as shown in Figure 29. 
 After binding and uptake of the ZnO-HCV-RGD-GFP NPs by the MCF-7 cells, and like 
MDA-MB-231 cells, diffuse green fluorescence from the GFP could be observed inside the 
cells (Figure 73, f and Figure 74). This diffuse green fluorescence could be present due to 
dissolution of the ZnO-HCV-RGD-GFP NPs inside the highly acidic compartments of the 
lysosomes. Confocal microscope and orthogonal view of a stack of images of the MCF-7 cells 
showed that ZnO-HCV-RGD-GFP (white arrows) penetrated the cytoplasm of the MCF-7 cells 
after 81 min exposure (Figure 74).  
  After 4 h of incubation with the ZnO-HCV-RGD-GFP NPs, some MCF-7 cells started 
to die as indicated by the double staining of their nuclei, without obvious blebbing (Figure 
75, a). After 5 h, however, more cells started to die and blebbing could be clearly observed 
with some cells after 10 h exposure (Figure 75, b-e (white arrows)). After blebbing, the MCF-
7 cells lost their cell membrane integrity as indicated by the intracellular penetration of PI 
and the double staining of their nuclei (Figure 73, b-e). After 13 h of exposure to the ZnO-
HCV-RGD-GFP NPs, 60% of the cells were dead (139/233 cells). A video that shows binding 
and uptake of the ZnO-HCV-RGD-GFP NPs by live MCF-7 cells and subsequent cell death is 
attached (Video 6, MCF-7, ZnO-HCV-RGD-GFP NPs, uptake). 
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 Most of the control MCF-7 cells incubated with the HEPES confocal imaging buffer 
alone survived the laser power for the time of imaging (Figure 76). However, 11% (27/252 
cells) of the cells did not withstand the laser and were dead at the end of imaging (Figure 76, 
b). A video of control MCF-7 cells is attached (Video 7, MCF-7, ZnO-HCV-RGD-GFP NPs, 
uptake). 
 
Figure 73: Confocal images showing uptake of 75 μg/ml ZnO-HCV-RGD-GFP NPs (white arrows) by MCF-7 cells at: (a-f) 
zero, 5, 13, 31, 61, and 81 min exposure, respectively. Cells developed extensions of large projections from the plasma 
membrane (black arrows) that extended into the cytoplasm to internalise the NPs. The orthogonal slice view through 
the ZnO-HCV-RGD-GFP NPs (white arrows 1 and 2) in image f is shown in Figure 74. 
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Figure 74: Confocal microscope image (a) and average projection through a stack of images (b, c) of ZnO-HCV-RGD-GFP 
NPs (1 and 2; respectively)  penetrating the cytoplasm of MCF-7 cells after 81 min at 37°C (green=ZnO-HCV-RGD-GFP 
NPs, blue=nuclei, green line=XZ plane red line=YZ plane, blue line=XY ). White arrows confirmed ZnO-HCV-RGD-GFP NPs 
presence inside the cells.  
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Figure 75: Confocal microscope images of MCF-7 after exposure to ZnO-HCV-RGD-GFP NPs (75 μg/ml) showing cell 
death. The cells lost their viability with time (image (a) to image (e)). Cells’ death started with blebbing (white arrows) 
and PI (red) started to penetrate the cells due to a loss of cell membrane integrity. Hoechst 33342 (blue) was used to 
stain live cells’ nuclei blue. 
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Figure 76: Confocal microscope images of control untreated MCF-7 incubated with HEPES confocal imaging buffer. (a) 
MCF-7 cells at 0 h exposure, (b) MCF-7 cells after 13 h of imaging showing that 11% of the cells (27/252) lost their 
viability due to laser damage of the cells. Hoechst 33342 (blue) was used to stain live cells nuclei blue. PI (red) was used 
as a viability indicator. 
 Uptake of ZnO-HCV-RGD-GFP nanoparticles into live MCF-10-2A cells  5.2.1.3
The MCF10-2A cells are healthy human breast cells. These cells are chosen to test the 
selectivity and differences in cellular responses of the ZnO-HCV-RGD-GFP NPs compared to 
breast cancer cells. Before exposure to ZnO-HCV-RGD-GFP NPs, the MCF-10-2A cells had a 
healthy morphology and tended to grow in clusters (Figure 77, a). The cells were relatively 
consistent in size and shape in monolayer proliferation, and had big nuclei. All cells were 
viable as indicated by Hoechst stain of their nuclei and the absence of PI staining (Figure 77, 
a). Upon exposure, the ZnO-HCV-RGD-GFP NPs showed low or no binding to the surface of 
the MCF-10-2A cells (Figure 77, b). This is probably due to the fact that they lack the integrin 
αvβ3 receptors on their surface, as has been already shown (Figure 29). However, 
extensions from the cell membrane of some cells were developed (Figure 77, c-d, arrows) 
and uptake of some of the ZnO-HCV-RGD-GFP NPs could be observed. The cells were alive 
after 2 h exposure to 150 μg/ml ZnO NPs (Figure 77, d), and this coincides with the viability 
assays (3h exposure to the ZnO-HCV-RGD-GFP NPs, Figure 34).  
The control MCF-10-2A survived 2 h of imaging before they started to die in the 
confocal microscope (Figure 78). After 2 h imaging, 10% of the MCF-10-2A cells (29/277) lost 
151 
 
their viability due to laser damage of the cells (Figure 78, b) Therefore, comparisons to the 
MCF-7 and MDA-MB-231 cells using confocal microscopy were not feasible. 
 
Figure 77: Confocal microscope images of MCF-10-2A after exposure to 150 μg/ml ZnO-HCV-RGD-GFP NPs for 2 h. (a) 
Zero time exposure to ZnO-HCV-RGD-GFP NPs. (b) After 32 min exposure cells started shrinking. (c, d) After 60 and 120 
min exposure, cells started to develop extensions (white arrows) from the plasma membrane. Hoechst (blue) was used 
to stain live cells’ nuclei blue. 
 
Figure 78: Confocal microscope images of control untreated MCF-10-2A cells incubated with HEPES confocal imaging 
buffer for 120 min. (a) The MCF-10-2A cells at zero time of imaging. (b) The MCF-10-2A cells after 2 h of imaging showing 
that 10% of the cells (29/277) lost their viability due to laser damage of the cells. Hoechst (blue) was used to stain live 
cells’ nuclei blue. PI was used as a viability indicator. 
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 Correlation of uptake and dissolution of bare ZnO nanoparticles by live MDA-MB-5.2.1.4
231 cells 
The aim of this section was to compare binding, uptake and dissolution of the bare ZnO NPs, 
as well as its effect on the MDA-MB-231 cells viability to that of the targeted ZnO-HCV-RGD-
GFP NPs. The MDA-MB-231 cells were used here because they expressed a higher 
percentage of the integrin αvβ3 receptors and therefore the effect of targeting can be 
investigated. The MDA-MB-231 cells were loaded with the cellular permeant Zn2+-selective 
indicator, FluoZin3-AM, and were incubated with the bare ZnO NPs and images were 
acquired over a time period of 16 h. The red fluorescent viability dye PI was used to stain 
the nuclei of dead cells. Bright field imaging was used to view the changes in cell 
morphology and to track the uptake of the NPs. The results are summarised in the following 
sections. 
1. Changes in cell morphology upon exposure to the bare ZnO NPs  
As observed in the previous sections, the MDA-MB-231 cells displayed an elongated shape 
and adhered to the culture plates before exposure to the bare ZnO NPs (Figure 79, a). After 
exposure to 150 μg/ml of the bare ZnO NPs, the MDA-MB-231 cells immediately changed 
their morphology and they became round (Figure 79, b). After 2 h exposure, the cells shrank 
in size, and stopped moving (Figure 79, c). This alteration in morphology could probably 
again arise due to the release of soluble Zn2+ in the HEPES confocal imaging buffer. As 
illustrated in the ICP dissolution experiment (Figure 17, a), the bare ZnO NPs dispersions 
released about 4 μg/ml of ionic zinc (Zn2+) in the HEPES confocal imaging buffer at pH 7.4.  
The morphology of the untreated control cells, however, remained unaltered up to 
16 h of imaging under the same conditions (Figure 80). All these cellular responses in the 
MDA-MB-231 cells to the bare ZnO NPs were comparable to those observed with the 
targeted ZnO NPs. 
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Figure 79: Bright-field confocal images of MDA-MB-231 cells exposed to the bare ZnO NPs. MDA-MB-231 cells were 
exposed to 150 μg/ml bare ZnO NPs for 2 h. The cells had altered morphology to control cells after exposure to 150 
μg/ml bare ZnO NPs.  
 
Figure 80: Bright-field confocal image of control MDA-MB-231 cells in HEPES confocal imaging buffer after 16 h of 
imaging. Cells were elongated and adhered to the plate. 
2. Uptake and dissolution of the bare ZnO NPs by MDA-MB-231 cells  
Uptake and dissolution of the bare ZnO NPs over time was tracked in the MDA-MB-231 cells 
(Figure 81). After the immediate loss of shape (Figure 81, a, arrow head) upon exposure to 
ZnO NPs, extracellular extensions of large projections from the plasma membrane of the 
cells that extend into the matrix had formed (Figure 81, b and c, white arrows). These 
projections surrounded the bare ZnO NPs and fused together so that the NPs aggregates 
were completely surrounded by the cells (Figure 81, c). The process of particle 
internalisation was accompanied by an increase in the intracellular zinc ions indicated by an 
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increase in the intensity of FluoZin green fluoresce (Figure 81, d). Blebbing (Figure 81, d, 
black arrow) and rupture of cell membrane, as indicated by penetration of the cell 
impermeant PI into the cell (Figure 81, f), were observed. A video that shows uptake and 
dissolution of the bare ZnO NPs by live MDA-MB-231 cells, is attached (Video 8, MDA-MB-
231 cells, bare ZnO NPs, uptake, FluoZin). 
  Incubation with 150 μg/ml ZnO NPs lead to a steep increase in the FluoZin 
fluorescence inside the cells with time, which indicated rapid dissolution of the bare ZnO 
NPs inside the cells and a resulting increase in the intracellular levels of Zn2+ (Figure 81). In 
order to measure the amount of intracellular ionic zinc Zn2+ released and cell membrane 
integrity of the MDA-MB-231 exposed to the bare ZnO NPs, the fluorescent intensities of 
FluoZin and PI was measured for 17 cells in the imaging frame over 16 h exposure. The 
intensities of the ROI selected from the cells could not be averaged as the cells showed a 
heterogeneous response to the particles. However, representative ROIs are shown in Figure 
82 (plot b and c). After exposure to the bare ZnO NPs, the MDA-MB-231 cells in the field of 
view reacted quite differently regarding the release of ionic zinc and subsequent cell death. 
This could indicate differences in the resistance of the cells’ population to Zn2+ that requires 
further investigation (will be discussed in section 5.2.3). 41% of the MDA-MB-231 cells (7/ 
17) required about 1-1.5 h to reach the maximum concentration of ionic zinc (Zn2+) in the 
cytoplasm. In contrast, 59% cells (10/17) needed almost 3-4 h to achieve the highest levels 
of intracellular Zn2+. Once the concentration of Zn2+ had reached a maximum inside the cell 
(the peak value of FluoZin), some cells died immediately (penetration of PI staining inside 
the cells). This correlation was monitored by increasing intracellular levels of PI and a drop 
in FluoZin dye (Figure 82, b), indicating a loss of plasma membrane integrity. Figure 82 C, 
shows other cell that survived longer time with the highest levels of Zn2+ (plateau of 
FluoZin), and could resist a high intracellular concentration of Zn2+ before they started to 
die. Figure 17 showed that the solubility of the bare ZnO NPs in the HEPES confocal imaging 
buffer at pH 7.4 was < 9 μg/ml Zn2+. Therefore, any rise in intracellular Zn2+ upon exposure 
to the bare ZnO NPs must be due to the acidic dissolution of the ZnO NPs inside the 
lysosomes and the local release of toxic Zn2+ ions. A video that shows uptake and dissolution 
of the bare ZnO NPs by the MDA-MB-231 cells is attached (Video 9, MDA-MB-231 cells, bare 
ZnO NPs, dissolution, FluoZin). 
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 In the untreated control cell sample (Figure 82, a), the MDA-MB-231 cells 
incubated with the HEPES confocal imaging buffer did not show any increase in FluoZin-3 
fluorescence over the time of imaging. This confirms that the Zn2+ indicator did not fluoresce 
over time in the absence of zinc. Most cells did not suffer the fatal laser irradiation damage. 
However, 5% (7/140) of the cells were dead at the end of the experiment (Figure 80). A 
video of control MDA-MB-231 cells is attached (Video 10, control MDA-MB-231 cells, bare 
ZnO NPs, dissolution, FluoZin). 
 The rise of intracellular levels of Zn2+ and its effect on the cell viability in the MDA-
MB-231 cells after exposure to ZnCl2 was compared to those of the bare ZnO NPs. ZnCl2 was 
used in a concentration of 250 μg/ml. This concentration of ZnCl2 was chosen as it has the 
same Zn2+ concentration of 150 μg/ml ZnO. The same heterogeneity in the response of the 
MDA-MB-231 cells was observed after exposure to ZnCl2. Incubation of the cells with ZnCl2 
resulted in an increase of FluoZin fluorescence (Figure 82, d). Moreover, the distribution of 
Zn2+ was more diffuse inside the cytoplasm, indicating a less local rise in intracellular Zn2+ 
concentrations. Muller et al. showed the same effect of ZnCl2 in human monocyte derived 
macrophages [10].  
  
156 
 
 
Figure 81: Confocal fluorescence and bright-ﬁeld images of MDA-MB-231 cells showing internalization and dissolution of 
bare ZnO NPs. The MDA-MB-231 cells were loaded with the cell-permeant Zn
2+
 indicator FluoZin3-AM (green 
fluorescent) prior to incubation with 150 μg/ml ZnO for 16 h. (a) The MDA-MB-231 cells (white arrow head) lost its 
spindle shape and became round upon exposure to the bare ZnO NPs. (b-c) Uptake of the bare ZnO NPs (white arrows) 
by extracellular extensions of the plasma membrane. (e) Blebbing of the cells (black arrow), (f) Death of the cell and loss 
of cell membrane integrity. (a-f) Dissolution of the bare ZnO NPs inside the cells.  
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Figure 82:  Intensity curves of FluoZin and PI in MDA-MB-231 cells after exposure to the bare ZnO NPs showing increase 
in intracellular Zn
2+
 and subsequent cell death. The MDA-MB-231 cells were loaded with the cell-permeant Zn
2+
 indicator 
FluoZin3-AM prior to incubation with (a) imaging buffer (NA control), (b, c) 150 μg/ml bare ZnO NPs, or (d) 250 μg/ml 
ZnCl2 (with equivalent Zn
2+
 concentration from 150 μg/ml ZnO). FluoZin fluoresces green upon binding ionic zinc (Zn
2+
). 
PI was included to stain the nuclei of dead cells (red). Images were acquired over a time course of 16 h.  
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3. Loss of cellular viability of the MDA-MB-231 cells after exposure to the bare ZnO NPs 
and ZnCl2 
The MDA-MB-231 cells lost their viability upon exposure to the bare ZnO NPs (150 μg/ml). 
There was a lot of heterogeneity in the resistance to the bare ZnO NPs within the cell 
population. Figure 83 shows the rise of intracellular Zn2+ and subsequent cell death of the 
MDA-MB-231 cells after 4 and 16 h exposure to the bare ZnO NPs and ZnCl2. The MDA-MB-
231 cells showed 54% (62/115 cells) and 100% (115/115) death after 4 and 16 h incubation 
with the bare ZnO NPs, respectively (Figure 83, A and B). The difference in the response of 
the MDA-MB-231 cells to the bare ZnO NPs could be due to the different local 
concentrations of the particles around the cells and their different agglomeration states or 
to the different sensitivity of the cells to ionic zinc.  
After exposure of the MDA-MB-231 cells to ZnCl2, 21 % of the cells (48/230) in the 
imaging view were dead after 4 h, while 90 % of the cells (207/230) were dead after 16 h of 
exposure (Figure 83, C and D). The differences in the cellular responses of the MDA-MB-231 
cells to the ZnO and ZnCl2 could be due to different mechanism of cytotoxicity. Eukaryotic 
cells have a remarkable ability to regulate their levels of intracellular zinc using several 
pathways [192]. Although cells are exposed to micromolar ranges of free zinc, the 
intracellular levels of free zinc that regulate the transcription of zinc influx, efflux or 
sequestration machinery are in the femtomolar range. The intracellular zinc homeostasis is 
maintained by several proteins, including the ZRTIRT-like protein (ZIP) family zinc 
transporters, zinc transporter (ZnT) family zinc transporters and zinc-sequestering 
metallothioneins [193-196]. While the released Zn2+ from ZnCl2, which is taken up by Zn-
receptors expressed on the surface of the cell membrane [197], is the cause of cytotoxicity, 
both the ZnO NPs and the intracellularly released Zn2+ could be the cause of toxicity after 
exposure to the bare ZnO NPs. 
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Figure 83: Confocal images of MDA-MB-231 cells showing rise of intracellular Zn
2+
 and subsequent cell death after 
exposure to (A and B) the bare ZnO NPs and (C and D) ZnCl2. The MDA-MB-231 cells were loaded with the cell-permeant 
Zn
2+ 
indicator FluoZin3-AM prior to incubation with 150 μg/ml of bare ZnO NPs or equivalent zinc ions concentration 
from ZnCl2. Flouzin3 fluoresce green upon binding Zn
2+
. PI was included to stain the nuclei of dead cells. 
5.2.2 Binding and uptake of ZnO nanoparticles to breast cancer cells by electron 
microscopy 
 SEM analysis of binding of bare ZnO nanoparticles to MDA-MB-231 cells  5.2.2.1
To study the interaction of the particles with the plasma membrane of the MDA-MB-231 
cells SEM and energy-dispersive X-ray spectroscopy (EDX) analysis were performed. Cells 
were incubated with 30 μg/ml of the bare ZnO NPs for 4 h, or cultured in the absence of the 
bare ZnO NPs for 4 h. After exposure to the bare ZnO NPs, the cells were fixed immediately 
to minimize any artefactal dissolution of the ZnO NPs during processing [10]. High resolution 
images of the MDA-MB-231 cells were taken at 2 keV using secondary electron (SE) detector 
(Figure 84). Large aggregate of ZnO NPs (1.1 μm) were observed on the surface of the MDA-
MB-231 cells which appeared to be in the process of uptake (Figure 84, a). A more striking 
indication of the ZnO NPs uptake by the cells can be observed on the surface of the cells 
(indicated by arrows in Figure 84, b). The samples were then screened at 20 keV using the 
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back scattered electron (BSE) detector to locate areas with high atomic number (Z), and an 
EDX spectrum was acquired from those areas at 20 keV. Many regions with high atomic 
number (Z) were found in the BSE SEM images of the bare ZnO NPs-treated cells. The EDX 
spectra from treated cells clearly showed high intensity zinc peaks at 1.035, 8.639 and 9.572 
keV from L, K-shells respectively (Figure 85). 
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Figure 84: SEM images of MDA-MB-231 exposed to 150 μg/ml of the bare ZnO NPs for 4 h. Images show cells at 
increasing magnifications from the upper to the lower panels with ZnO NPs (arrows) bound to their surface (a) 
aggregates of ZnO NPs on the periphery of the cell and (b) ZnO NPs on the top of the cell. 
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Figure 85: EDX spectra taken from the red box in the inset in the SE image of bare ZnO treated MDA-MB-231 cells. 
 TEM analysis of uptake of ZnO nanoparticles by breast cancer cell lines 5.2.2.2
 TEM analysis of uptake of the bare ZnO nanoparticles by MCF-7 and MDA-MB-5.2.2.2.1
231 cells 
To confirm the confocal microscopy findings of binding and uptake of the bare ZnO NPs, 
electron microscopy imaging and analysis of exactly the same cells imaged in the confocal 
microscopy was used. Electron microscopy was also used to study how the ultrastructure of 
the cells was altered by the ZnO NPs to produce clues about the mode of cell death. 
  TEM of MDA-MB-231 cells exposed to the bare ZnO nanoparticles 5.2.2.2.1.1
The MDA-MB-231 cells were exposed to a 20 μg/ml bare ZnO NPs for 6 and 24 h. Black NPs 
suggestive of ZnO NPs were observed on the surface of the cells after 6 h of exposure 
(Figure 86, A, black arrow). EDX spectra taken from the particles confirmed the presence of 
Zn L and K peaks at 1.011 and 8.615 keV, respectively (Figure 86, B; black arrow). 
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Figure 86: (A) BF TEM image of MDA-MB-231 cells exposed to 20 μg/ml bare ZnO NPs for 6 h showing ZnO NPs on the 
surface of the cells, (B) EDX spectra taken from the particles in the inset image and labelled with an arrow in (A) showing 
Zn L and K peaks at 1.011 and 8.615 keV, respectively. JEM 2100F operated at 300 kV was used to image the cells on a 
gold grid. 
 After 24 h exposure of the MDA-MB-231 cells to the bare ZnO NPs, the 
organisation of the cell was almost completely lost and the damage involves essentially all 
the subcellular structures (Figure 87). Irregular clumping of chromatin (Figure 87, black 
arrow), formation of small vacuoles inside the cells (Figure 87, white arrows), most likely, 
they are dilated vesicular endoplasmic reticulum or swollen and empty mitochondria [198]. 
Similar effects of Zn2+ were reported in literature; Zn2+ was reported to cause loss in integrity 
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of mitochondrial membranes, rupturing of plasma and nuclear membranes, separation of 
nuclear components, fragmentation of endoplasmic reticulum, and extensive autophagic 
vacuolization in hepatocytes [199].  
 
Figure 87: BF TEM image of MDA-MB-231 cells showing morphology indicative of late apoptosis after 24 h exposure to 
20 μg/ml bare ZnO NPs. The organisation of the tumour cell is almost completely lost and the damage involves 
essentially all the subcellular structures. Irregular clumping of chromatin (black arrow). Small vacuoles formed inside the 
cells (white arrows), most likely, they are dilated endoplasmic reticulum. The cellular organelles were also disintegrated.  
 TEM of MCF-7 cells exposed to bare ZnO nanoparticles 5.2.2.2.1.2
Figure 88 shows black NPs, suggestive of ZnO NPs, inside and on the surface of the MCF-7 
cells exposed to a 20 μg/ml bare ZnO NPs after 6 h of exposure. The presence of the ZnO 
NPs extracellularly is an indication that the particles are not dissolved outside the cells and 
any toxic effects are due to their intracellular dissolution and the release of Zn2+. 
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Figure 88: BF TEM images of MCF-7 cells exposed to 20 μg/ml bare ZnO NPs for 6 h showing (A) ZnO NPs inside the cells, 
(B) ZnO NPs inside and on the surface of the cell. (C, D) ZnO NPs on the cell membrane of the cells. 
 After 24 h exposure of the MDA-MB-231 cells to the bare ZnO NPs, mitochondria 
was swollen with less cristae (Figure 89, white arrows) compared to the untreated control 
(Figure 90, white arrows). Black NPs suggestive of ZnO were observed on the cell membrane 
and inside the MCF-7 cells after 24 h exposure to the ZnO NPs (Figure 91). The presence of 
the ZnO NPs extracellularly after 24 h of exposure is an indication that the NPs are not 
dissolved outside the cells and any toxic effects are due to their intracellular dissolution and 
the release of Zn2+. 
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Figure 89: TEM image of MCF-7 cells exposed to 20 μg/ml ZnO NPs for 24 h showing swelling of the mitochondria (white 
arrow) with reduced cristae. n= nucleus. 
 
Figure 90: TEM image of control MCF-7 cells showing normal mitochondria (white arrow). n= nucleus. 
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Figure 91: TEM image of MCF-7 cells showing bare ZnO NPs on the surface (black arrow) and inside the cells (white 
arrow) after 24 h exposure to 20 μg/ml bare ZnO NPs for 24 h. 
 TEM analysis of uptake of ZnO-HCV-RGD-GFP nanoparticles by MDA-MB-231 5.2.2.2.2
cells 
To investigate binding and uptake of the targeted ZnO-HCV-RGD-GFP NPs to the MDA-MB-
231 cells and to assess their effect on the cell, the MDA-MB-231 cells were incubated with 
the ZnO-HCV-RGD-GFP NPs and confocal live imaging was performed to track their binding 
to the cells. Upon exposure of the MDA-MB-231 cells to the ZnO-HCV-RGD-GFP NPs, 
agglomerates of the NPs had bound to the plasma membrane of the cells (Figure 92). This 
binding of the ZnO-HCV-RGD-GFP NPs to the cells was rapid, and the GFP labelled ZnO-HCV-
RGD NPs bound to the surface of the cells after 22 min exposure (Figure 92, A). 3D images of 
the exposed cells showed green fluorescent diffused layer, which could indicate 
internalisation of the ZnO-HCV-RGD-GFP NPs, inside the cells (Figure 92, B and C). 
Bright field TEM (BF-TEM) images of the MDA-MB-231 cells exposed to the ZnO-HCV-
RGD-GFP NPs show 227.4x177.6 nm aggregate of NPs on the plasma membrane which were 
being internalised by the cells Figure 93 (A-D). Compared to the as-prepared ZnO NPs, the 
NPs within the aggregate were less spherical and the NPs had an altered appearance (Figure 
93, E). High resolution phase contrast (HRTEM) image of the NPs, that shows the lattice 
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fringes of the NPs, is shown in Figure 93 (F). EDX spectra collected from the aggregates, in 
image (F) of Figure 93, confirmed the presence of Zn L peak at 1.015 keV (Figure 94).  
 
Figure 92: 2D (A) and 3D (B and C) confocal images of MDA-MB-231 incubated with GFP labelled ZnO-HCV-RGD NPs 
(arrows in (a) and arrow head in (C)) before TEM processing. Hoechst 33342 was used to stain the nuclei of live cells 
blue. 
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Figure 93: (A-D) BF-TEM images of MDA-MB-231 cells showing ZnO-HCV-RGD-GFP NPs (black arrows) bound to the 
plasma membrane and being endocytosed by the cells, (E) a higher magnification image showing non-spherical NPs with 
altered appearance, and (F) An HRTEM image showing lattice fringes. MDA-MB-231 cells were incubated with 150 μg/ml 
ZnO-HCV-RGD-GFP for 22 min before TEM processing. n= nucleus. 
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Figure 94: EDX spectra taken from the ZnO-HCV-RGD-GFP NPs labelled with an arrow in Figure 93. 
 BF-TEM image (Figure 95, A) of the MDA-MB-231 cells exposed to the targeted 
ZnO-HCV-RGD-GFP NPs also showed aggregates inside the cells. Energy-filtered TEM (EF-
TEM) jump ratio mapping at Zn L2,3 edges confirmed that the crystalline precipitate was Zn-
rich (Figure 95, B). Compared to the as-prepared ZnO NPs, morphology of the ZnO-HCV-
RGD-GFP NPs inside the cells was again less spherical and the particles had an altered 
appearance (Figure 95, A). This could be again attributed to some dissolution of the particles 
while incubation with the imaging buffer and upon internalisation inside the cells. An HR-
TEM image of the NPs that shows the lattice fringes is presented in Figure 95 (C). The 
corresponding FFT obtained from the image in Figure 95 (C) shows that the ZnO NPs were 
polycrystalline (Figure 95, D).  
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Figure 95: (A) A TEM image of MDA-MB-231 exposed to ZnO-HCV-RGD-GFP NPs showing particles inside vesicles inside 
the cells. (B) An EF-TEM jump ratio map showing Zn-rich deposits (light colored areas) taken at Zn L2,3 edge using 40 eV 
energy slit and using pre- and postedge energy windows centred at 995 ± 20 and 1040 ± 20 eV, respectively.  (C) An HR-
TEM image of particles showing crystalline lattice fringes taken at the Zn L2,3 edge using 40 eV energy slit and using pre- 
and post-edge energy windows centred at 995 ± 20 and 1040 ± 20 eV, respectively, and (D) the corresponding FFT 
obtained from the black box in image (C). 
 Since the Cu grid used with the cryosectioned TEM samples of the MDA-MB-231 
cells exposed to the ZnO-HCV-RGD-GFP NPs was interfering with the EDX spectra of zinc, 
other sections of the ZnO-HCV-RGD-GFP NPs-exposed MDA-MB-231 cells were prepared 
onto a gold grid (Figure 96). BF-TEM images of the MDA-MB-231 cells showed aggregates of 
the ZnO-HCV-RGD-GFP NPs inside the cells (Figure 96, A and B), and on the plasma 
membrane of the cells which were being internalised by the MDA-MB-231 cells (Figure 96, C 
and D). The aggregate of the ZnO-HCV-RGD-GFP NPs found on the cell membrane of the cell 
in Figure 96 (C and D) was composed of smaller particles of 34.47 ± 9.78 nm. These particles 
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are smaller than the size of the original ZnO NPs measured by TEM, which was 56.7 ± 21.7 
nm (section 3.2.1, Figure 6, a). The mottled appearance of these particles and their altered 
morphology compared to the original NPs could have arisen due to the dissolution of the 
ZnO-HCV-RGD-GFP NPs in the HEPES confocal imaging buffer while incubation with the cells. 
EDX spectra collected from the particles on the plasma membrane of the cells confirmed the 
presence of Zn L peak at 1.025 keV (Figure 97).  
 Remnants of the ZnO NPs could be seen inside vesicles in the MDA-MB-231 cells 
after exposure to ZnO-HCV-RGD-GFP NPs (Figure 98, A, area 1 and 2). These could be a 
result of dissolution of the ZnO NPs in the lysosomes after internalisation of the targeted 
ZnO-HCV-RGD-GFP NPs. EDX spectra from area 2 in Figure 98-A confirmed the presence of 
Zn L peak at 1.025 keV.  
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Figure 96: BF-TEM images of MDA-MB-231 exposed to ZnO-HCV-RGD-GFP NPs for 22 min and prepared cryogenically. 
NPs (arrows) were found inside the cells (A, B), and at the plasma membrane of the cells (C, D). The particles were 
composed of smaller particles of 34.47 ± 9.78 nm in diameter (D). 
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Figure 97: EDX spectra taken from the ZnO-HCV-RGD-GFP particles labelled with an arrow in Figure 96 (c and d). 
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Figure 98: (A) BF-TEM images of MDA-MB-231 exposed to ZnO-HCV-RGD-GFP NPs. Cells were incubated with ZnO-HCV-
RGD-GFP NPs for 22 min, fixed cryogenically prior to processing for TEM. The red circles outline vesicles inside the cells 
which contain ZnO-HCV-RGD-GFP NPs. (B) EDX spectra collected from area 2 in image A. 
5.2.3 Cancer stem cell markers (CSCs) 
The results of the uptake and the dissolution of the ZnO NPs obtained in this chapter 
showed heterogonous responses in the breast cancer cell lines. This heterogeneity in the 
response to the ZnO NPs was also observed within the same breast cancer cell line. Most 
cancers comprise a heterogeneous population of cells with different proliferative and 
tumorigenic potentials [200, 201]. According to the recent cancer stem cell hypothesis, a 
tumor consists of differentiated highly proliferative cells, and undifferentiated low-cycling 
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cells with self-renewal capacity, the so called cancer stem cells (CSCs) [202]. CSCs should 
have a higher resistance than the differentiated cancer cells, and may be highly resistant to 
radiation and chemotherapy [203]. Therefore, the heterogeneity in the types of breast 
cancer cells could be a factor that account for the observed heterogeneity in the response 
of the breast cancer cells to the ZnO NPs. Herein, the presence and the percentage of these 
CSCs expressed by the MCF-7 and the MDA-MB-23 1 cells was measured. 
CSCs could be morphologically indistinct from the bulk of the cancer, therefore, the 
most effective method of identifying these cells is through differential cell surface protein 
expression [204]. Because these two cell types could account for the heterogeneity of the 
response and sensitivity of the tested breast cancer cells to ZnO NPs, a number of CSC 
markers were tested for both the MCF-7 and MDA-MB-231. However, the relevance of the 
current stem cell markers is still controversial [205].  
  Among the markers that are currently used to identify breast CSCs [206], the 
expression of CD44, CD24, CD90, and EpCAM (epithelial cell adhesion molecule) were 
tested. CSCs are reported as CD44+, CD24-, EpCAM-/low and CD90- [207]. In this study, the 
MDA-MB-231 cells and the MCF-7 showed different expression of these markers (Figure 99). 
While the MCF-7 were CD44low /CD24+/ EpCAM+ and CD90+ (Figure 99, a), the MDA-MB-231 
cells were CD44+/CD24-/EpCAMlow and CD90- (Figure 99, b). This coincides with the 
published work for these cells [207, 208].   
  CD44+/CD24- breast cancer cells were reported to disseminate in the bone marrow 
and they were also resistant to chemotherapy [209]. Therefore, the ability of ZnO NPs to 
eradicate these CSCs will further enrich the therapeutic value of this material for the 
treatment of cancer.  
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Figure 99: Flow cytometric analysis of expression of cancer stem cells (CSCs) markers; CD44/ CD24/ EpCAM and CD90 in 
(a) MCF-7 and (b) MDA-MB-231 cells. 
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5.3 Summary and conclusions 
In this study, the targeted ZnO-HCV-RGD-GFP NPs were found to bind to the breast cancer 
MDA-MB-231 cells and to a lesser extent to the MCF-7 cells. This difference in binding of the 
breast cancer cells to the ZnO-HCV-RGD-GFP is probably due to higher expression of the 
integrin αvβ3 receptors in the former cells. After binding, the RGD-targeted ZnO NPs were 
internalised by both breast cancer cell lines. In the MDA-MB-231 cells, the RGD-targeted 
ZnO NPs were found inside pits at the plasma membrane and inside the cells, possibly in 
endosomes and in the cytoplasm of the cells. The mechanism of uptake of the ZnO-HCV-
RGD-GFP NPs is most probably clathrin-mediated endocytosis. The bare ZnO NPs were also 
internalised by the MCF-7 and the MDA-MB-231 cells. The bare ZnO NPs were found to bind 
to the cell surface and have been internalised by pinocytosis. The presence of the bare and 
targeted ZnO NPs outside and inside the cells is an indication that the NPs have not 
dissolved outside the cells and any toxic effects are due to their intracellular dissolution and 
the release of Zn2+. 
 ZnO NPs (both bare and targeted) dissolution was found to be dependent on the 
pH within various cell compartments (extracellular, intracellular and lysosomes). At 
extracellular pH 7.4, the dissolution was significantly less than that observed in the 
lysosomes at pH 5.2. Following their uptake, the NPs were most probably transported to 
early endosomes. The endosomes then fuse with low pH lysosomes, where the NPs 
dissolved to release Zn2+ which might enter the cellular cytosol. However, other cell 
components (e.g. Golgi apparatus pH=6.4, endosomes pH=6 [210, 211]) have a pH <7, and 
therefore the toxicity of ZnO NPs could be significant inside the cells. Once Zn2+ ions 
released inside the cells, it initiate toxic responses in the cells. The effect of Zn2+ on the 
apoptosis of cancer cells has been previously reported [5, 181]. It has been reported that 
Zn2+ mediated Tamoxifen-induced cell death in the MCF-7 breast cancer cells via increase in 
oxidative stress and induction of lysosomal membrane permeabilization [180]. This could 
explain why Zn2+ could directly correlate to cell death in breast cancer cells after exposure to 
the ZnO NPs.   
 The breast cancer cells showed heterogeneity in response to the ZnO NPs. This 
heterogeneity in breast cancers is already reported [212]. The MDA-MB-231 cells were 
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found to have the characteristics of CSCs while the MCF-7 cells did not show CSCs like 
properties. The heterogeneity in response of the MDA-MB-231 cells to the ZnO NPs and Zn2+ 
ions needs to be investigated. This heterogeneity of cancer cells introduces significant 
challenges in designing effective treatment strategies. Therefore, understanding and 
characterizing heterogeneity is crucial in the development of refined treatment strategies. 
The ability of ZnO NPs to kill the CSCs that could be resistant to classic treatments while 
possessing potent tumor-forming capacity is another advantage of using this material in 
cancer therapeutics. 
 The morphology of the bare and targeted ZnO NPs was changed upon exposure to 
the cells. This change in the morphology of the NP suggests that dissolution of the NPs had 
occurred in the intracellular environment. Muller et al., (2010) also observed similar 
dissolution of ZnO NWs inside human monocyte derived macrophage cells triggered by the 
acidic pH of the lysosomes [10]. Interaction of the NPs with the amino acids and proteins 
present in the media during incubation and subsequent formation of the protein corona 
could also have account for the change in the morphology. However, in this work, the 
targeted ZnO-HCV-RGD-GFP NPs were added to the cells in HEPES confocal buffer at pH 7.4. 
Therefore, dissolution of these ZnO NPs inside the cells is the only reason that could account 
for the change in their morphology.  
 It was discussed earlier in section 4.3 of chapter 4 that the RGD-targeted ZnO NPs 
were more toxic to the MCF-7 and MDA-MB-231 cells than the bare NPs. In confocal 
microscopy, however, quantitative comparisons between the cytotoxicity of the targeted 
and the bare ZnO NPs could not be drawn due to the heterogeneity in the response to the 
bare and targeted ZnO NPs in each breast cancer cell line. For this reasons quantitative 
comparisons between the results of the viability assays and confocal microscopy was not 
feasible. However, the following factors should be taken into consideration even in the 
qualitative comparisons; DMEM media supplemented with FBS was used in the viability 
assays while HEPES confocal imaging buffer was used in confocal imaging. Therefore, the 
hydrodynamic size of the ZnO NP aggregates was different in these vehicles. Also, a protein 
corona on the surface of the ZnO NPs will develop when the NPs are suspended in media, 
but not in the HEPES confocal imaging buffer. Both factors could affect the bioreactivity of 
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the ZnO NPs. It is also worth to comment on the effect of the number of the ZnO NPs used 
per cell in the viability assays and confocal microscopy. Although the same density of the 
cells were plated per area in the 96 well plates, used for the viability assays, and the 
confocal microscopy culture plates, the number of particles exposed per cell was different in 
both cases. In the viability assays, 100 μL of the NPs dispersions were added to the cells 
plated on an area of 0.3165 cm2, while 2 ml of the NPs dispersion in the confocal microscopy 
were added to the cells plated on an area of 3.143 cm2. Whether the toxicity of the ZnO NPs 
is based on the number of particles per cell or a concentration dependent was not possible 
to measure, due to the limitations of the viability assays.  
 The intracellular dissolution, of the targeted and bare ZnO NPs showed differences 
between the kinetics of these processes. The bare ZnO NPs, showed a clear time dependent 
increase in intracellular dissolution while the targeted ZnO NPs showed a very low 
intracellular dissolution with time and then a sudden burst of ionic zinc release. Also, once 
the concentration of the released Zn2+ ions inside the cells reach toxic levels after exposure 
to the bare ZnO NPs, the cell lost the integrity of their cell membrane and a gradual drop on 
intracellular Zn2+ could be measured. With the targeted NPs, on the other hand, a sudden 
increase in cellular death was accompanied the sudden increase in the intracellular Zn2+. 
This finding is most likely due to the different mechanisms of internalisation of the bare and 
the RGD-targeted NPs, and therefore altered intracellular distribution [91]. It has been 
reported that the RGD-grafted NPs enter cells through integrin-mediated endocytosis or 
clathrin-mediated endocytosis and are localised in perinuclear regions while the 
nontargeted NPs are transferred by different mechanisms [48, 213]. 
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6 Plasma protein binding to bare zinc oxide nanoparticles and 
formation of protein corona 
Adsorption of proteins from serum, and formation of NP-protein corona at the NPs surface 
may lead to a substantial change in the physicochemical properties of the NPs (size, shape, 
reactivity, surface area, etc.) [96, 107]. These changes of the NPs could, in turn, critically 
affect the interaction of these NPs with the cell membrane and eventually their 
biodistribution, uptake mechanisms, intracellular localisation of the NPs in vivo [60] and 
clearance mechanisms [214]. Consequently, understanding how, and why plasma proteins, 
are adsorbed to these NPs may be important for understanding their biological responses 
and will be the key point to the development of NPs with a long circulation time.  
 In in vitro viability assays, different media are used to culture cells. The composition 
of the media could largely affect the composition of protein corona around the NPs 
investigated, which in turn could affect the outcomes of the viability assays. Gabriele et al.,  
have shown that 15 nm gold (Au) NPs- protein corona was different in DMEM and RPMI 
medium supplemented with 10% FBS [215]. A Large time-dependent protein corona was 
formed in DMEM, while that in RPMI shows different dynamics with reduced protein 
coating. They also found that the average composition of protein corona does not reflect 
the relative abundance of serum proteins and that proteins/NP complexes formed affected 
the uptake and toxicity of these NPs. Rahman et al. also reported that the cellular/tissue 
responses depend on the composition of corona [97]. In this study, as discussed earlier in 
chapter 3, the protein corona formed on the surface of the bare ZnO NP changed their 
surface charge and this could highly affect the NP bioreactivity [136].  
 Tumour tissues are characterised by increased capillary permeability or what is 
called the ‘enhanced permeability and retention’ (EPR) effect. The EPR effect allows an 
increased rate of tumoural uptake of NPs [35]. However, the protein corona formed on the 
surface of NPs could act as ‘opsonins’. Opsonins can be recognised by scavenger receptors 
on the macrophage cell surface and internalised. This internalisation by macrophages leads 
to significant loss of NPs from the circulation. The macrophages responsible for the loss of 
injected dose of NPs are also known as the reticuloendothelial system (RES). IgG and IgM, to 
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a lesser extent, can act as an opsonin and promote phagocytosis of NPs by macrophages or 
other phagocytic cells [216, 217]. Therefore, characterisation of the composition of the 
protein corona is essential for prediction of the interaction of the protein-NPs complex with 
the immune system in vivo. 
Only few studies on ZnO NP-protein interactions have been reported. In most 
studies, bovine serum albumin (BSA) was used as a model protein [218-220]. It was found 
that BSA interacts with ZnO NPs to form a stable hard corona [218, 220]. This interaction is 
spontaneous and electrostatic interactions dominate [221]. ZnO NP-protein corona 
equilibrium is achieved within the first few minutes of incubation [8]. The interaction of BSA 
with ZnO NPs occurs through Tryptophan residues of BSA [218, 219] and results in 
conformational changes to the BSA [218, 220].  
The uptake and the toxicity of several classes of NPs have been shown to be reduced 
by the formation of protein corona in serum [59]. However, the toxicity of ZnO NPs to MCF-
7 human breast cancer cell line was not reported to be reduced by serum [59]. The effect of 
the ZnO NP-protein corona on ZnO NPs uptake and lipid packing and the hydration state of 
the plasma membrane has also been investigated [60]. It has been reported that serum 
albumin enhances the membrane activity of ZnO NPs by stabilising the nanoscale size 
distribution of aqueous dispersions of ZnO NPs [60]. 
 The composition of ZnO NP-protein corona was characterised only by Deng et al. 
[8]. Proteins with important biological functions were identified in the protein corona of 
ZnO NPs [8]. These include; immunoglobulins, lipoproteins, acute-phase proteins and 
proteins involved in complement pathways and coagulation. However, Deng et al. study 
used a high centrifugation force of 50,000 xg for long time (40 min) to pellet the NP-protein 
complex, which could result in the loss of the soft protein corona, and even part of the hard 
corona. They also used 2D gel electrophoresis to analyse the composition of the protein 
corona, which is not as sensitive as other protein analysis methods such as liquid 
chromatography/mass spectroscopy (LC/MS), and therefore, they reported one unknown 
protein in the corona.  
183 
 
In this study, the composition of protein corona formed from human plasma 
proteins onto the surface of the bare ZnO NPs at different temperatures, centrifugation 
forces and compositions, as well as concentrations of human plasma, was analysed by 
LC/MS.  
6.1 Materials and Methods 
6.1.1 Materials  
DL-Dithiothreitol, iodoacetamide, ammonium bicarbonate, Acetonitrile, trifluoro acetic acid  
were purchased from Sigma Aldrich Ltd, UK and were of biological grade (>99% pure).  
6.1.2 Preparation of human plasma 
The whole blood was collected in sodium citrate tubes (BD Vacutainer), to prevent 
coagulation of the blood, and the plasma was separated from the blood cells by 
centrifugation for 5 min at 800 xg. The supernatant (plasma) was stored in aliquots at -80 °C. 
On thawing, the plasma was centrifuged for 2 min at 12,000 xg before use. 
6.1.3 Incubation of human plasma proteins with the bare ZnO NPs 
The ethanolic stock dispersion of the bare ZnO NPs was sonicated for 20 min and the bare 
ZnO NPs were then prepared in HEPES buffer at pH=7.4 (10 mM HEPES and 50 mM NaCl2) at 
10 mg/ml. The particles were then sonicated for 10 min, using table top sonicator. The bare 
ZnO NP-human plasma protein solutions were prepared by mixing human plasma (to a final 
concentration of 10% v/v) with the bare ZnO NPs (to a final concentration of 1 mg/ml). The 
NPs were then incubated with the plasma for 1 h at 4°C while rotating end over end. Several 
experiments indicated that incubation times longer than 1 h did not result in a significant 
change in the composition of adsorbed proteins [222]. Plasma without NPs was used as a 
control to ensure there was no protein precipitation. At the end of incubation time, samples 
were centrifuged at 16,000 xg for 15 min at 4°C. The supernatants were then removed and 
ZnO NPs, with the adsorbed proteins, were washed three times in HEPES buffer (10 mM 
HEPES+50 mM NaCl2). The tube was changed after the first wash. The pellet was then 
processed for mass spectroscopy analysis. The experiment was repeated twice and the 
average result is presented.  
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 To check for the presence of proteins in the last wash, a 200 μL aliquot taken from 
the supernatant was analysed for protein content by an acetone precipitation method 
[223]. The 200 μL sample of the supernatant was diluted six times with chilled acetone (-
20°C). The sample was then mixed and stored for 60 min at -20°C. The sample was then 
centrifuged at 16,000 xg for 30 min at 4°C. The supernatant was carefully decanted so as not 
to dislodge the protein pellet. The protein pellet was then air dried for 10-20 min. Finally, 
the pellet was processed in the same way as the ZnO NP-protein corona pellet. 
 To study the effect of incubation temperature on the resulted protein corona, the 
experiment was repeated and the bare ZnO NPs were incubated with human plasma 
proteins at 37°C, and the same procedure was followed. The effect of centrifugation power 
on the NP-protein corona was investigated by centrifuging the NP-protein complex sample 
at 6,000 xg for 20 min, at end of incubation time. Finally, the effect of human plasma 
concentration was studied by increasing the final concentration of the plasma incubated 
with the bare ZnO NPs to 90%. The volume of plasma used per cm2 of the particles was 
calculated. Assuming that the particles were spherical, their surface area was calculated 
from the equation: surface area of the particles= 4nπr2, where n: no of particles and r: 
radius of one particle. The number of the particles was calculated from their volume using 
the equation: Volume of the particles=4/3πnr3, and using the density of ZnO which is 5.61 
g/cm3. The average particle size of the ZnO NPs in the vehicle (10 mM HEPES+ 50 mM NaCl) 
measured by DLS (Table 4) was used to calculate the radius of the NPs (r=560.5 nm).  
6.1.4 Depletion of human plasma from serum albumin and immunoglobulins 
Human serum albumin (HAS) and immunoglobulins G (IgG) were depleted from human 
plasma using the Spin Trap columns (GE Healthcare Life Sciences, UK), according to the 
manufacturer’s protocol. The columns were prepacked with high performance Sepharose 
based media with an affinity for HSA and IgG. For protein corona analysis, the HSA and IgG 
depleted plasma was incubated with ZnO NPs, as described in section 6.1.3.  
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6.1.5 Preparation of bare ZnO NP-protein corona for mass spectroscopy 
 Reduction of the disulphide bonds 6.1.5.1
The resulting ZnO NP-protein complexes were reduced with 20 μL of the 5 mM DTT 
prepared in ammonium bicarbonate, incubated at 37°C for 30 min while shaking at 1,000 
rpm. DTT is a reducing agent that prevents intramolecular and intermolecular disulphide 
bonds from forming between cysteine residues of proteins. The proteins were further 
reduced with 50 mM iodoacetamide prepared in 100 mM ammonium bicarbonate to a final 
concentration of 14 mM at 37°C for 30 min, while shaking at 1,000 rpm. Iodoacetamide is an 
alkylating agent that binds covalently with the thiol group of cysteine, so the protein cannot 
form disulphide bonds.    
 Proteolyzation of the adsorbed proteins 6.1.5.2
Trypsin is used to digest proteins (polypeptide) by cleaving the peptide chain at specific 
sites. Trypsin cleaves the peptide chain after Lysine (K) or Arginine (R) residues (amino 
acids), except when followed by a Proline (P) residue.  
 Trypsin was freshly prepared by dissolution in trypsin solubilisation buffer (acetic 
acid solution) (0.2 μg/μL). The solution was then neutralised using a trypsin reaction buffer 
(50 mM ammonium bicarbonate) to a final concentration of 20 ng/μL trypsin. The ZnO NP-
protein corona complexes were proteolyzed with 40 ng trypsin overnight at 37°C. The 
resulting peptides were centrifuged at 16,000 xg for 10 min at 4°C. The supernatant was 
then collected without disturbing the particles.     
 Concentrating and purifying the peptides 6.1.5.3
The resulting peptides/and proteins were desalted using disposable Silica-C18 tip (Zip Tip, 
Millipore) with 0.1% trifluoro acetic acid (TFA). The peptides and proteins were eluted by 
pipetting the tip into the elution solution (0.1% TFA in 50% acetonitrile) at least three times. 
The sample was then dried by vacuum centrifugation using Speedvac (Thermo Scientific), 
dissolved in 0.1% formic acid. Finally, the sample was centrifuged for 5 min at 16,000 xg at 
4°C and the supernatant was analysed by LC/MS (LTQ-Orbitrap Velos, Thermo scientific) 
coupled with Easy-nLC (Thermo Scientific). The LC/MS analysis was performed by the core 
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labs at King Abdullah University for Science and Technology (KAUST). Proteins were 
identified by their isoelectric points and mass using the ExPASy database 
(http://au.expasy.org/swiss-2dpage/viewer).  
6.2 Results 
The protein coronas from human serum proteins formed onto the surface of the bare ZnO 
NPs were composed of several proteins. No proteins were identified in the last wash of the 
corona-NP complex sample nor precipitated from the control protein sample. All the 
proteins identified in the ZnO NP-corona are listed in Table 9 at the end of this chapter.  
6.2.1 Effect of incubation temperature 
The bare ZnO NPs were incubated with the whole plasma at 4 and 37°C, and the ZnO NP-
protein complex was centrifuged at 16,000 xg. The experiment was repeated twice and the 
average of the number of proteins identified in the corona is presented in Figure 100. The 
incubation temperature affected the composition and the percentage of adsorbed proteins 
in the ZnO NP-corona. The number of identified proteins in the human corona was 42 and 
39 proteins after incubation with the bare ZnO NPs at 4 and 37°C, respectively (Figure 100, 
Table 9). It was found that, the lower molecular weight proteins (<20 kDa) were more bound 
to the NPs at lower temperature (4°C), and a higher percentage of the high molecular 
weight proteins (60-150 kDa) were bound to the bare ZnO NPs at 37°C. Therefore, a protein 
like clusterin (Apolipoprotein J), protein shroom3, and most of the IgG were missing from 
the corona when the particles were incubated with the serum at 37° C (Table 9). On the 
other hand other proteins (e.g. complement C5, gelsolin, hornerin, plasminogen, and 
suprabasin proteins) were identified in the protein corona at 37°C, but not at 4°C (Table 9). 
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Figure 100: The protein corona identified on the surface of bare ZnO NPs classified according to their (A) molecular 
weight (MW) and (B) isoelectric point (pI). Bare ZnO NPs were incubated with human plasma (total concentration of 
10%) for 1 h at either 4 or 37°C. The NP-protein complex was then centrifuged at 16,000 xg, washed three times and 
processed for LC/MS. 
6.2.2 Effect of albumin and IgG depletion 
Human plasma consists of more than 289 proteins [224]. The most abundant plasma 
proteins are HSA and IgG, and they tend to obscure the signals of less abundant proteins 
[225]. The high abundance of albumin and IgG also interferes with the detection of other 
proteins by preventing a sufficient amount of less abundant proteins from being included in 
the analysis [225]. By depleting samples of albumin and IgG, the quality of the analysis can 
be greatly enhanced. Depletion of the two proteins removes more than 60% of the total 
protein content in human plasma, allowing proteins normally obscured by albumin and IgG 
to be visualized. 
 Bare ZnO NPs were incubated with the whole and depleted plasma at 37°C, and the 
ZnO NP-protein complex was centrifuged at 16,000 xg. The number of proteins identified in 
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the protein corona from albumin and IgG depleted human plasma was 31, while those 
obtained from the whole plasma were 39 (Figure 101, Table 9). More types of 
apolipoproteins and complement factor proteins were found in the depleted corona but not 
in the non-depleted one. For example complement component C6, could be part of the soft 
corona, was detected in the depleted plasma but not in the whole plasma when centrifuged 
at 16,000 xg.  
 
 
Figure 101: The protein corona identified on the surface of bare ZnO NPs classified according to their (A) molecular 
weight (MW) and (B) isoelectric point (pI). Bare ZnO NPs were incubated for 1 h with either whole or albumin and IgG 
depleted human plasma (total concentration of 10%) at 37°C. The NP-protein complex was then centrifuged at 16,000 
xg, washed three times and processed for LC/MS. 
6.2.3 Effect of centrifugation force  
Higher numbers of proteins in the ZnO-NP corona were identified at lower centrifugation 
force; 39 proteins were identified in the ZnO NP-protein corona at 16,000 xg while 57 
proteins were identified at 6,000 xg (Figure 102, Table 9). This is expected, since the 
adsorption of proteins on the surface of nanoparticle is governed by protein–nanoparticle 
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binding affinities, as well as protein–protein interactions [226]. Therefore, the NP-protein 
corona is composed of a dynamic layer of proteins, low affinity proteins being gradually 
replaced by lower abundance, higher affinity proteins [33]. These low affinity proteins form 
the “soft corona”, while the higher affinity proteins form the “hard corona” [97]. The hard 
corona proteins interact directly with the nanomaterial surface, while the soft corona 
proteins interact with the hard corona via weak protein–protein interactions [98]. Therefore 
upon centrifugation at high speed, most of the soft corona is depleted and probably part of 
the hard corona. Deng et al. [8] for example, used 50,000 xg centrifugation force which 
could result in the loss of most proteins in the corona.  
The centrifugation force affected the apolipoproteins composition of the ZnO NP-
corona; Anastellin, Antithrombin, most of the complement components, some 
immunoglobulins, and clusterin, for example, were identified at 6,000 xg force but not at 
16,000 xg (Table 9). However, some other proteins like apolipoproteins, albumin, most 
complement components, coagulation factors, plasminogen, and prothrombin were 
identified at both centrifugation forces, which could imply their strong interaction with the 
ZnO NPs surface (Table 9).  
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Figure 102: The protein corona identified on the surface of bare ZnO NPs classified according to their (A) molecular 
weight (MW) and (B) isoelectric point (pI). Bare ZnO NPs were incubated with human plasma (total concentration of 
10%) for 1 h at 37°C. The NP-protein complex was then centrifuged either at 16,000 or 6,000 xg, washed three times and 
processed for LC\MS. 
6.2.4 Effect of human plasma concentration 
It has been shown that the total number of proteins in the corona adsorbed on the surface 
of NPs increase with increasing concentration of the serum [97]. The same study, however, 
showed that the amount of the highly abundant proteins like albumin is not affected, while 
the amount of some other proteins could reduce by increasing the concentration of the 
plasma. Therefore, it was important here to study the effect of increasing plasma 
concentration on the protein corona formed on the surface of the ZnO NPs. In their study of 
the ZnO NP-protein corona, Deng et al. [8] used only one concentration of the plasma (10% 
v/v of the plasma to NPs). 
  A total of 57 proteins were identified in the corona when bare ZnO NPs were 
incubated with whole human plasma at a concentration of 10% v/v (119 ml/cm2), while a 
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higher number of 108 proteins where identified in the corona when bare ZnO NPs were 
incubated with 90% v/v (596 ml/m2) human plasma (Table 9). Many proteins were identified 
in the ZnO NP-corona only when high plasma concentration was used. Examples of proteins 
identified when a higher plasma concentration was used: proteins include: many 
complement factor proteins, many immunoglobulins, most of the coagulation factors, which 
is required for integrin-mediated platelet adhesion [227], like coagulation V, X, XI, XIII B, 
fermitin family homolog 3, which is required for integrin-mediated platelet adhesion [227],  
and radixin, which plays a crucial role in the binding of actin filaments to the plasma 
membrane [228] (Table 9).   
 
 
Figure 103: Protein corona identified on the surface of bare ZnO NPs classified according to their (A) molecular weight 
(MW) and (B) isoelectric point (pI). Bare ZnO NPs were incubated with human plasma (total concentration of 10% (10 or 
90%, in which the ratio of plasma to NPs is 119 ml/cm
2
 or 596 ml/cm
2
, respectively) for 1 h at 37°C. The NP-protein 
complex was then centrifuged either at 6,000 xg, washed three times and processed for LC/MS.  
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6.3 Summary and conclusions 
It is important to understand the role of protein binding to ZnO NPs as this may affect the 
extent of interaction of the NPs with cells by modifying what the cell “sees”. In addition, 
protein corona can result in modifying the solubility of the NPs by formation of soluble 
complexes [49]. Therefore, understanding the composition of plasma proteins bound to ZnO 
NPs is important in predicting their biodistribution, biocompatibility and therapeutic 
efficacy. Although several experiments have been conducted to study the interaction of 
proteins with a range of NPs, a comprehensive picture is still missing. This could be due to 
the different conditions under which experiments have been performed. Therefore, this 
field is in need of more studies to further our understanding of protein corona formation 
and its biological consequences [229]. 
 In this study, many factors were found to affect the protein corona composition of 
the ZnO NPs. These include the incubation temperature, the percentage of the plasma used, 
centrifugation force, and depletion of the plasma from HSA and IgG. All these factors had to 
be taken into consideration when studying the protein corona of the ZnO NPs since the type 
of protein bound to the ZnO NPs could dictate the bioreactivity of these NPs. In this study, 
the identified proteins in the ZnO NPs corona at different conditions are summarized in 
Table 9.  
 We found that, the lower molecular weight proteins (<20 kDa) were more likely to 
be bound to the NPs at lower temperature, and a higher percentage of the high molecular 
weight proteins (60-150 kDa) were bound to the bare ZnO NPs at 37°C. Therefore, a protein 
like clusterin (Apolipoprotein J) was missing from the corona when the particles were 
incubated with the serum at 37°C. On the other hand, complement C5, gelsolin, hornerin, 
plasminogen, and suprabasin proteins were identified in the protein corona at 37°C, but not 
at 4°C. More types of apolipoproteins and complement factor proteins were found in the 
depleted corona but not in the non-depleted one. For example complement component C6, 
could be part of the soft corona, it was only detected when the plasma was depleted. The 
centrifugation force affected the apolipoproteins composition of the ZnO NP-corona; 
anastellin, Antithrombin, most of the complement components, some immunoglobulins, 
and clusterin were identified at low centrifugation force but not at 16,000 xg. However, 
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albumin and IgG and plasminogen were identified at both centrifugation forces, which could 
imply their strong interaction with the ZnO NPs surface. Many proteins were identified in 
the ZnO NP-corona only when high plasma concentration was used. Examples of these 
proteins include: many complement factor proteins (which is involved in inflammatory 
responses in the body [230]), most of the coagulation factors, like coagulation V, X, XI, XIII B, 
fermitin family homolog 3 (which is required for integrin-mediated platelet adhesion 
[227]), and radixin, which plays a crucial role in the binding of actin filaments to the 
plasma membrane [228]. Apolipoproteins E, which was reported to be involved in the 
mediation of the transport of drugs bound to NPs across the BBB [231], on the other hand, 
was identified in the ZnO NP-corona at all conditions. This was also the case with some 
other proteins like fibrinogen (alpha and beta), coagulation factor XIII A, prothrombin, most 
of the apolipoproteins, and most of the complement components. This could imply the 
strong interaction of these proteins with the surface of the ZnO NPs.  
 It has been reported that the nanoparticle's composition and surface chemistry 
dictate the extent and specificity of protein binding [217]. However, although the same 
chemical composition of the ZnO NPs was used in our study and Deng, et al. [8] study, there 
were differences in the corona obtained. The pregnancy zone protein and hepatogolbin 
proteins were not identified in our study. Many other proteins were identified in our study 
but not in their study but not in Deng’s et al. study [8]. This could indicate the effect of 
experimental conditions on the corona formed. This again emphasizes the fact that rigorous 
conditions should be applied when conducting these studies in order to draw the right 
comparisons and conclusions. 
 The development of targeted ZnO NPs for clinical applications in breast cancer will 
depend on a deeper understanding of the targeted ZnO NP/protein interaction. The 
interaction between a NP and the cell membrane is mainly controlled by the adsorbed 
protein at the NP surface. Although we assessed the protein corona adsorbed onto the 
surface of the bare ZnO NPs, the protein corona adsorbed onto the RGD-targeted ZnO NPs 
has to be assessed. This is because the functional groups could strongly affect the type of 
protein, the amount, and also the conformation [24]. Future work should be aimed at 
studying the protein corona formed from human plasma onto the targeted ZnO-HCV-RGD-
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GFP NPs, and to test whether this corona will affect targeting of the NPs to the integrin αvβ3 
receptors on the breast cancer cells. In a preliminary experiment, the ZnO-HCV-RGD-GFP 
NPs were suspended in DMEM in the presence and absence of FBS and were introduced to 
the MDA-MB-231 cells under flow using a flow chamber. Binding of the ZnO-HCV-RGD-GFP 
ZnO NPs to the cells was tracked using confocal microscope. The targeted NPs were more 
homogenously distributed in the DMEM media supplemented with 10% FBS. Under flow, 
the ZnO-HCV-RGD-GFP NPs were rolling over and binding the MDA-MB-231 cells, binding 
was most likely mediated by integrin (data not shown). Proteins did not affect binding of the 
targeted ZnO NPs to the surface of the cells. However, quantification of binding in the 
presence and absence of FBS is required. No nonspecific binding of the targeted ZnO-HCV-
RGD-GFP NPs to the glass of the chamber was observed in a control experiment without the 
cells (date not shown). 
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Table 9: Proteins detected on the surface of bare ZnO NPs after 1 h exposure to human plasma. 
No.  
Identified proteins 4°C, 10% 
plasma, 
16,000 xg 
37°C, 10% 
plasma, 
16,000 xg 
37°C,  10% 
depleted 
plasma, 
16,000 
37°C, 10% 
plasma, 
6,000 xg 
37°C,  
90% plasma, 
6,000 xg 
1 Actin, cytoplasmic 1 OS=Homo sapiens 
GN=ACTB PE=1 SV=1    X 
 
2 Actin, cytoplasmic 2, N-terminally 
processed OS=Homo sapiens GN=ACTG1 
PE=4 SV=1     
 
X 
3 Alpha-1-antitrypsin OS=Homo sapiens 
GN=SERPINA1 PE=1 SV=3    X 
 
X 
4 Alpha-2-antiplasmin OS=Homo sapiens 
GN=SERPINF2 PE=1 SV=3     
 
X 
5 Alpha-2-HS-glycoprotein OS=Homo 
sapiens GN=AHSG PE=4 SV=1   X  
 
X 
6 Alpha-2-macroglobulin OS=Homo 
sapiens GN=A2M PE=4 SV=1 X X X X 
 
X 
7 Anastellin OS=Homo sapiens GN=FN1 
PE=4 SV=1 X   X 
 
X 
8 Antithrombin-III OS=Homo sapiens 
GN=SERPINC1 PE=1 SV=1    X 
 
9 Apolipoprotein A-I OS=Homo sapiens 
GN=APOA1 PE=4 SV=1 X  X X 
 
X 
10 Apolipoprotein A-II OS=Homo sapiens 
GN=APOA2 PE=1 SV=1 X  X X 
 
X 
11 Apolipoprotein A-IV OS=Homo sapiens 
GN=APOA4 PE=1 SV=3 X X X X 
 
X 
12 Apolipoprotein B-100 OS=Homo sapiens 
GN=APOB PE=1 SV=2 X X X X 
 
X 
13 Apolipoprotein C-II OS=Homo sapiens 
GN=APOC2 PE=1 SV=1     
 
X 
14 Apolipoprotein C-III OS=Homo sapiens 
GN=APOC3 PE=1 SV=1  X X X 
 
X 
15 Apolipoprotein E OS=Homo sapiens 
GN=APOE PE=1 SV=1 X X X X 
 
X 
16 Apolipoprotein L1 OS=Homo sapiens 
GN=APOL1 PE=4 SV=1 X X X  
 
X 
17 Apolipoprotein (a) OS=Homo sapiens 
GN=LPA PE=1 SV=1     
 
X 
18 Beta-2-glycoprotein 1 OS=Homo sapiens 
GN=APOH PE=1 SV=3    X 
 
X 
19 C4B1 OS=Homo sapiens GN=C4B PE=4 
SV=1     
 
X 
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No.  
Identified proteins 4°C, 10% 
plasma, 
16,000 xg 
37°C, 10% 
plasma, 
16,000 xg 
37°C,  10% 
depleted 
plasma, 
16,000 
37°C, 10% 
plasma, 
6,000 xg 
37°C,  
90% plasma, 
6,000 xg 
20 C4b-binding protein alpha chain 
OS=Homo sapiens GN=C4BPA PE=1 
SV=2 X   X 
 
 
X 
21 C4b-binding protein beta chain 
OS=Homo sapiens GN=C4BPB PE=1 
SV=1     
 
X 
22 Carboxypeptidase N catalytic chain 
OS=Homo sapiens GN=CPN1 PE=1 SV=1     
 
X 
23 CD5 antigen-like OS=Homo sapiens 
GN=CD5L PE=1 SV=1     
 
X 
24 Ceruloplasmin OS=Homo sapiens 
GN=CP PE=1 SV=1    X 
 
X 
25 Clusterin OS=Homo sapiens GN=CLU 
PE=1 SV=1 X   X 
 
X 
26 Coagulation factor V OS=Homo sapiens 
GN=F5 PE=1 SV=4     
 
X 
27 Coagulation factor X OS=Homo sapiens 
GN=F10 PE=1 SV=2     
 
X 
28 Coagulation factor XI OS=Homo sapiens 
GN=F11 PE=3 SV=1     
 
X 
29 Coagulation factor XII OS=Homo sapiens 
GN=F12 PE=1 SV=3  X X X 
 
X 
30 Coagulation factor XIII A chain 
OS=Homo sapiens GN=F13A1 PE=1 SV=4 X X X X 
 
X 
31 Coagulation factor XIII B chain 
OS=Homo sapiens GN=F13B PE=1 SV=3     
 
X 
32 Complement C1q subcomponent 
subunit A OS=Homo sapiens GN=C1QA 
PE=1 SV=2    X 
 
33 Complement C1q subcomponent 
subunit B (Fragment) OS=Homo sapiens 
GN=C1QB PE=4 SV=1  X  X 
 
 
X 
34 Complement C1q subcomponent 
subunit C OS=Homo sapiens GN=C1QC 
PE=1 SV=3    X 
 
 
X 
35 Complement C1r subcomponent 
OS=Homo sapiens GN=C1R PE=1 SV=2 X X  X 
 
X 
36 Complement C1s subcomponent 
OS=Homo sapiens GN=C1S PE=1 SV=1 X X  X 
 
X 
37 Complement C3 OS=Homo sapiens 
GN=C3 PE=1 SV=2 X X X X 
 
X 
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No.  
Identified proteins 4°C, 10% 
plasma, 
16,000 xg 
37°C, 10% 
plasma, 
16,000 xg 
37°C,  10% 
depleted 
plasma, 
16,000 
37°C, 10% 
plasma, 
6,000 xg 
37°C,  
90% plasma, 
6,000 xg 
38  Complement component C4B  
OS=Homo sapiens GN=C4B-1 PE=4 SV=1 X X X X 
 
39 Complement C5 OS=Homo sapiens 
GN=C5 PE=1 SV=4  X X X 
 
X 
40 Complement component C6 OS=Homo 
sapiens GN=C6 PE=1 SV=3   X X 
 
41 Complement component C8 beta chain 
OS=Homo sapiens GN=C8B PE=1 SV=3    X 
 
42 Complement component C9 OS=Homo 
sapiens GN=C9 PE=1 SV=2    X 
 
X 
43 Complement factor B (Fragment) 
OS=Homo sapiens GN=CFB PE=3 SV=1   X X 
 
X 
44 Complement factor D OS=Homo sapiens 
GN=CFD PE=1 SV=5     
 
X 
45 Complement factor H OS=Homo sapiens 
GN=CFH PE=1 SV=4 X  X X 
 
X 
46 Dynactin subunit 1 OS=Homo sapiens 
GN=DCTN1 PE=4 SV=1     
 
X 
47 Desmoglein-1 OS=Homo sapiens 
GN=DSG1 PE=1 SV=2  X   
 
48  Desmoplakin OS=Homo sapiens 
GN=DSP PE=1 SV=3  X   
 
49  Desmocollin-1 Isoform 1BOS=Homo 
sapiens GN=DSC1  X X  
 
50 Fermitin family homolog 3 OS=Homo 
sapiens GN=FERMT3 PE=1 SV=1     
 
X 
51 Fibrinogen alpha chain OS=Homo 
sapiens GN=FGA PE=1 SV=2 X X X X 
 
X 
52 Fibrinogen beta chain OS=Homo sapiens 
GN=FGB PE=1 SV=2 X X X X 
 
X 
53 Ficolin-3 OS=Homo sapiens GN=FCN3 
PE=1 SV=2    X 
 
X 
54 Filamin-A OS=Homo sapiens GN=FLNA 
PE=2 SV=1     
 
X 
55 Gelsolin OS=Homo sapiens GN=GSN 
PE=1 SV=1  X X X 
 
X 
56 Glyceraldehyde-3-phosphate 
dehydrogenase OS=Homo sapiens 
GN=GAPDH PE=3 SV=1  X   
 
57 Hornerin OS=Homo sapiens GN=HRNR 
PE=1 SV=2  X   
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No.  
Identified proteins 4°C, 10% 
plasma, 
16,000 xg 
37°C, 10% 
plasma, 
16,000 xg 
37°C,  10% 
depleted 
plasma, 
16,000 
37°C, 10% 
plasma, 
6,000 xg 
37°C,  
90% plasma, 
6,000 xg 
58 Haptoglobin-related protein OS=Homo 
sapiens GN=HPR PE=1 SV=2     
 
X 
59 HCG1745306, isoform CRA_a OS=Homo 
sapiens GN=HBA2 PE=3 SV=1     
 
X 
60 Heparin cofactor 2 OS=Homo sapiens 
GN=SERPIND1 PE=1 SV=3    X 
 
X 
61 Histidine-rich glycoprotein OS=Homo 
sapiens GN=HRG PE=1 SV=1    X 
 
X 
62 HPX protein OS=Homo sapiens GN=HPX 
PE=2 SV=1     
 
X 
63 Hemopexin OS=Homo sapiens GN=HPX 
PE=1 SV=2    X 
 
64 Ig alpha-1 chain C region OS=Homo 
sapiens GN=IGHA1 PE=1 SV=2    X 
 
X 
65 Ig gamma-1 chain C region OS=Homo 
sapiens GN=IGHG1 PE=1 SV=1 X X  X 
 
X 
66 Ig gamma-2 chain C region OS=Homo 
sapiens GN=IGHG2 PE=1 SV=2 X   X 
 
X 
67 Ig gamma-3 chain C region OS=Homo 
sapiens GN=IGHG3 PE=1 SV=2 X X  X 
 
X 
68 Ig heavy chain V-I region V35 OS=Homo 
sapiens PE=1 SV=1     
 
X 
69 Ig heavy chain V-III region BRO 
OS=Homo sapiens PE=1 SV=1 X    
 
X 
70  Ig heavy chain V-III region TIL OS=Homo 
sapiens PE=1 SV=1 X    
 
71 Ig heavy chain V-III region CAM 
OS=Homo sapiens PE=1 SV=1     
 
X 
72 Ig heavy chain V-III region KOL 
OS=Homo sapiens PE=1 SV=1     
 
X 
73 Ig kappa chain V-I region HK101 
(Fragment) OS=Homo sapiens PE=4 
SV=1     
 
X 
74 Ig kappa chain V-II region RPMI 6410 
OS=Homo sapiens PE=4 SV=1     
 
X 
75 Ig kappa chain V-II region TEW 
OS=Homo sapiens PE=1 SV=1     
 
X 
76 Ig kappa chain V-III region HIC OS=Homo 
sapiens PE=2 SV=2     
 
X 
77  Ig kappa chain V-II region Cum 
OS=Homo sapiens PE=1 SV=1 X    
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No.  
Identified proteins 4°C, 10% 
plasma, 
16,000 xg 
37°C, 10% 
plasma, 
16,000 xg 
37°C,  10% 
depleted 
plasma, 
16,000 
37°C, 10% 
plasma, 
6,000 xg 
37°C,  
90% plasma, 
6,000 xg 
78  Ig kappa chain V-III region SIE 
OS=Homo sapiens PE=1 SV=1 X   X 
 
79  Ig kappa chain V-III region B6 OS=Homo 
sapiens PE=1 SV=1 X    
 
80 Ig lambda chain V-I region BL2 
OS=Homo sapiens PE=2 SV=1     
 
X 
81 Ig lambda chain V-I region NEWM 
OS=Homo sapiens PE=1 SV=1     
 
X 
82 Ig lambda chain V-I region WAH 
OS=Homo sapiens PE=1 SV=1     
 
X 
83 Ig lambda chain V-III region LOI 
OS=Homo sapiens PE=1 SV=1     
 
X 
84 Ig lambda chain V-I region HA OS=Homo 
sapiens PE=1 SV=1 X    
 
85 Ig lambda chain V-III region SH 
OS=Homo sapiens PE=1 SV=1 X    
 
86 Ig lambda chain V-IV region Bau 
OS=Homo sapiens PE=1 SV=1 X    
 
87 Ig lambda chain V-IV region Hil 
OS=Homo sapiens PE=1 SV=1 X    
 
X 
88  Ig lambda-2 chain C regions OS=Homo 
sapiens GN=IGLC2 PE=1 SV=1 X   X 
 
X 
89 Ig kappa chain C region OS=Homo 
sapiens GN=IGKC PE=1 SV=1 X X  X 
 
X 
90 Isoform 2 of Ig mu chain C region 
OS=Homo sapiens GN=IGHM X    
 
91  Ig lambda-like polypeptide 5 OS=Homo 
sapiens GN=IGLL5 PE=2 SV=2 X   X 
 
X 
92 Ig mu chain C region OS=Homo sapiens 
GN=IGHM PE=1 SV=3 X X  X 
 
X 
93 Ig J chain OS=Homo sapiens GN=IGJ 
PE=1 SV=4 X X   
 
X 
94 Insulin-like growth factor-binding 
protein 3 OS=Homo sapiens GN=IGFBP3 
PE=4 SV=1     
 
 
X 
95 Insulin-like growth factor-binding 
protein 5 OS=Homo sapiens GN=IGFBP5 
PE=1 SV=1     
 
 
X 
96 Insulin-like growth factor-binding 
protein complex acid labile subunit 
OS=Homo sapiens GN=IGFALS PE=4 
SV=1    X 
 
  
X 
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No.  
Identified proteins 4°C, 10% 
plasma, 
16,000 xg 
37°C, 10% 
plasma, 
16,000 xg 
37°C,  10% 
depleted 
plasma, 
16,000 
37°C, 10% 
plasma, 
6,000 xg 
37°C,  
90% plasma, 
6,000 xg 
97 Integrin alpha-IIb OS=Homo sapiens 
GN=ITGA2B PE=1 SV=3     
 
X 
98 Integrin beta-3 OS=Homo sapiens 
GN=ITGB3 PE=4 SV=1     
 
X 
99 Inter-alpha (Globulin) inhibitor H2 
OS=Homo sapiens GN=ITIH2 PE=2 SV=1     
 
X 
100 Inter-alpha-trypsin inhibitor heavy chain 
H1 OS=Homo sapiens GN=ITIH1 PE=2 
SV=1 X X X X 
 
 
X 
101 Inter-alpha-trypsin inhibitor heavy chain 
H2 OS=Homo sapiens GN=ITIH2 PE=1 
SV=2  X X X 
 
 
102 inter-alpha-trypsin inhibitor heavy chain 
H4 OS=Homo sapiens GN=ITIH4 PE=4 
SV=1   X X 
 
 
X 
103 Junction plakoglobin OS=Homo sapiens 
GN=JUP PE=1 SV=3  X   
 
104 Kininogen-1 OS=Homo sapiens 
GN=KNG1 PE=1 SV=2   X X 
 
X 
105 Keratinocyte proline-rich protein 
OS=Homo sapiens GN=KPRP PE=1 SV=1  X   
 
106 Mannan-binding lectin serine protease 
1(Isoform 4 of) OS=Homo sapiens 
GN=MASP1     
 
 
X 
107 Methylcytosine dioxygenase TET3 
OS=Homo sapiens GN=TET3 PE=2 SV=3     
 
X 
108 Peptidyl-prolyl cis-trans isomerase A 
OS=Homo sapiens GN=PPIA PE=1 SV=2     
 
X 
109 Plasma kallikrein light chain (Fragment) 
OS=Homo sapiens GN=KLKB1 PE=3 SV=1     
 
X 
110 Plasma protease C1 inhibitor OS=Homo 
sapiens GN=SERPING1 PE=3 SV=1     
 
X 
111 Plasma serine protease inhibitor 
OS=Homo sapiens GN=SERPINA5 PE=1 
SV=3     
 
X 
112 Plasminogen OS=Homo sapiens GN=PLG 
PE=1 SV=2  X X X 
 
X 
113 Platelet basic protein OS=Homo sapiens 
GN=PPBP PE=1 SV=3     
 
X 
114 Platelet factor 4 variant OS=Homo 
sapiens GN=PF4V1 PE=1 SV=1     
 
X 
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No.  
Identified proteins 4°C, 10% 
plasma, 
16,000 xg 
37°C, 10% 
plasma, 
16,000 xg 
37°C,  10% 
depleted 
plasma, 
16,000 
37°C, 10% 
plasma, 
6,000 xg 
37°C,  
90% plasma, 
6,000 xg 
115 Platelet glycoprotein Ib beta chain 
OS=Homo sapiens GN=GP1BB PE=4 
SV=1     
 
X 
116 Profilin-1 OS=Homo sapiens GN=PFN1 
PE=1 SV=2     
 
X 
117 Prothrombin OS=Homo sapiens GN=F2 
PE=1 SV=2 X 
 
X X X 
 
X 
118 Putative annexin A2-like protein 
OS=Homo sapiens GN=ANXA2P2 PE=5 
SV=2  X X  
 
119 Radixin OS=Homo sapiens GN=RDX 
PE=2 SV=1     
X 
120 REVERSED Fibrinogen beta chain 
OS=Homo sapiens GN=FGB PE=1 SV=2     
 
X 
121 Secreted phosphoprotein 24 OS=Homo 
sapiens GN=SPP2 PE=1 SV=1     
 
X 
122 Selenoprotein P (Fragment) OS=Homo 
sapiens GN=SEPP1 PE=4 SV=1     
 
X 
123 Serum albumin OS=Homo sapiens 
GN=ALB PE=4 SV=2 X X  X 
 
X 
124 Serum amyloid P-component OS=Homo 
sapiens GN=APCS PE=1 SV=2     
 
X 
125 Shroom3 OS=home sapiens 
GN=SHROOM3 PE=1 SV=2 X    
 
126 Sulfhydryl oxidase 1 OS=Homo sapiens 
GN=QSOX1 PE=1 SV=3     
 
X 
127 Suprabasin OS=Homo sapiens GN=SBSN 
PE=4 SV=1  X X  
 
 
128 Transcription initiation factor TFIID 
subunit 9B OS=Homo sapiens 
GN=TAF9B PE=1 SV=1 X    
 
X 
129 Talin 1 OS=Homo sapiens GN=TLN1 
PE=2 SV=1     
 
X 
130 Tetranectin OS=Homo sapiens 
GN=CLEC3B PE=4 SV=1  X X  
 
131 Transthyretin OS=Homo sapiens 
GN=TTR PE=3 SV=1    X 
 
X 
132 Tubulin beta chain OS=Homo sapiens 
GN=TUBB PE=3 SV=1     
 
X 
133 Vitamin K-dependent protein C heavy 
chain OS=Homo sapiens GN=PROC PE=3 
SV=1     
 
X 
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No.  
Identified proteins 4°C, 10% 
plasma, 
16,000 xg 
37°C, 10% 
plasma, 
16,000 xg 
37°C,  10% 
depleted 
plasma, 
16,000 
37°C, 10% 
plasma, 
6,000 xg 
37°C,  
90% plasma, 
6,000 xg 
134 Vitamin K-dependent protein S 
OS=Homo sapiens GN=PROS1 PE=1 
SV=1 X X  X 
 
 
X 
135 Vitronectin OS=Homo sapiens GN=VTN 
PE=1 SV=1  X X X 
 
X 
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7 Synthesis of ZnO nanowires (NWs) and their toxicity to MDA-MB-
231 breast cancer cells 
Among the various morphologies of ZnO NMS, nanowires (NWs) have recently attracted 
particular attention due to their unique one dimensional structure with highly controlled 
length and diameters. Compared to ZnO NPs, the ZnO NWs have the advantage of efficient 
tumor targeting due to the polyvalency effect, which are characterised by the simultaneous 
binding of multiple ligands on one biological entity [232], and the potential for 
multifunctional agents. ZnO is a wide band gap semiconductor (3.37 eV) with high exciton 
binding energy (60 meV), which leads to efficient excitonic blue and near-UV emission [233] 
with potential use as optical probes for bioimaging applications [234]. The use of ZnO NWs 
for bioimaging has the advantage of enhancing the intensity of the luminescence of ZnO 
[12].  
 High aspect ratio ZnO NWs have been shown to exhibit toxic effects on a number of 
prokaryotic and eukaryotic cells [235]. They also demonstrated successful results in breast 
cancer photodynamic therapy [85]. It has been reported that ZnO NWs significantly 
improved the antitumor activity of the conventional drug Daunorubicin against 
hepatocarcinoma cells [86].   
 In this study, the ZnO NWs were synthesized by both template assisted and 
template free electrodeposition and they were characterised by SEM and TEM. Because the 
amount of the NWS obtained by template electrodeposition was low, free electrodeposition 
of ZnO NWs on glass was used to prepare the ZnO NWs for cell exposure experiments. The 
effect of the in-house prepared ZnO NWs on the metabolic activity of the MDA-MB-231 was 
assessed using the ATP assay.  
7.1 Synthesis of 1D ZnO nanostructures 
Some of the several methods developed to synthesize ZnO NWs will be discussed in this 
chapter with the focus on electrochemical method.  
 ZnO is a versatile functional material and it has a rich family of 1D nanostructures 
such as nanotubes, nanorods, nanowires, nanobelts, nanorings, and nanosprings [116]. 
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Various chemical, electrochemical and physical deposition techniques have been used to 
synthesize 1D ZnO nanostructures with different diameter and length [188]. The growth 
mechanisms of 1D ZnO nanostructures in all these techniques are based on two main 
methods; vapour-phase method and solution-phase method. These methods are discussed 
in details by Singh in his comprehensive review paper about the growth and synthesis of 
ZnO NWs [236]. Some of these methods will be discussed here with the focus on the 
solution phase methods.  
7.1.1 Vapour phase method 
The vapour phase method is a well-developed method which gives good crystallinity and 
controlled morphology of the prepared nanostructures [237-239]. However, it requires 
sophisticated equipment and conditions (e.g. high vacuum and temperature). In this 
method, condensed or powder source material is vaporised at high temperature, then the 
resultant vapour phase condenses at certain conditions of temperature, pressure, substrate, 
etc. to produce the desired nanostructure. To control the diameter, aspect ratio and 
crystallinity different techniques are employed, these include thermal chemical vapour 
deposition (CVD) [240-243], metal-organic chemical vapour deposition (MOCVD) [244], 
pulsed laser deposition (PLD) [245] and direct thermal evaporation [246, 247]. These growth 
methods are based on two mechanisms: vapour-liquid-solid (VLS) or vapour-solid (VS) [236]. 
7.1.2 Solution phase method 
The solution phase method is a less complicated and a more recent growth method. Herein, 
the deposition operates at a lower temperature and under atmospheric pressure, thus 
reducing the cost and the complexity of fabrication. ZnO NWs and nanorods growth has 
been successfully achieved in high yields in solution. In order to guide and confine the 
growth direction, a number of approaches have been used. These can be grouped into 
template-free method and template-assisted methods.  
 Template-assisted method 7.1.2.1
This method makes use of periodically structured templates to define the morphology and 
size of nanostructures. A variety of templates have been used to produce 1D 
nanostructures, for example, anodic aluminium oxide membranes (AAM) have hexagonally 
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ordered nanochannels which can be filled to form 1D nanostructures. ZnO NWs have been 
successfully obtained by template assisted electrodeposition [248, 249]. 
  Template-Free Method 7.1.2.2
Recent progress using solution phase techniques has resulted in the creation of 1D ZnO 
nanostructures by template-free methods. There are three common approaches to 
fabricate 1D nanostructures by this method, these include hydrothermal [250-252], 
chemical bath deposition (CBD) [253], and electrochemical deposition (ECD) [254, 255]. 
These methods benefits from the inherent anisotropic growth of ZnO because of variation in 
surface energy due to its surface polarity along the c-axis in the layered wurtzite structure 
[116].  A seeding layer on the substrate which could be ZnO powder, Zn powder or ZnO NPs 
and molecular capping agents, such as surfactants [256] can also be used to control the 
growth of more complex 1D ZnO nanostructures. The molecular capping agents control the 
kinetics of nanocrystal growth by preferentially adsorbing to specific crystal facets or by 
chelating the Zn2+ ion in solution, thus modifying the growth process. 
7.1.3 Electrochemical deposition (ECD)  
This method has several key advantages over the other deposition techniques, including 
simplicity, low temperature, low cost, and scalability [188, 257-259]. It employs a potential 
applied between two electrodes immersed in a solution which contains a salt of the metal 
species to be deposited. A third electrode (reference electrode) is used to monitor the 
reaction. Using this method, the morphology of the obtained nanostructures is largely 
influenced by a number of parameters, namely, electrolyte pH, the temperature of the 
solution [258, 260, 261], stirring rates, type and concentration of precursor  and the applied 
potential [258, 262]. Ryan and co-workers have reported the effect of ECD time and 
substrate surface preparation on the growth of ZnO nanorods and nanoplates [263]. 
 The first deposition of ZnO films by electrochemical method from aqueous 
solutions have been reported by both Izaki’s group and Lincot’s group in 1996 [264]. Izaki 
and Omi (1996) [265] cathodically deposited transparent ZnO films from aqueous zinc 
nitrate (Zn(NO3)2) solution on a glass substrate coated with tin oxide. On the other hand, 
Peulon et al. [188] used zinc chloride (ZnCl2) to deposit ZnO films on tin oxide deposited on 
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glass substrate. Two years later, Lincot’s group reported a detailed mechanism of the 
process [188]. They concluded that the deposition temperature and the bath composition 
are the key parameters that determine the quality of the deposited films. At temperatures 
below 50°C, amorphous insulating zinc hydroxide films are formed, whereas, well-
crystallized and semi-conducting zinc oxide films are obtained at higher temperatures.  
 Template-free electrodeposition of ZnO nanowires 7.1.3.1
As mentioned earlier, several studies have been reported on the synthesis of ZnO NWs and 
nanorods by template-free electrodeposition [253, 255, 266, 267] . In this method ZnO NWs 
are achieved by utilising the intrinsic anisotropic crystallographic structure of a targeted 
material. Wong et al.,[267] for example, have grown ZnO nanorods on polycrystalline Zn foil 
by cathodic electrodeposition in an aqueous solution of CaCl2 at 80°C.  
 Template – assisted electrodeposition of ZnO nanowires 7.1.3.2
Among various NWs fabrication methods, template synthesis combined with 
electrodeposition is an effective and an elegant method for preparing 1D nanostructure. As 
mentioned earlier, this method uses a template to direct the 1D growth. ZnO NWs have 
been electrodeposited into two kinds of templates, AAM and track-etched polycarbonate 
templates with cylindrical channels.  The obtained NWs shape, direction and size are all 
determined by the architecture of the porous template. In template assisted ECD, the ions 
in the electrolyte solution can access deep inside the pores of the template for the 
deposition process. 
 In general, the template assisted electrodeposition of 1D nanostructure follows the 
following scheme (Figure 104). Firstly, one side of the template is coated with a thin layer of 
metal (Au, Ag, etc.) to act as the working electrode in the three electrode electro-chemical 
cell. Secondly, the deposition of the 1D structure occurs inside the nanopores of the 
template, starting from the deposited metal side. Secondly, the 1D nanostructure, which 
could be NWs or nanotubes, will be formed in the nanopores of the template after 
electrodeposition under proper conditions for certain duration. The duration of 
electrochemical deposition will determine the length of the prepared wires. Finally the 
deposited NWs can be obtained by the removal of the conductive layer and the template. 
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The templates can be removed by dissolving them in a solvent in which the desired wires 
are insoluble [268, 269]. 
 
Figure 104: Schematic of electrosynthesis of nanomaterials within a template containing cylindrical pores (adapted from 
[268]). 
 Template assisted ECD of ZnO NWs has been obtained by direct one step and 
indirect ECD. The one step ECD of ZnO NWs using templates is suggested as follows; 
hydroxide ions are first generated in the mild acidic solution of Zn2+ by the reduction of an 
oxygen precursor which could be either dissolved oxygen, nitrate ions or hydrogen peroxide 
as shown in equations 1, 2 and 3, respectively. The formation of the hydroxide ions 
increases the pH in the vicinity of the working electrode causing precipitation of Zn2+ ions as 
zinc hydroxide at the cathode (equation 4). Finally, zinc hydroxide spontaneously 
dehydrates into ZnO (equation 4). ZnO particles precipitate on the working electrode at the 
base of the membrane channels and then ZnO nanorods grow due to the transport of Zn2+ 
and the hydroxide precursor from the bulk solution to the working electrode. The indirect 
ECD of ZnO NWs is based on electrodeposition of Zn metal and then oxidation of metallic 
zinc NWs by annealing the templates to obtain ZnO NWs arrays. 
O2 + 2H2O + 4e
- → 4OH-    Equation 1 
No3
- + H2O + 2e
- → No2
- + 2OH-      Equation 2 
H2O2 + 2e
- → 2OH-                   Equation 3       
Zn2+ + 2OH-             Zn(OH)2 → ZnO(s) + H2O      Equation 4  
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 Two types of membranes have been used for template assisted electrodeposition 
of ZnO NWs; AAM [248, 249] and nuclear track-etched polymer (polycarbonate) membranes 
[270]. Compared to inorganic membranes, polycarbonate membranes are flexible and can 
be used in some special circumstances. Track-etched polycarbonate membranes can be 
easily removed to release the as-deposited nanostructures by dissolving in dichloromethane 
or chloroform solvents. They are commercially available with a wide range of pore 
diameters (10 - 2000 nm), however their pore density is relatively low (109 pores/cm2), an 
order of magnitude smaller than AAM. Additionally, some channels may intersect within the 
membranes due to the pore-production process [268].  
 ZnO NWs were electrochemically produced within track etched polycarbonate 
membranes (PCM) in an aqueous solution of potassium chloride and zinc chloride using 
H2O2 as an oxygen precursor [271]. Lai and Riley [272], 2006, synthesised ZnO nanorods by 
electrodeposition into polycarbonate membranes. In the presence of Zn2+ ions, 
monocrystaline ZnO NWs were grown using nitrate ions (0.01 M Zn(NO3)2) at a constant 
potential of -0.7 V at 90 °C, while polycrystals were deposited from peroxide ions at a fixed 
potential of -0.2  V at 22 °C.  [270, 273] also managed to fabricate ZnO NWs using PCM. The 
ECD was conducted under -0.8 V at 90°C [273] and under  -0.7 V at 70°C [270] in 0.1 M 
Zn(NO3)2 solution. They suggested that increasing the temperature of deposition increases 
the structural quality of the obtained wires.  Recently, Sharma et al. [269] synthesized ZnO 
NWs using 0.1 M Zn(NO3)2 at 75 °C. The electrodeposition was performed at different 
potentials of -0.8, -1.0 and -1.2 V. They concluded that the ZnO NWs grown at higher 
negative potential have a higher fraction of large size crystallites and are polycrystalline in 
nature. Another recent fabrication of ZnO NWs using polycarbonate templates has been 
carried out by Müller et al. [10]. High aspect ratio ZnO NWs were prepared by ECD into PCM 
in an aqueous solution of 0.1 M Zn(NO3)2 solution under -0.8 potential and at 65:C [261]. 
7.2 Materials and Methods 
7.2.1 Materials 
All materials were of analytical grade and used without further purification. Zinc nitrate 
(Zn(NO3)2.6H2O) (assay ≥ 99.0%) was obtained from Sigma-Aldrich. Zinc standard in nitric 
acid at 1000 ppm was supplied by MBA Analytical Ltd, UK. PCMs were obtained from Agar 
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Scientific (Dorset, UK). Dichloromethane was supplied from VWR. KCl (99%) was purchased 
from BDH. ZnCl2 (98%) was obtained from Sigma-Aldrich. Ethanol (absolute, 99.9%) and 
hexane (95%) were from VWR.  
7.2.2   ZnO nanowires template- assisted electrodeposition 
Nanoporous track-etched polycarbonate membranes were used as templates for ZnO NWs 
growth by electrochemical deposition.  
1. Electrodeposition 
ZnO NWs were fabricated by electrodeposition into nuclepore PCMs according to Müller et 
al. with modifications. The membrane was 6 μm thick, 25 mm in diameter, and the pore 
density was 6 x 108 pores/cm2. The nominal pore size of the membrane was 50 nm. One side 
of the membrane was coated with layer of gold, 100 nm thick, by sputter deposition, using 
Emitech k575X sputter coater, to serve as a working electrode. The counter electrode used 
was a platinum mesh and Ag/AgCl/KCl (3.5 M) electrode was used as the reference 
electrode. Based on previous work, electrodeposition was conducted using 0.1 M Zn(NO3)2 
aqueous solution under a constant potential of -0.8 V vs. Ag/AgCl and at 70 °C with an 
accuracy of ±1 °C, using a hot plate (Heidolph Instruments) equipped with a temperature 
sensor. The ECD was carried out for 30 min. Before starting electrodeposition, the 
membrane was left in the cell with Zn(NO3)2 solution for 15 min to equilibrate the 
temperature and dislodge air bubbles from the membrane and allow its wetting. As 
mentioned earlier, ZnO precipitation in this system is induced by the formation of hydroxide 
ions generated by reduction of the nitrate ions in the aqueous solution as shown in 
equations 2 and 4 previously described in section 7.1.3.2. 
2. Liberation of ZnO nanowires from their template and purification 
 After electrodeposition, the electrolyte solution was discarded and the polycarbonate 
template was removed from the electrodeposition cell, the area of the membrane exposed 
to electrodeposition (≈1cm2) was incubated in 2 ml dichloromethane for 1 h to dissolve the 
PCM. The solution was then gently agitated to dislodge the NWs, and the gold foil was then 
removed with a pair of forceps. After that, the ZnO NWs were collected by centrifugation at 
3000 xg for 10 min and the resulting pellets were washed six times with 2 ml 
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dichloromethane to remove the undissolved polycarbonate residue. Finally, the 
dichloromethane was evaporated from the pellet using a stream of nitrogen and the 
resulted wires were suspended in pure ethanol to serve as the stock solution.  
 In order to study how the ZnO NWs dislodged from the gold layer, a piece of the 
whole membrane with gold was removed from the dichloromethane after few minutes of 
incubation of the membrane with dichloromethane, then it was examined under SEM after 
coating with gold to prevent charging. To check the reproducibility of the aspect ratio of the 
obtained wires by template assisted electrodeposition, another two batches of the ZnO 
nanowires were prepared and the length of the wires obtained from each batch was 
characterised. 
7.2.3  Zinc oxide nanowires deposition on gold coated glass plates (template free 
method) 
1. Preparation of the working electrode 
The working electrode for the cathodic deposition of ZnO NWs was a 12 nm gold film 
sputtered on glass prepared by Emitech k575X sputter coater. The microscope glass slides 
(VWR) were successively washed prior to sputtering in Acetone (VWR, 99.9%), methanol 
(VWR, 99.8%), 1.0 M Sodium Hydroxide (NaOH) (VWR, 99%), and deionized water (Purite 
deionizer). The electrical connection between the sample and an electrical wire was 
achieved by a drop of silver paint (Agar). The contact was then covered with copper tape 
and insulating paint (Miccro Super XP200 Lacquer, Hi-Tek Products Ltd). Before deposition, 
the electrode was cleaned with compressed air. 
2. Electrodeposition 
Potassium Chloride (KCl, 0.1 M) was used as the supporting electrolyte and Zinc Chloride 
(ZnCl2, 0.1 mM) was used as the zinc precursor. All the chemicals were of analytical grade 
and used without further purification. Oxygen gas (O2) (BOC Gases Ltd) was bubbled for 30 
min prior to electrodeposition so that the solution becomes saturated with O2. Bubbling was 
maintained during the deposition. The temperature was kept constant at 85 °C, with an 
accuracy of ±1 °C, using a hot plate (Heidolph Instruments) equipped with a temperature 
sensor. The electrochemical cell employed a three-electrode setup. The gold coated glass 
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slide served as the working electrode while a platinum mesh and a Ag/AgCl/KCl (3.5 M) 
electrode were used as the counter and reference electrode, respectively. Electrodeposition 
was performed under the potentiostatic transient mode, with a potential of -0.9 V vs. 
Ag/AgCl. A potentiostat (Princenton VersaSTAT 3) connected to a PC was used to control the 
potential and measure the current. The deposition was terminated when the desired 
amount of charge had passed through the system. The deposited films were gently soaked 
in deionized water, dried in ambient atmosphere and stored in a desiccator.   
3. Liberation of Nanowires from the substrate 
In order to liberate the NWs from the substrate, the gold film was oxidized by the 
application of an anodic potential. Potassium Chloride (KCl, 0.05 M) (VWR, 100%) was used 
as the electrolyte in a similar setup as for electrodeposition. A potential of 1.4 V Ag/AgCl 
was maintained until all of the gold was oxidized. The substrate was left to dry in ambient 
atmosphere. The electrical connections were carefully removed and the substrates were 
sonicated in ethanol for 5 min. The ethanol dispersion of the wires was transferred to 50 mL 
centrifuge tubes and hexane was added so that the hexane: ethanol ratio was 2:1. The NWs 
were then collected by centrifugation at 4500 rpm for 15 min and allowed to dry. The 
resulting precipitates were redispersed in ethanol and transferred to eppendorf tubes.  
7.2.4 Characterisation of ZnO nanowires 
After the preparation of the ZnO NWs, different techniques were used to characterise their 
shape, size and structure. Information on the morphology and size of ZnO NWs was 
obtained by SEM and TEM. Energy dispersive X-ray (EDX) was used for chemical analysis. 
  Scanning electron microscopy (SEM) 7.2.4.1
 Information on the morphology of the NWs prepared by both template assisted 
and template free methods was obtained by SEM (LEO 1525) operating in secondary 
electron mode at 5 kV using the In lens detector.  
After electrochemical deposition of ZnO NWs into the polycarbonate template, the 
template was incubated with dichloromethane for few minutes and a piece of the whole 
membrane coated with a layer of gold, was removed from the dichloromethane solution 
and imaged in the SEM on an aluminium stub. To prevent sample charging, the sample was 
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coated with 5 nm gold layer. Also, after liberation of the ZnO NWs from their template, a 
drop of the NWs dispersed in ethanol was transferred to an aluminium stub and then dried 
at ambient temperature. The wires were then examined in the SEM after coating with gold 
to prevent charging. 
 After electrochemical deposition of ZnO NWs on glass substrate, the dried 
substrate with the ZnO NWs was transferred to an aluminium stub and the wires were 
examined in the SEM after coating with gold to prevent charging. Also, after liberation of 
the ZnO NWs from their substrate, a drop of the NWs dispersed in ethanol was transferred 
to an aluminium stub and then dried at ambient temperature. The wires were then 
examined in the SEM after coating with gold to prevent charging. The size distribution of the 
ZnO NWs was calculated using SEM images and ImageJ software (http://rsbweb.nih.gov/ij/).  
  Transmission electron microscopy (TEM) 7.2.4.2
The shape and the structure of the ZnO NWs prepared by template electrodeposition was 
also assessed in the JEOL 2000 (Peabody, MA, USA) operated at 200 kV. Microfilms were 
prepared by immersing lacy carbon coated copper TEM grids (Agar Scientific Ltd, UK) into 
the ethanolic ZnO NWs dispersions and drying at RT. The diameter and length of the ZnO 
NWs was calculated using bright-field TEM images and ImageJ software 
(http://rsbweb.nih.gov/ij/). Chemical characterisation of the ZnO NWs prepared into the 
polycarbonate template was studied using EDX. 
7.2.5 ATP viability assay 
The MDA-MB-231 cells were plated in flat-bottomed 96- well plates (Fisher Scientific Ltd, 
UK) as described in section 4.1.2 of this study. The template assisted electrodeposition 
produced a low yield of the ZnO NWs, while a reasonable yield could be obtained by 
electrodeposition of the NWs on glass substrates; therefore, electrodeposition on glass was 
used to prepare ZnO NWs for the ATP viability assay. Suspensions of the ZnO NWs were 
prepared in ethanol, to ensure the NWs sterility for the assays; ethanol was then 
evaporated in sterile conditions at RT. The NWs were suspended aseptically in the same 
DMEM media used to test the viability of the bare and the targeted ZnO NPs and stored at 
4°C. The ZnO NWs stock dispersions were first sonication for 20 s on a bench sonicator and 
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working concentrations of 20, 30 and 50 μg/ml were freshly prepared in DMEM 
supplemented with 1% FBS and directly applied to the MDA-MB-231 cells for 24 and 48 h. 
The assay was repeated twice and the result was represented as average viability ± SD. 
Statistical analysis was carried out using a paired Student's t-test. The level of significance 
was accepted at p≤0.05. The levels of significance was indicated by the Asterisks: *p < = 
0.05, **p < = 0.01 [160].  
7.3 Results and Discussion 
7.3.1 Characterisation of zinc oxide nanowires  
High aspect ratio ZnO NWs were successfully fabricated by electrodeposition into high 
quality polycarbonate membrane filters and gold coated glass substrates and the obtained 
ZnO NWs have a very smooth flat surface.  
 ZnO nanowires template- assisted electrodeposition 7.3.1.1
Size and morphology of the ZnO NWs 
Examination of the PCM by SEM after few minutes of incubation with dichloromethane 
revealed that the ZnO NWs do not detach themselves directly at the point of attachment 
with gold, but they rather break close to the gold layer, and this occurs as soon as the 
polycarbonate membrane starts to dissolve. After breakage, residues of the wires could be 
observed clearly attached to the gold layer (Figure 105, A). The as-prepared ZnO NWs had a 
tapered shape with a broad base and a narrow tip (Figure 105, A). After 1 h incubation of 
the ZnO NWs in dichloromethane and subsequent cleaning, the wires were successfully 
liberated from their template and appeared clean (Figure 105, B, C). The TEM images also 
showed a high degree of agglomeration of the wires (Figure 105, D). There was a variation in 
the length of the ZnO NWs due to their damage during liberation from the polycarbonate 
templates and subsequent purification, the frequency distribution of the ZnO NWs after 
centrifugation is shown in Figure 106. The average length of the wires was 1462 ± 673 nm 
(n=343). Chemical analysis of the prepared ZnO NWs confirmed the presence of zinc (Zn Lα 
and Kα peaks) (Figure 107). 
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Figure 105: Characterisation of ZnO NWs prepared by template assisted electrodeposition. (A) SEM image of ZnO NWs 
after few minutes of incubation of the polycarbonate templates with dichloromethane. (B) SEM image of the purified 
ZnO NWs. (C) TEM image of an individual purified ZnO nanowire. (D) TEM image of aggregated ZnO NWs. 
 
Figure 106: Length frequency distribution curve of ZnO NWs prepared by polycarbonate template electrodeposition. 
Average size =1462 ± 673 nm (n=343). 
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Figure 107: EDX spectra of the electrodeposited ZnO NWs. 
 Zinc oxide nanowires electrodeposited on glass substrates  7.3.1.2
The ZnO NWs prepared by electrochemical deposition on glass substrates were successfully 
liberated from their substrates (Figure 108). The wires had a uniform diameter 37 ± 12 nm 
(n=259) throughout their length, but showed a variation in the length with an average of 
330 ± 344 nm (n=1750). The diameter and length frequency distribution of the ZnO NWs are 
presented in Figure 109 and Figure 110, respectively. 
 
Figure 108: SEM image of ZnO NWs prepared by electrodeposition on glass plates after liberation from the substrate.  
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Figure 109: Diameter frequency distribution curve of ZnO NWs prepared on glass substrates. Average diameter =37 ± 12 
nm (n=259). 
 
Figure 110: Length frequency distribution curve of ZnO NWs prepared on glass substrates. Average length =330 ± 344 nm 
(n=1750). 
7.3.2 Toxicity of ZnO NWs to the MDA-MB-231 cells 
The ATP assay showed that the ZnO NWs resulted in a dose and time dependent toxicity in 
the MDA-MB-231 cells (Figure 111). The toxicity of the NWs to the cells was statistically 
significant after exposure to 30 and 50 μg/ml ZnO NWs for 24 h and 48 h. Figure 112 shows 
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the dose response curve of the MDA-MB-231 cells to the ZnO NWs after 24 h with an IC50 of 
24 μg/ml.  
 
 
 
Figure 111: ATP viability assay of MDA-MB-231 cells exposed to ZnO NWs. Experiments were repeated in duplicates 
(n=2) and represented as the mean ± SD.  *P ≤ 0.05, **P ≤ 0.01. 
 
Figure 112: Dose response sigmoidal fit of viability of MDA-MB-231 cells exposed to ZnO NWs for 24 h. IC50= 24 μg/ml. 
The values represent the mean ± STD of two experiments each performed in triplicate. 
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7.4 Summary and conclusions 
High aspect ratio ZnO NWs were successfully fabricated by electrodeposition into high 
quality polycarbonate membranes filters and gold coated glass substrates and the obtained 
ZnO NWs have a very smooth flat surface. The template assisted electrodeposition 
produced a low yield of the ZnO NWs while a reasonable yield could be obtained by free 
electrodeposition of the NWs on glass substrates. A methodology to release the wires from 
the template by anodic oxidation for gold was established and, therefore, electrodeposition 
on glass was used to prepare ZnO NWs for the ATP viability assay. The ZnO NWs prepared 
on glass substrates had a uniform diameter of 37 ± 12 nm (n=259) throughout their length 
and they had a length of 330 ± 344 nm (n=1750).  
 Toxicity assays showed that the ZnO NWs resulted in a dose and time dependent 
reduction in the viability of the MDA-MB-231 cells (Figure 111) with an IC50 of 24 μg/ml after 
24 h exposure (Figure 112). This IC50 of the ZnO NWs in the MDA-MB-231 cells after 24 h 
exposure is lower than that obtained for the bare ZnO NPs, which was 36 μg/ml (Figure 44). 
This indicates that the ZnO NWs were more toxic to the MDA-MB-231 cells than the ZnO 
NPs. The cytotoxic responses to the ZnO NWs in the MCF-7 cells, as well as the healthy MCF-
10-2A cells, have to be further investigated.  
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8 Conclusions and Future work 
8.1 Conclusions 
This thesis developed a platform technology where the local release of high dose of Zn2+ 
from ZnO NMs, coupled to simultaneous targeted-delivery, can be used for effective 
treatment of a range of cancer cells including the triple negative resistant tumours.  
 Taken together, the results of this work have enabled us to propose a new 
mechanism for ZnO NMS uptake and cytotoxicity in the breast cancer MCF-7 and MDA-MB-
231 cells. In brief, upon being added to the culture medium, ZnO NPs are rapidly coated by 
serum proteins. The protein corona induces the formation of small aggregates of ZnO NPs 
that are taken up by the cells, possibly by non-specific endocytosis for the bare ZnO NPs, 
and a combination of endocytosis and receptor mediated processes for the targeted ZnO-
HCV-RGD-GFP NPs. The ZnO-protein corona complex is then transported, most probably, 
into lysosomes by vesicles. Inside the lysosomes, the ZnO NPs rapidly dissolved to release 
zinc ions (Zn2+). The released zinc ions induce a cascade of cellular events that lead to 
cellular death. 
 The ZnO NPs (both bare and targeted) induced necrosis in the MCF-7, but apoptosis 
in the MDA-MB-231 cells at concentrations 10-60 μg/ml. The cytotoxicity of the bare and 
the targeted ZnO NPs to the MCF-7 was dose - but not time- dependent. The MCF-7 cells 
showed all signs of necrosis, which includes a sudden drop in the metabolic activity at 
concentrations around the 24 h IC50, and cell lysis with high release of LDH after 24 h 
exposure to the bare ZnO NPs. In the MDA-MB-231 cells, on the other hand, the bare and 
targeted ZnO NPs showed a time and dose dependent cytotoxicity with signs of apoptosis 
which includes a linear reduction in the metabolic activity and the low release of LDH after 
24 h exposure to the ZnO NPs. In the Annexin V/7AAD assay, the MDA-MB-231 cells showed 
significant time and dose dependent increase in the apoptotic population, while MCF-7 
cells, in contrast, did not show any increase in the apoptotic population, compared to the 
untreated controls at any tested concentration. The confocal imaging of these cells exposed 
to the ZnO NPs supported these findings. The MDA-MB-231 cells undergoing cell death 
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displayed distinct morphological features typical of apoptotic cells such as shrinkage and 
blebbing, while the MCF-7 cells did not display these features.  
 The toxic susceptibility of the cells to the ZnO NPs to the cells used in this study was 
as follows; MCF-7> MDA-MB-231> MCF-10-2A cells. The bare ZnO NP showed a selective 
toxicity to the breast cancer cell lines compared to the healthy breast epithelial cells at 
concentrations 25-40 μg/ml of the bare ZnO NPs after 3 h exposure. A dose of 35 μg/ml of 
the bare ZnO NPs could be used as a toxic dose to the breast MCF-7 and MDA-MB-231 
cancer cells with minimal toxic effects on the healthy breast MCF-10-2A cells, which showed 
>65% viability at this concentration. The higher sensitivity of the breast cancer cells 
compared to the healthy breast epithelial cells to ZnO is not fully understood, however, this 
could be related to the effect of ionic zinc. It has been reported that zinc may protect 
normal human lymphocytes against DNA-damaging action and increase this action in human 
myelogenous lukemia K562 cancer cells, which indicates the dual action of this element in 
dependency of target cells and can be useful in cancer therapy [274].  
 The RGD-targeting of the ZnO NPs to the integrin αvβ3 receptors led to an increase 
in the toxicity of the ZnO NPs to the breast cancer cells that over express the integrin αvβ3. 
The combination of RGD-targeting and the inherent selective toxicity of the ZnO NMs to 
breast cancer cells but not the healthy epithelial cells will open new options for this material 
in cancer therapy. 
 High aspect ratio ZnO NWs were successfully fabricated by electrodeposition and 
the obtained NWs have a very smooth flat surface with a uniform diameter. The ZnO NWs 
resulted in a dose and time dependent toxicity in the MDA-MB-231 cells with an IC50 lower 
than that of the bare ZnO NPs.  
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8.2  Future work 
 In this thesis three cell lines (two cancer cell lines and a control cell line), three ZnO NPs 
(bare, targeted and NWs), and three viability assays (Alamar Blue, LDH and ATP) were used 
in this study. However, not all of the combinations were tested. This is because the toxicity 
assays are very lengthy and months of work were needed to optimize the conditions of each 
of the assays used. For example which cell culture medium to use to preserve cell 
metabolism and minimise dissolution of the ZnO NPs. Such conditions also include, the 
incubation time of the NPs with the cells as well as with cell culture medium. Different cells 
could have been tested using the same culture medium to save time, however our results 
showed that this is not correct (which may explain a lot of the discrepancy between data 
reported in the literature), so months have been spent to optimise the culturing protocols to 
perform highly controlled experiments. Ideally a complete data set should be generated to 
draw conclusions. Nevertheless, the results of this thesis show significant differences 
between the MCF-7 and MDA-MB-231 cells and in one assay a comparison to the healthy 
cells was conducted. A large advancement over what has been done in the literature in 
development of assays to test the toxicity ZnO nanomaterials has been achieved. The future 
work will cover all the other possible combinations. 
 
 Although we have proposed new mechanism by which targeted and bare ZnO NPs 
destroy cancer cells, the underlying mechanism by which they exert their toxicity requires 
further investigations. Qualitative and quantitative changes in cancer cell death are essential 
determinants of malignant disease responsiveness to therapy *275+. Therefore, by better 
understanding the mechanisms of action, and cellular consequences, resulting from ZnO 
NMs interactions with cancer cells and their mechanisms of action, the inherent toxicity and 
selectivity of ZnO NMS against cancer may be further improved to make them attractive new 
anti-cancer agents. This could be achieved by further investigations into ZnO-induced 
mechanisms of cell death, and to accurately and dynamically differentiate between necrosis 
and apoptosis by using specific intracellular enzymes (apoptotic markers) that are activated 
in apoptosis (e.g. caspase-3, 7, and 9 *276+). This could also be achieved by suing well-known 
anti-apoptotic genes (e.g. Bcl-2), which inhibit most types of apoptotic cell death *277+, and 
therefore it could be possible to indirectly discriminate between the two cell deaths. Cell 
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cycle analysis of breast cells after exposure to the ZnO NPs will help understanding the 
genetic responses of the cells after exposure. This could be achieved by flow cytometry 
analysis of cells exposed to the ZnO NPs. It has also been reported that ZIP10, a receptor 
that control zinc influx into the cytosol, plays an essential role in the migratory activity of 
highly metastatic MDA-MB-231 breast cancer cells *197+. Therefore, the involvement of the 
ZIP10 and other zinc receptors in the uptake of ZnO NMs or zinc ions after ZnO NMs 
treatments is worthy of further investigation.  
 
 The reported alteration in the intracellular distribution of NMS after uptake, because of 
the RGD targeting *91+, necessitates further investigations into the subcellular localization of 
both the bare and the RGD-grafted ZnO NPs. Mapping the subcellular localization of the ZnO 
NPs (both bare and targeted) could provide insights into the observed higher breast cancer 
toxicity of RGD-targeted ZnO NPs, compared to the bare NPs, as well as their different 
intracellular dissolution profiles.  
 
 An avenue of future work would be to further widen the window in which the ZnO NPs 
only show toxicity to the breast cancer cells. This could be achieved by the use of a 
combination of attaching targeting ligands to the surface of the particles and the 
incorporation of dopants (e.g. Al, Cr) into the ZnO, to tune the solubility and bioreactivity of 
the ZnO NPs, to generate a system that is biocompatible with healthy cells and therefore can 
be applied in biomedical applications. In addition, other variables could be explored, such as 
varying the size or charge of the ZnO NPs. Use of PEG-ylation to increase the colloidal 
stability of the ZnO NPs and non-specific adsorption of proteins should also be studied. 
 
 Quantification of the effect of serum proteins on the binding and internalization of bare 
and targeted ZnO NMS by breast cancer and healthy cells need further investigations. This 
could be achieved by FACS and also by conducting confocal experiments on live breast 
cancer cells in a chamber of controlled temperature and under 5% CO2 with the use of ZnO 
NMS prepared in cell culture media with and without FBS. Preliminary flow chamber 
experiments, conducted in this study, looked extremely promising and will also help to 
assess the effect of protein corona on the RGD-targeting efficiency of the ZnO NMS to 
integrin αvβ3 receptors. 
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 Although the RGD-targeted ZnO NPs showed a higher toxicity to the breast cancer cells 
than the bare NPs, and they were shown to bind to the integrin αvβ3 receptors expressed on 
the surface of the breast cancer cells, quantification of the amount of this binding is crucial. 
This could be achieved by conducting flow cytometry assays of breast cells exposed to the 
RGD-targeted ZnO NPs and to the negative control ZnO-GGG NPs. Comparisons of binding of 
the RGD-targeted ZnO NPs before and after either blocking or knock-out of the integrin αvβ3 
receptors could also help to quantify binding of the targeted ZnO NPs to the breast cancer 
cells. Blocking of the integrin αvβ3 receptors can be achieved by exposure of the breast 
cancer cells to RGD protein before ZnO NPs treatment. The knock down of the integrin αvβ3 
receptors can be achieved by siRNA transfection.  
 
 Although the RGD peptide is an effective ligand for tumor targeting of the integrin αvβ3 
receptors, which are selectively expressed on breast cancer cells, optimization of delivery of 
ZnO NMs could be achieved by considering other candidates. Such alternative candidates, 
which have also been shown to target breast cancer cells, include 
GSPQCPGGFNCPRCDCGAGY *278+ and ASANPFPTKALL *279+. Future work should explore 
these options. 
 
 The future work will also aim to correlate our promising in vitro results with in vivo 
models of breast cancer in mice. This can be achieved by IV injection of the RGD-targeted 
ZnO NPs in a mammary breast cancer model and monitor the distribution of these NPs. The 
in vivo distribution of the RGD-targeted ZnO NPs could be monitored via radionuclide-based 
imaging techniques, such as positron emission tomography (PET) with 64Cu-Labeled RGD-
targeted ZnO NPs *25+. PET is very sensitive, quantitative, and clinically relevant with superb 
tissue penetration *21+. Particle agglomeration is commonly observed in studies involving 
ZnO NPs *19+, particularly when diluted in media with high ionic strength (> 10 mM). This 
agglomeration can affect their bioavailability and could impose significant challenges for 
designing in vivo toxicological studies; however there are successful methods available to 
improve the colloidal stability of these particles. 
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 The addition of chemotherapeutic molecules (e.g. epiruibicin, formulated as a Cl- salt and 
compatible with the processing of the ZnO NMs) into the ZnO mixture during growth so that 
the drug is incorporated into the ZnO matrix, could also help to treat the disease. This 
method has been previously used to incorporate phthalocyanine molecules into ZnO 
nanostructures in our laboratory (unpublished data). Using this synthesis method, the ZnO 
NMs can be used as vector that can target of the chemotherapeutic drug to breast cancer 
cells, by using targeting ligands, as well as the synergistic effect of ZnO NMs their after 
dissolution inside the cancer cells.  
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MDA-MB-231 cells after 2 h exposure to ZnO-HCV-RGD-GFP NPs. The MDA-MB-231 cells 
were exposed to 150 μg/ml ZnO-HCV-RGD-GFP NPs (green) and confocal imaging was 
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Appendix 
Formulation for Minimum Essential Medium (MEM). 
Minimum Essential Medium (MEM), Life technologies, catalogue number: 31095029 
Components Molecular Weight Concentration (mg/L) Concentration (mM) 
Amino acids 
L-Arginine hydrochloride 211.0 126.0 0.5971564 
L-Cystine 240.0 24.0 0.1 
L-Glutamine 146.0 292.0 2.0 
L-Histidine hydrochloride-H2O 210.0 42.0 0.2 
L-Isoleucine 131.0 52.0 0.39694658 
L-Leucine 131.0 52.0 0.39694658 
L-Lysine hydrochloride 183.0 73.0 0.3989071 
L-Methionine 149.0 15.0 0.10067114 
L-Phenylalanine 165.0 32.0 0.19393939 
L-Threonine 119.0 48.0 0.40336135 
L-Tryptophan 204.0 10.0 0.04901961 
L-Tyrosine 181.0 36.0 0.19889502 
L-Valine 117.0 46.0 0.3931624 
Vitamins 
Choline chloride 140.0 1.0 0.007142857 
D-Calcium pantothenate 477.0 1.0 0.002096436 
Folic Acid 441.0 1.0 0.0022675737 
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Minimum Essential Medium (MEM), Life technologies, catalogue number: 31095029 
Niacinamide 122.0 1.0 0.008196721 
Pyridoxal hydrochloride 204.0 1.0 0.004901961 
Riboflavin 376.0 0.1 2.6595744E-4 
Thiamine hydrochloride 337.0 1.0 0.002967359 
i-Inositol 180.0 2.0 0.011111111 
Inorganic salts 
Calcium Chloride (CaCl2 -2H2O) 147.0 264.0 1.7959183 
Magnesium Sulfate (MgSO4-7H2O) 246.0 200.0 0.8130081 
Potassium Chloride (KCl) 75.0 400.0 5.3333335 
Sodium Bicarbonate (NaHCO3) 84.0 2200.0 26.190475 
Sodium Chloride (NaCl) 58.0 6800.0 117.24138 
Sodium Phosphate monobasic (NaH2PO4-
2H2O) 
156.0 158.0 1.0128205 
Other components 
D-Glucose (Dextrose) 180.0 1000.0 5.5555553 
Phenol Red 376.4 10.0 0.026567481 
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Formulation for Dulbecco's Modified Eagle Medium (DMEM). 
Dulbecco's Modified Eagle Medium (DMEM) (1X) liquid (high glucose), Life technologies, catalogue number: 
11880028 
Components Molecular Weight Concentration (mg/L) Concentration (mM) 
Amino acids 
Glycine 75.0 30.0 0.4 
L-Arginine hydrochloride 211.0 84.0 0.39810428 
L-Cystine 2HCl 313.0 63.0 0.20127796 
L-Histidine hydrochloride-H2O 210.0 42.0 0.2 
L-Isoleucine 131.0 105.0 0.8015267 
L-Leucine 131.0 105.0 0.8015267 
L-Lysine hydrochloride 183.0 146.0 0.7978142 
L-Methionine 149.0 30.0 0.20134228 
L-Phenylalanine 165.0 66.0 0.4 
L-Serine 105.0 42.0 0.4 
L-Threonine 119.0 95.0 0.79831934 
L-Tryptophan 204.0 16.0 0.078431375 
L-Tyrosine 181.0 72.0 0.39779004 
L-Valine 117.0 94.0 0.8034188 
Vitamins 
Choline chloride 140.0 4.0 0.028571429 
D-Calcium pantothenate 477.0 4.0 0.008385744 
Folic Acid 441.0 4.0 0.009070295 
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Dulbecco's Modified Eagle Medium (DMEM) (1X) liquid (high glucose), Life technologies, catalogue number: 
11880028 
Niacinamide 122.0 4.0 0.032786883 
Pyridoxine hydrochloride 206.0 4.0 0.019417476 
Riboflavin 376.0 0.4 0.0010638298 
Thiamine hydrochloride 337.0 4.0 0.011869436 
i-Inositol 180.0 7.2 0.04 
Inorganic salts 
Calcium Chloride (CaCl2-2H2O) 147.0 264.0 1.7959183 
Ferric Nitrate (Fe(NO3)3"9H2O) 404.0 0.1 2.4752476E-4 
Magnesium Sulfate (MgSO4-7H2O) 246.0 200.0 0.8130081 
Potassium Chloride (KCl) 75.0 400.0 5.3333335 
Sodium Bicarbonate (NaHCO3) 84.0 3700.0 44.04762 
Sodium Chloride (NaCl) 58.0 6400.0 110.344826 
Sodium Phosphate monobasic (NaH2PO4-
2H2O) 
154.0 141.0 0.91558444 
Other components 
D-Glucose (Dextrose) 180.0 1000.0 5.5555553 
Sodium Pyruvate 110.0 110.0 1.0 
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Formulation for of DMEM/F-12 Medium. 
DMEM/F-12 (1:1), catalogue no. 11320-033, Life technologies, catalog Number(s) 11320033 , 11320074 , 11320082 
Components Molecular Weight 
 
Concentration (mg/L) Concentration (mM) 
Amino acids 
Glycine 75.0 18.75 0.25 
L-Alanine 89.0 4.45 0.049999997 
L-Arginine hydrochloride 211.0 147.5 0.69905216 
L-Asparagine-H2O 150.0 7.5 0.05 
L-Aspartic acid 133.0 6.65 0.05 
L-Cysteine hydrochloride-H2O 176.0 17.56 0.09977272 
L-Cystine 2HCl 313.0 31.29 0.09996805 
L-Glutamic Acid 147.0 7.35 0.05 
L-Glutamine 146.0 365.0 2.5 
L-Histidine hydrochloride-H2O 210.0 31.48 0.14990476 
L-Isoleucine 131.0 54.47 0.41580153 
L-Leucine 131.0 59.05 0.45076334 
L-Lysine hydrochloride 183.0 91.25 0.4986339 
L-Methionine 149.0 17.24 0.11570469 
L-Phenylalanine 165.0 35.48 0.2150303 
L-Proline 115.0 17.25 0.15 
L-Serine 105.0 26.25 0.25 
L-Threonine 119.0 53.45 0.44915968 
L-Tryptophan 204.0 9.02 0.04421569 
L-Tyrosine disodium salt dihydrate 261.0 55.79 0.21375479 
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DMEM/F-12 (1:1), catalogue no. 11320-033, Life technologies, catalog Number(s) 11320033 , 11320074 , 11320082 
L-Valine 117.0 52.85 0.4517094 
Vitamins 
Biotin 244.0 0.0035 1.4344263E-5 
Choline chloride 140.0 8.98 0.06414285 
D-Calcium pantothenate 477.0 2.24 0.0046960167 
Folic Acid 441.0 2.65 0.0060090707 
Niacinamide 122.0 2.02 0.016557377 
Pyridoxine hydrochloride 206.0 2.013 0.009771844 
Riboflavin 376.0 0.219 5.824468E-4 
Thiamine hydrochloride 337.0 2.17 0.0064391694 
Vitamin B12 1355.0 0.68 5.0184503E-4 
i-Inositol 180.0 12.6 0.07 
Inorganic salts 
Calcium Chloride (CaCl2) (anhyd.) 111.0 116.6 1.0504504 
Cupric sulfate (CuSO4.5H2O) 250.0 0.0013 5.2E-6 
Ferric Nitrate (Fe(NO3)3.9H2O) 404.0 0.05 1.2376238E-4 
Ferric sulfate (FeSO4-7H2O) 278.0 0.417 0.0015 
Magnesium Chloride (anhydrous) 95.0 28.64 0.30147368 
Magnesium Sulfate (MgSO4) (anhyd.) 120.0 48.84 0.407 
Potassium Chloride (KCl) 75.0 311.8 4.1573334 
Sodium Bicarbonate (NaHCO3) 84.0 2438.0 29.02381 
Sodium Chloride (NaCl) 58.0 6995.5 120.61207 
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DMEM/F-12 (1:1), catalogue no. 11320-033, Life technologies, catalog Number(s) 11320033 , 11320074 , 11320082 
Sodium Phosphate dibasic (Na2HPO4) 
anhydrous 
142.0 71.02 0.50014085 
Sodium Phosphate monobasic (NaH2PO4.H2O) 138.0 62.5 0.45289856 
Zinc sulfate (ZnSO4 .7H2O) 288.0 0.432 0.0015 
Other components 
D-Glucose (Dextrose) 180.0 3151.0 17.505556 
Hypoxanthine Na 159.0 2.39 0.015031448 
Linoleic Acid 280.0 0.042 1.4999999E-4 
Lipoic Acid 206.0 0.105 5.097087E-4 
Phenol Red 376.4 8.1 0.021519661 
Putrescine 2HCl 161.0 0.081 5.031056E-4 
Sodium Pyruvate 110.0 55.0 0.5 
Thymidine 242.0 0.365 0.0015082645 
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Formulation for Leibovitz’s L-15 Medium. 
Leibovitz’s L-15 Medium, ATCC 30-2008 
Components Concentration (mg/L) 
Amino Acids  
L-Alanine  225.00 
L-Arginine (free base)  225.00 
L-Asparagine·H2O  250.00 
L-Cysteine (free base)  120.00 
L-Glutamine  300.00 
Glycine  200.00 
L-Histidine (free base)  250.00 
L-Isoleucine  125.00 
L-Leucine  125.00 
L-Lysine·HCl  93.70 
L-Methionine  75.00 
L-Phenylalanine  125.00 
L-Serine  200.00 
L-Threonine  300.00 
L-Tryptophan  020.00 
L-Tyrosine·2Na·2H2O  430.00 
L-Valine  100.00 
Vitamins 
Choline Chloride  1.00 
Riboflavin-5-PO4·Na·2H2O  0.10 
Folic Acid   1.00 
myo-Inositol  2.00 
Nicotinamide  1.00 
D-Pantothenic Acid  (hemicalcium) 1.00 
Pyridoxine·HCl  1.00 
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Leibovitz’s L-15 Medium, ATCC 30-2008 
Thiamine·PO4·Cl·2H2O  1.00 
Inorganic salts 
CaCl2 (anhydrous)  140.00 
MgCl2·6H2O  200.00 
MgSO4 (anhydrous)  97.67 
KCl  400.00 
KH2PO4 (anhydrous)  60.00 
NaCl  8000.00 
Na2HPO4 (anhydrous)  190.00 
Other components 
D-Galactose  900.00 
Phenol Red, Sodium Salt  10.00 
Sodium Pyruvate  550.00 
 
 
 
 
 
